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ABSTRACT
Terpene indole alkaloids are a class of natural products produced by
plants, many of which are used clinically for the treatment of human disease.
Natural products, are not produced by the organism for the purpose of treating
human disease and often tailoring of the natural product scaffold results in drugs
with improved properties. Precursor directed biosynthesis (PDB) describes the
inclusion of biosynthetic precursor analogs in the growth media of a producing
organism for the production of secondary metabolite derivatives derived from
these exogenous precursors. These studies examine precursor directed
biosynthesis of alkaloid analogs in Catharanthus roseus hairy roots and
seedlings. All terpene indole alkaloids are derived from tryptamine and
secologanin, which are coupled to form strictosidine by the enzyme strictosidine
synthase (STR). Analysis of the tryptamine substrate specificity of strictosidine
synthase (STR) revealed a subset of tryptamine analogs which were converted
to the corresponding strictosidine analogs. The strictosidine analogs generated
were processed by the next enzyme in the pathway strictosidine-p-glucosidase
(SGD). With a set of accepted tryptamine substrates in hand, the precursor
analogs were fed to C. roseus cultures for the production and identification of
novel alkaloids produced by precursor directed biosynthesis. Representative
alkaloid analogs for the major C. roseus alkaloids were produced and isolated
from C. roseus cultures. The specific alkaloid analogs produced depends on the
position of the modification on the tryptamine and the steric and electronic
properties of the substitution. Detailed alkaloid metabolite analysis revealed
bottlenecks for the production of specific alkaloids, representing the substrate
specificity of enzymes which have not been examined on an enzymatic or
genetic level. Furthermore, since the enzymes catalyzing the late steps in the
biosynthesis of alkaloids are not known, photo-reactive tryptamine analogs and
secologanin analogs containing a bio-orthogonal tag were combined to form a bi-
functional probe, used to label and identify C. roseus biosynthetic enzymes in cell
free extracts. The probe labeled several enzymes with the proposed biological
activity necessary for the bio-transformations catalyzed in vivo.
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Chapter 1
Background and Significance
1. Introduction
Natural products generated by an organism are typically not essential for
normal cellular function and are therefore often referred to as secondary
metabolites [1]. Secondary metabolites enhance the ability of the producing
organism to survive by attracting or repelling other organisms [1]. The
biosynthesis of these metabolites evolved as one survival strategy. Secondary
metabolites are derived from starting materials in primary metabolism and fall
into 6 main classes based on the primary metabolic materials used for their
construction: fatty acids and polyketides, aromatic amino acids and
phenylpropionoids, terpenoids and steroids, alkaloids, peptides, and
carbohydrates (Figure 1.1) [2].
The sub-class of secondary metabolites that is the focus of this research
is the plant-derived monoterpene indole alkaloids (TIA). This subset of over
2000 known compounds is highly complex and structurally diverse, and all derive
from the same precursors, tryptamine I and secologanin 2 (Figure 1.2) [3]. The
initial step in the biosynthesis combines these precursors to form strictosidine 3,
the central intermediate to all TIA (Figure 1.2). Several of the main structural
groups include the corynanthe group (ajmalicine 4, serpentine 5 and yohimbine
6), the aspidosperma group (tabersonine 7, and vindoline 8), the iboga group
(catharanthine 9), the strychnos group (akuammicine 10 and strychnine 11), the
quinoline group (quinine 12 and camptothecin 13), the ajmalan group (ajmaline
14), and the bisindole alkaloids (vinblastine 15, vincristine 16) (Figure 1.2) [4, 5].
Each TIA producing plant contains specialized biosynthetic machinery for the
20
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Figure 1.1: Examples of the six main classes of natural products and their medicinal uses.
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Figure 1.2: Example terpene indole alkaloids derived from stricotisine 3. Representative examples of the
various structural classes of TIA produced by plants and the variety of medicinal applications.
NH2
iboga
production of a unique subset of the possible structures derived from the central
intermediate strictosidine 3 (Figure 1.2).
The research described here focuses on TIA produced by the medicinal
plant Catharanthus roseus (Vinca rosea, Madagascar periwinkle). This plant
produces a subset of approximately 130 TIA [6]. The diversity of structures
produced by this single organism spans the corynanthe, strychnos,
aspidosperma, iboga, and bisindole alkaloid families, showing that great
structural diversity can be produced by a single organism (Figure 1.2). The
biosynthesis of the TIA produced by Catharanthus roseus or any TIA producing
plant has not been fully elucidated at the enzymatic level and indeed key
enzymes involved in the biosynthesis of these compounds have eluded
researchers for the past 50 years [3].
Our interest in these secondary metabolites lies in their commercial use
for the treatment of disease. However, secondary metabolites are not produced
by the organism for these pharmaceutical purposes and often require structural
modification to produce optimized drug candidates [7]. For example,
camptothecin 13, a TIA produced by Camptotheca acuminata, exhibited potent
anti-tumor activity, but failed pre-clinical trials due to poor solubility properties.
Renewed interest in camptothecin 13 upon discovery of its cellular target, DNA
topoisomerase I, led to the development of water soluble derivatives of
camptothecin, topotecan 17 (Hycamtin, Glaxosmithkline) [8], which was the first
topoisomerase I inhibitor to be approved by the FDA, and irinotecan 18
(Camptostar, Pfizer) (Figure 1.3). Clinical uses for topotecan included the
13 Camptothecin
17 Topotecan
R1, 2 ,3= H
R1 = H; R2 =CH 2N(CH 3)2, R3 = OH
18 Irinotecan R1 = CH 2CH 3; R2 =H, R3=
0
N N
o-O
Figure 1.3: Topoisomerase I inhibitors derived from camptothecin.
R2 R,
R3 0
15 
N
N0 O
treatment of ovarian cancer and small cell lung cancer; and clinical uses for
irinotecan include the treatment of colon cancer [9].
In addition to total chemical synthesis and semi-synthetic methods, there
are several biochemical methods for the production of secondary metabolite
derivatives. These methods include precursor-directed biosynthesis (PDB),
mutasynthesis, and genetic engineering (Figure 1.4) [7]. Each of these methods
has advantages and disadvantages for the production of specific natural product
analogs.
Precursor-directed biosynthesis utilizes the feeding of substrate analogs
to generate secondary metabolite derivatives (Figure 1.4B). It is limited to the
inherent promiscuity of the biosynthetic machinery and the availability of
substrate analogs. It results in the production of a mixture of secondary
metabolites derived from the naturally occurring starting material and the fed
precursor. Under optimal conditions, PDB is an efficient method for the
production of a diverse array of secondary metabolite derivatives. Mutasynthesis
is a logical extension of PDB, which utilizes mutant organisms deficient in an
important step in the assembly of one of the starting substrates of the natural
product (Figure 1.4C). The absence of the endogenous starting material allows
exclusive formation of the desired secondary metabolite derivative upon feeding
of the modified precursor.
Genetic engineering involves the mutation or insertion of a biosynthetic
enzyme or pathway to alter the natural product (Figure 1.4D). Use of genetic
engineering expands the scope of possible modifications to the parent secondary
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metabolite scaffold, and can utilize substrate analogs generated in vivo if the
biosynthetic pathway for the substrate is genetically inserted. Genetic
engineering and mutasynthesis afford the greatest control over the final natural
product analog produced. However, both genetic engineering and mutasynthesis
require knowledge of the organism's secondary metabolic pathways on a genetic
level and techniques for facile genetic transformation.
The research presented aims to explore the use of substrate analogs to
produce derivatives of alkaloids in the medicinal plant C. roseus. Gaps exist in
our genetic knowledge of the C. roseus TIA biosynthetic pathway, limiting our
ability to generate TIA analogs by genetic engineering or mutasynthesis.
Therefore, precursor directed biosynthesis represents the ideal method for
generation of TIA analogs in C. roseus.
Additional uses of substrate analogs include identification of protein-ligand
interactions by affinity based protein profiling [10]. In this method, substrate
analogs covalently modify their protein partners and allow for identification of the
protein-ligand interactions on the micro and macro scale. Precursor directed
biosynthesis with photo-active substrates, which can covalently modify the
enzyme active site, represents a unique method for identification of the elusive
TIA biosynthetic enzymes. This chapter introduces the use of substrate analogs
for the production of natural product derivatives, the current understanding of the
biosynthesis of TIA in C. roseus, and the use of substrate analogs to label and
identify proteins.
2. Precursor Directed Biosynthesis
Precursor directed biosynthesis (PDB) describes the inclusion of
biosynthetic precursor analogs in the growth media of a producing organism for
the production of secondary metabolite derivatives derived from these
exogenous precursors (Figure 1.4) [7]. PDB begins by establishing and
maintaining a cell line of an organism with desired secondary metabolites. The
ideal cell line contains a characterized biosynthetic pathway with known
synthetically tractable intermediates. It is essential that an analytical technique
for identification of the secondary metabolites and the derivatives exists and
allows differentiation between the derivatives generated and the natural
compounds produced by the organism. With an appropriate analytical system in
hand, variation in the timing and concentration of the synthetic precursors fed
establishes optimal parameters for high yielding production of secondary
metabolite derivatives. Finally, after optimization, isolation and further
characterization of the proposed metabolite derivatives validates these methods.
PDB in microbial and fungal cultures produces a diverse array of
secondary metabolite derivatives. For example, PDB generates derivatives of
antibiotics such as the carbohydrate, paulomycins [11, 12] and the polyketide,
manumycin [13-16], and immunosuppressants, such as the polypeptide
cyclosporine [17, 18]. In combination with mutasynthesis, PBD has been used to
generate analogs of the polyketide antibiotic erythromycin [19], among others
reviewed elsewhere [7, 20]. In recent years, plant biosynthetic pathways for
stilbenes and flavanoids have been genetically engineered into E. coli, in
combination with PDB, to generate libraries of these natural product analogs [21,
22]. Occasionally, the secondary metabolite derivatives produced exhibit
improved properties compared to the naturally occurring product. For example
PDB of aureobasidin A analogs resulted in production of aureobasidin derivatives
with improved antifungal activity toward select fungal strains [23].
Few examples exist of precursor directed biosynthesis in plants. The sole
example, to my knowledge, produced fluorinated tropane alkaloids in Datura
stramonium root cultures [24]. Recently, as mentioned above, the biosynthesis of
plant flavanoids and stilbenes, reconstituted in E. coli, produced flavanoind and
stilbene analogs upon feeding of synthetic precursors [21, 22]. Precursor-
directed biosynthetic studies in TIA producing organisms lack precedent. Over
the past 50 years, extensive research has established many of the biosynthetic
steps responsible for the production of TIA in C. roseus. These fundamental
studies lay the groundwork necessary for successful precursor-directed
biosynthesis in C. roseus.
3. Catharanthus roseus TIA
3.1 Medicinally Active TIA Produced in C. roseus
The medicinal plant C. roseus produces several important TIA used
clinically for the treatment of human disease. Most notably, vinblastine 15 and
vincristine 16 are used for the treatment of non-Hodgkin's lymphomas as well as
other cancers (Figure 1.2) [6, 25]. In addition to these anti-cancer compounds,
C. roseus cultures produce several other compounds with diverse biological
activities. These include, ajmalicine 4, a known anti-hypertensive agent clinically
used in a combination treatment for rehabilitation following a stroke [26];
serpentine 5, a known topoisomerase II inhibitor [27]; akuammicine 10 shown to
have opioid activity [28]; and yohimbine 6 an alpha-2-andrenergic receptor
antagonist used to treat erectile dysfunction (Figure 1.2) [29, 30].
3.2 C. roseus Producing Cultures
Analysis of production of TIA in whole plants and various cell cultures has
established the specific TIA produced by C. roseus in a wide variety of culture
types. There are many advantages in using plant tissue culture to study
secondary metabolism including, shorter sub-culture periods, reduced space
requirements, elimination of environmental variables such as temperature,
weather and infection, and increased ease of genetic manipulation [31]. Several
of the commonly used cultures for C. roseus TIA production include; cell
suspension cultures, callus culture, shoot culture (not shown) and hairy root
cultures (Figure 1.5) [32]. Each of these cultures has different properties, which
make them ideal for various applications. For PDB of TIA, C. roseus hairy root
cultures represent the optimal culture for production of TIA. Hairy root cultures,
established by infection of the plant with Agrobacterium rhizogenes, are widely
used in basic research of C. roseus TIA biosynthesis. These cultures
demonstrated stable natural product production [33] with doubling times similar to
that of cell suspension cultures. The disadvantage is that, in general, hairy root
cultures produce only a subset of the alkaloids produced in the whole plant.
Cell Suspension
Callus Seedlings
Figure 1.5: Catharanthus roseus cultures.
Hairy Root
However, the alkaloids are produced in higher titers in hairy root cultures than is
found in other culture types, making it ideal for the production of TIA analogs
[34].
3.3 Biosynthesis of C. roseus TIA
Initial studies in the biosynthesis of TIA established a sequence for the
biosynthesis by isolation of alkaloids at early stages of germination and
identification of intermediates not seen in high yields in the mature plants,
establishing the fundamental relationship between the different structural classes
of alkaloids. It was observed that the first alkaloids generated after germination
were of the corynanthe type including corynanthe aldehyde 19, geissoschizine
20, and ajmalicine 4 [35, 36]. Next researchers observed TIA with the
corynanthe-strychnos skeleton including pre-akuammicine 21 and stemmadenine
22. Finally, 72 hours after germination researchers observed the production of
the aspidosperma alkaloid tabersonine 7 and at 100 hours the iboga alkaloid
catharanthine 9. Additional studies, such as feeding of labeled biosynthetic
intermediates geissoschizine 20 and stemmadenine 22 to seedlings, resulted in
the incorporation of the label into the later metabolites tabersonine 7 and
catharanthine 9, thereby establishing a biosynthetic route for TIA biosynthesis
[35-37]. Following the identification of intermediates in the biosynthesis of this
highly branched biosynthetic pathway, researchers aimed to identify the enzymes
involved in the biosynthesis to elucidate the mechanism of production of these
alkaloids in C. roseus.
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3.3.1 Early Steps in TIA biosynthesis
The early steps in TIA biosynthesis involve the biogenesis of the
precursors tryptamine 1 and secologanin 2 and their condensation to form the
central intermediate strictosidine 3 (Figure 1.6). Secologanin 2 is a terpene
glycoside derived from the dimethylallyl pyrophosphate (DMAPP) 23 and
isopentenyl pyrophosphate (IPP) 24 precursors. In the case of secologanin 2
biosynthesis, the precursors (23 and 24) derive from the relatively recently
discovered "non-mevalonate" pathway [38, 39]. Many of the enzymes involved in
the biosynthesis of both the DMAPP (23) and IPP (24) precursors as well as later
steps in secologanin 2 biosynthesis have been discovered, however, to date the
pathway has not been fully elucidated on a genetic level [40]. The second
precursor, tryptamine 3, is derived from tryptophan 25 by the action of tryptophan
decarboxylase (TDC) (Figure 1.6). TDC, cloned from C. roseus, shows
specificity for its tryptophan substrate, compared to other aromatic amino acid
decarboxylases, which often process multiple aromatic amino acids [41]. TDC
decarboxylates tryptophan 25 in the cytosol and tryptamine 1 is then transported
to the vacuole where strictosidine synthase (STR) catalyzes the formation of the
central intermediate strictosidine 3 (Figure 1.6) [42].
3.3.2 Strictosidine Synthase (STR)
Strictosidine synthase (STR) catalyzes a stereoselective Pictet-Spengler
condensation [43, 44] between tryptamine 1 and secologanin 2 to form
strictosidine 3, the precursor to over 2000 TIA (Figure 1.6) [45-50]. First reported
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Figure 1.6: Early Steps in TIA biosynthesis. TDC, tryptophan decarboxylase; DMPP, dimethylallyl
pyrophosphate; IPP, isopentenyl pyrophosphate; STR, strictosidine synthase; SGD, strictosidine-p-glucosidase
in a cell-free system of Catharanthus roseus and other TIA producing cultures
[46], STR was later purified and cloned from several other TIA producing species
[50-61]. STR was then heterologously expressed in bacteria [52, 56, 57], yeast
[62], insect cell cultures [63] and tobacco [64]. The steady-state kinetic
parameters were determined for the purified enzymes from many of these
sources [59].
Knowledge of the specificity of this early enzyme is essential for the
generation of TIA derivatives via PDB from tryptamine 1 or secologanin 2
analogs. The aromatic amine and terpene substrate specificity was determined
for partially purified STR from C. roseus [49]. Several tryptamine analogs
including 7-methyltryptamine, 6-hydroxytryptamine, 7-fluorotryptamine, 5-
fluorotryptamine, and 5-hydroxytryptamine formed the corresponding strictosidine
analogs when incubated with STR and secologanin. Amine substrates 5-
methyltryptamine and 5-methoxytryptamine, 5,6- and 5,7-dihydroxytryptamine,
DL-a-methyltryptamine, N-methyltryptamine, a-ethyltryptamine, and D- and L-
tryptophan were not converted to strictosidine analogs by the enzyme. Similar
substrate specificity studies examining STR affinity for analogs of secologanin
revealed that 2'-O-methyl, 3'-O-methyl, and dihydrosecologanin formed the
corresponding strictosidine derivatives.
3.3.3 Strictosidine Glucosidase (SGD)
Upon identification of the glucoside strictosidine as the precursor to the
TIA, researchers proposed that a deglycosylation step would occur early in the
biogenesis of the downstream alkaloid structures [65]. Strictosidine-p-D-
glucosidase (SGD, EC.3.2.1.105), first observed in crude cell extracts of C.
roseus as part of an "ajmalicine synthase" complex [66], was purified from C.
roseus cell suspension cultures many years later [67]. SGD activity, isolated
from C. roseus cultures, eluted as an estimated 1500 kDa complex, which upon
several purification steps exhibited glucosidase activity specific for strictosidine 3.
Further analysis revealed that SGD exists as a multimer and is likely part of a
larger multi-enzyme complex in vivo. The cDNA encoding the SGD was isolated
from multiple TIA producing plants and expressed in E. coli and yeast [68-71].
SGD from R. serpentina revealed some substrate specificity [70]. SGD
deglycosylated 5-a-carboxystrictosidine, 18,19-dihydrostrictosidine, Np-
methylstrictosidine, NP-acetylstrictosidine, and the precursor to the ipecac
alkaloids, deacetyisosipecoside. However, SGD did not turnover other known R.
serpentina TIA glucosides.
After deglycosylation, the aglucone 26 can open to form a reactive
tricyclic dialdehyde 27, which reacts with the secondary amine to form an
intermediate proposed to be in equilibrium with multiple forms 28-30 [72-75]
(Figure 1.6). Cathenamine 30 has been identified as the major deglycosylation
product in vitro [72], but how the equilibrium is controlled in vitro or in vivo is
poorly understood [73, 74].
3.3.4 Late Stage of TIA Biosynthesis
The enzymes responsible for the biosynthetic steps immediately following
deglycosylation are not known on a genetic level. However, a valid biosynthetic
pathway was established based on studies of radio-labeled precursor feeding,
cell free conversion of intermediates, and product isolation and identification. It is
proposed that cathenamine 30 is reduced to form ajmalicine 4 (Figure 1.7) [72,
76]. Two NADPH dependent reductases were partially purified from of C. roseus
cell cultures that specifically reduce cathenamine 30 to form either 20-H-a-
ajmalicine (tetrahydroalstonine) 31 or both ajmalicine 4 and 19-epi-ajmalicine 32
[77]. Additionally, feeding of geissoschizine 20 to C. roseus cell cultures and
mature plants resulted in label incorporation into ajmalicine 4 [78]. An NADP+
dependent dehydrogenase isolated from C. roseus cultures, specifically converts
20 to 4, through the proposed intermediates 29 and 30 [78, 79]. Ajmalicine 4
and tetrahydroalstonine 31 are known to be transported to the vacuole for
storage, where they are further oxidized by a peroxidase to form serpentine 5
and alstonine 33 which accumulate in the vacuole (Figure 1.7) [80].
In addition to the corynanthe alkaloid ajmalicine 4, labeled geissoschizine
20 was incorporated into akuammicine 10, tabersonine 7, and catharanthine 9,
members of the strychnos, aspidosperma, and iboga family of alkaloids
respectively (Figure 1.8) [37]. Biosynthesis of the more complex strychnos,
aspidosperma and iboga classes of alkaloids remains more cryptic. A logical
pathway entails oxidation of geissoschizine 20, followed by rearrangement and
reduction to form pre-akuammicine 21 (Figure 1.8). Alternatively, geissoschizine
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20 could be reduced to form isositsirikine 34, by an NADPH dependent reductase
[81]. Several possible mechanisms for the formation of pre-akuammicine 21 from
geissoschizine 20 were proposed, all of which invoke oxidation at the indole-3-
position (geissoschizine-7-position, Figure 1.9) [82]. Proposed intermediates
include p-hydroxyindolenine 35 or geissoschizine-oxindole 36 [83], neither of
which are commonly isolated from C. roseus. One mechanism entails the
conversion of geissoschizine-oxindole 36 intermediate to the corresponding
imino-ether 37, which would give the molecule the required reactivity for reaction
with the enol form of the methyl ester [84], to generate pre-akuammicine 21 upon
reduction. Alternatively, P-hydroxyindolenine 35 intermediate could react through
direct attack at the p-hydroxyindolenine 2- or 7-position by the enol form of the
methyl ester to form intermediates 38 or 39 followed by a 2,7- alkyl shift to
generate the aldehyde intermediate, which is reduced to then form pre-
akuammicine 21.
In recent years, researchers reported bio-mimetic entry into the strychnos
skeleton via beta-chlorination of deformylated geissoschizine 20.1 [85, 86]. First,
researchers attempted the bio-mimetic synthesis of akuammicine through a
deformylated geissoschizine-oxindole 36.1. Oxindole alkaloids from other TIA
producing cultures equilibrate in solution between diastereomers in a pH and
solvent dependent manner [87, 88]. Interestingly, geissoschizine-oxindole 36 is
unique when compared to naturally occurring oxindoles in the localization of the
vinyl group. In the case of deformyl geissoschizine-oxindole 36.1 generated in
this bio-mimetic study the major isomers isolated had 3-R stereochemistry, which
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prevented reaction with the enol ester [85, 86]. The formation of the 3-R
stereoisomer over the 3-S stereoisomer was proposed to be due to steric
interactions between the vinyl group and methyl ester. Previous feeding studies
with chemically synthesized labeled geissoschizine-oxindole 36 resulted in
incorporation of the label into both akuammicine (0.55%) and tabersonine
(0.05%) [83]. However, no characterization of the geissoschizine-oxindole 36 fed
to this culture was reported nor was the study subjected to peer review.
Under conditions in which the p-chlorinated deformylgeissoschizine 35.1
was generated and reacted directly with enol ester through a strictamine
intermediate 39.1, akuammicine 10 was formed [85, 86]. However, no feeding
studies directly linking 16-formylstrictamine 39 to pre-akuammicine 21, have
been performed. These conflicting studies leave doubt to the mechanism for the
formation of pre-akuammicine 21.
Pre-akuammicine 21 isolated from C. roseus rapidly decomposes at room
temperature to form akuammicine 10 [82], an alkaloid with the corynanthe-
strychnos structure (Figure 1.8). Whether the formation of akuammicine 10 in
vivo occurs spontaneously or is enzymatically catalyzed is not known. Reduced
pre-akuammicine, stemmadenine 22, has been isolated from TIA producing
cultures [35], and feeding of labeled stemmadenine 22 to seedlings is
incorporated into vindoline 8 and catharanthine 9 (Figure 1.8) [35]. Additionally,
feeding unlabeled stemmadenine 22 to C. roseus cell suspension cultures
resulted in a significant increase in the formation of tabersonine 7, catharanthine
9, and condylocarpine 40 after 1 hour of incubation, suggesting it was directly
converted to these products (Figure 1.8) [89]. These results suggest that
stemmadenine 22 is a potential link between the corynanthe and
aspidosperma/iboga alkaloids.
The conversion of stemmadenine 22 to catharanthine 9 and tabersonine 7
is proposed to proceed through a dihydropyridine acrylic ester intermediate,
dehydrosecodine 41 (Figure 1.8) [90-95]. The formation of dehydrosecodine 41
from stemmadenine 22 can be hypothesized to proceed through a reverse
Mannich reaction. Dehydrosecodine 41, can either undergo a Mannich reaction
or a Diels-Alder 4+2 cyclo-addition reaction to form tabersonine (7) or
catharanthine (9) [92]. Feeding of labeled secodine 42 to cultures resulted in
minimal incorporation into vindoline 8, a tailored derivative of tabersonine, [96,
97] supporting the role of dehydrosecodine 41 in the biosynthesis of
aspidosperma alkaloids. Dehydrosecodine 41 as an intermediate in the
formation of catharanthine 9 is largely based on bio-mimetic studies [90, 94]. In
addition, seedlings fed with labeled tabersonine 7 resulted in the label being
incorporated into both vindoline 8 (4.8%) and small amounts of catharanthine 9
(0.8%), suggesting that the formation of tabersonine 7 is reversible and that
tabersonine 7 and catharanthine 9 share a common intermediate (Figure 1.8)
[35].
Tabersonine 7 is then further tailored to yield vindoline 8 through six steps,
four of which have been characterized at the genetic level (Figure 1.10) [98-100].
The modification of tabersonine 7 to form vindoline 8 is performed in the aerial
parts of the plant [101] and is not observed in C. roseus hairy root or cell
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suspension cultures [102]. Tabersonine 7 is hydroxylated by tabersonine-16-
hydroxylase to form 43 and then methylated by 16-hydroxytabersonine O-
methyltransferase to form 44 (Figure 1.10) to initiate the biosynthesis of
vindoline 8. This reaction is proposed to be followed by the addition of water by
an unidentified enzyme to form 45. The intermediate is then methylated by an N-
methyltransferase to form deacetoxyvindoline 46. N-methyl transferase activity
has been observed in cell free extracts of C. roseus [103] but the enzyme has not
been cloned. Deacetoxyvindoline-4-hydroxylase (D4H) then hydroxylates
deacetoxyvindoline 46 [104-106] to form deacetylvindoline 47 followed by
acetylation by deacetylvindoline-acyltransferase (DAT) to yield vindoline 8 [107-
109]. A demethoxyvindoline 48 exists in the plant but the route of its
biosynthesis is unknown. After formation, vindoline 8 is dimerized with
catharanthine 9 by a known peroxidase to form the dimeric alkaloid a-3',4'-
anhydrovinblastine [110], which is further oxidized to yield vinblastine 15.
Labeled tryptophan 25 has also been administered to mature seedlings
[111]. In this study, labeled D,L-tryptophan was fed to 9 day old seedlings
through the roots and the labeling of alkaloids was observed. This study showed
that the formation of geissoschizine 20, followed by akuammicine 10 and
tabersonine 7, are observed in the first 4 hours. The order corresponds with
what is expected based on the proposed biogenesis of tabersonine 7 through a
pre-akuammicine 21 intermediate generated from geissoschizine 20. Over the
seven day time course little labeled tryptophan was incorporated into ajmalicine
4, suggesting that the flux of the tryptophan incorporated is not being shuttled
down the heteroyohimbine pathway but rather to the oxidative aspidosperma and
iboga biosynthetic pathways. After 3-4 days the incorporation into vindoline 8
was observed, along with a corresponding loss in labeled tabersonine 7.
Catharanthine 9 production linearly increased from day 2 to day 8 after an initial
burst in label incorporation on day 1. This study clearly demonstrates that upon
feeding of alkaloid precursor tryptophan, the compound is absorbed by the plant
and incorporated into the various TIA of interest. In addition, it appears that the
biosynthesis of alkaloids in seedlings is biased towards the generation of
vindoline 8 and catharanthine 9, the precursors to the dimeric alkaloids
vinblastine 15 and vincristine 16. This research lays the groundwork for PDB on
the C. roseus TIA biosynthetic pathway to generate alkaloid derivatives using
commercially available and easily synthesized substrate analogs.
4. Photo-reactive Small Molecules for the Identification of Enzymes
Substrates or inhibitors modified with photo-reactive groups are useful for
the study of the interactions between the biological ligand and its protein partner
[112]. This methodology has been employed to study biochemical interactions on
a macro-scale to find the ligand binding proteins and on a micro-scale to identify
the amino acid residues with which the ligand interacts. There are several
common photo-reactive groups employed to modify proteins, including aryl
azides, diazirines, and benzophenones (Figure 1.11) [113]. Aryl azides are one
of the most widely used photo-affinity labels due to their commercial availability
and their ease of synthesis. Photo-activation of aryl-azides results in the
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generation of a reactive nitrene. The reaction of nitrenes with active site residues
can produce nitrogen-carbon or a more labile nitrogen-heteroatom bond, which is
often unstable under the conditions used for identification of labeling by mass
spectroscopy. Additionally, aryl-azides upon generation of a reactive nitrene can
undergo a ring expansion reaction to generate ketenimine, a long-lived
electrophile, which cannot react with un-activated carbon hydrogen bonds [114,
115]. Finally, aryl-azides require shorter wavelength light to generate the
reactive nitrene, which can cause significant damage to the biomolecules of
interest in solution. However, their advantage is that the perturbation of the
ligand is minimal and provides the best chance for maintaining the specific
ligand-protein interactions. Diazirines, as photo-reactive groups, have had
success recently as isosteric analogs of amino acids and DNA nucleotides [113,
116, 117]. Upon photolysis a reactive carbene is generated and this linkage
produced from reaction of a carbene is generally more stable then the linkage
formed from the nitrenes generated upon photolysis of aryl azides [118].
Benzophenones are also commonly employed as analogs of amino acids and
nucleotides among other biomolecules [119]. Benzophenones are more stable
photophores then diazirines and aryl azides and are activated at longer
wavelength reducing UV damage to the proteins being labeled. However, the
large size of the benzophenone prohibits its use in many applications.
Radiolabels are commonly incorporated into these photo-active ligands for
detection of the labeled proteins, but the incorporation of the radiolabel is often
difficult and expensive. In recent years, development of alternative bio-
orthogonal label incorporation chemistries has allowed attachment of the
detectable label after incorporation of the photo-active ligand [120].
Multifunctional probes, containing both a photo-active or electrophilic group to
modify the protein and a bio-orthogonal handle for attachment of a molecule for
detection have recently been developed and employed to build upon the
commonly used photo-affinity labels for specific ligand-protein interactions. This
method is referred to as affinity based protein profiling (ABPP) or functional
genomics [10]. In this case, the probe contains both a group for chemical
modification of the protein (photo-reactive or electrophilic) and a second
modification (such as an alkyl azide or alkyne) that can by functionalized by a
bio-orthogonal reaction (Figure 1.11). There are two major bio-orthogonal
reactions that are commonly employed, the Staudinger Ligation [121, 122] and
the copper catalyzed Huisgen 1,3-dipolar cycloaddition, commonly referred to as
"click chemistry" [123]. The copper catalyzed Huisgen 1,3-dipoar cycloaddition is
used to couple alkyl-azides and terminal alkynes to form a triazole (Figure 1.11).
This bio-orthogonal reaction has been used to label enzymes modified with a
photo-reactive or electrophilic ligands [10].
The C. roseus biosynthetic pathway enzymes immediately following SGD
have not been cloned. Enzymes capable of the conversion of the cathenamine
30 intermediate to isomers of ajmalicine 4 have been partially purified from C.
roseus cell cultures [77]. Photochemical labeling of crude enzyme extracts with
bi-functional substrate analogs represents a new approach to the identification of
these elusive enzymes. Indole-azides have previously been utilized as photo-
affinity labels for several proteins [124-133]. Specifically, 6-azido-L-tryptophan
was used to inactivate tryptophan synthase [129]. Tryptamine-azides have
recently been synthesized [134]. Additionally, secologanin analogs containing an
alkyne functionality were synthesized by transesterification of secologanin [135].
The combination of these two starting materials represents a potential bi-
functional substrate for the covalent modification and labeling of TIA biosynthetic
enzymes from C. roseus cell cultures.
5. Substrate Analogs to Investigate Alkaloid Biosynthesis in C. roseus
The following experiments performed aimed to explore the production of
TIA derivatives via precursor-directed biosynthesis. Chapter 2 investigates the
substrate specificity of the initial enzymes STR and SGD, identifying a set of
tryptamine substrate analogs which are tolerated by the initial enzymes of the
TIA biosynthetic pathway. Following identification of a set of substrates which are
accepted by these initial enzymes, PDB of alkaloid analogs was performed in C.
roseus hairy roots and seedlings (Chapter 3). After optimization of alkaloid
analog production the alkaloid derivatives were quantified, isolated, and
characterized. These studies indicated that certain substrates were accumulating
intermediates not commonly produced in C. roseus cultures. In chapter 4, semi-
quantitative analysis of the alkaloid analog metabolic profiles determined the
substrate specificity and mechanistic limitations of enzymes not identified
previously due to difficulties in identification of the genes and enzymes of
interest. Finally, these studies indicated that many of the uncharacterized
enzymes could recognize substrate analogs containing a variety of chemical
modifications, but many substrates were not processed by specific pathway
enzymes due to the perturbation of the electronic nature of the indole ring.
Finally, chapter 5 explores the use strictosidine analogs generated by the
coupling of tryptamine-azides and a pentynyl ester analog of secologanin to
chemically modify enzymes involved in alkaloid biosynthesis. Several C. roseus
proteins labeled by this method are potential candidates for the biosynthetic
enzymes which have eluded researchers for the past 50 years.
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Chapter 2
Strictosidine Synthase Substrate Specificity
1. Introduction
The terpene indole alkaloids (TIA) are a diverse, structurally complex
class of alkaloids that are used for a variety of medicinal purposes such as anti-
cancer and anti-hypertensive agents [1]. In the early steps of the terpene indole
alkaloid biosynthetic pathway, tryptamine 1 and secologanin 2 are condensed to
form strictosidine 3 by the enzyme strictosidine synthase (STR) via a
stereoselective Pictet-Spengler condensation (Figure 2.1) [2-5]. Strictosidine is
then processed by strictosidine glucosidase (SGD) to yield a dialdehyde
intermediate 27, which rearranges to form cathenamine 30 along with other
isomers (28-30) in vitro (Figure 2.1) [6, 7]. Previous studies identified a number
of tryptamine and secologanin analogs that were processed by STR [4]. To
expand the understanding of STR substrate specificity, STR was systematically
probed for the electronic and steric requirements of the indole substrate with
amine substrate analogs la-x, and 49-54 (Figure 2.2) and the steady state
kinetics for a selection of these substrates was determined. Although the Pictet-
Spengler cyclization is critical for the biosynthesis of thousands of alkaloids, little
is known about the details of the enzymatic reaction. These studies provide
mechanistic insights into the STR catalyzed Pictet-Spengler reaction [8, 9].
Additionally, many biosynthetic pathways are flexible enough to
accommodate alternate starting materials [10, 11]. For example, numerous
polyketide and non-ribosomal peptide pathways are capable of producing a wide
variety of unnatural polyketide and peptide products. However, unlike polyketides
and non-ribosomal peptides that are synthesized by an iterative, "assembly-line"
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process [10], TIA are generated from a single common intermediate, strictosidine
that undergoes significant rearrangement to form the scaffolds of the various final
products. It was less clear whether these rearrangement reactions could support
unnatural substrates. A goal of this research is to probe whether the TIA
biosynthetic machinery can be used to produce analogs of alkaloid structures
with novel or improved biological properties. Exploring the substrate scope of the
initial enzymes, STR and SGD, represents the first step towards this goal.
2. Experimental Methods
2.1 Expression of C. roseus Strictosidine Synthase in E. coli
A synthetic gene encoding strictosidine synthase (GENEART) in pPCR-
Script was sub-cloned into the expression vector plADL16 [12] in frame with the
N-terminal maltose binding protein using Ndel and EcoR1 restriction sites. The
resulting vector, pMALCR, was transformed into BL21 (DH3) cells, cultured at
300C to an OD600 of 0.6 (500 mL LB with 2% w/v glucose and 30 pg/mL
kanamycin) and then induced with IPTG (0.5 mM) and incubated at 30°C for an
additional 6.5 hours. Cells were harvested by centrifugation at 41C, suspended
in column buffer (50 mM H2PO 4, 200 mM NaCI, pH 7.0) and lysed by sonication.
Cell lysate was centrifuged at 10,000 x g for 30 min, diluted 2 fold with column
buffer and poured over a column of amylose resin (New England Biolabs) (15
mL, flow rate of 1 mL per minute), washed with column buffer (120 mL) and the
protein was then eluted with elution buffer (50 mM NaH2PO 4, 200mM NaCI, 10
mM maltose, pH 7.0) (40 mL). Protein was dialyzed against column buffer and
concentrated to approximately 20 pM in a centricon concentrator. Expression
and purification was analyzed by SDS-PAGE (Figure 2.3). Protein concentration
was determined using Bio-Rad protein assay micro-assay protocol.
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Figure 2.3: SDS-PAGE of purified maltose binding protein fusion proteins of
strictosidine synthase (STR) and strictosidine glucosidase (SGD). Marker lane
(M) is precision plus dual color protein standards (Bio-rad).
2.2 Expression of C. roseus Strictosidine Glucosidase in E. coli
A synthetic gene encoding strictosidine glucosidase (GENEART) in pPCR-
Script was sub-cloned into the expression vector plADL16 [12] in frame with the
N-terminal maltose binding protein using Ndel and EcoR1 restriction sites. The
resulting vector, pMALCR-Glc, was transformed into BL21 (DH3) cells, cultured
at 30'C to an OD600 of 0.6 (500 mL LB with 2% w/v glucose and 30 [pg/mL
kanamycin) and then induced with IPTG (0.5 mM) and incubated at 300C for an
additional 6.5 hours. Cells were harvested by centrifugation, purified, and
analyzed as described above for STR (Figure 2.3).
2.3 Synthesis of Amine Substrates
Several methods exist for the synthesis of tryptamines. Initially 7-position
substituted tryptamines were synthesized by a Fischer indole synthesis as
previously described [13], since no indole starting materials were commercially
available. Initially, 4- and 6- methyltryptamines were synthesized from
commercially available indole-3-carboxylic acids as previously described [14, 15].
Later, 4-, 6-, and 7-position substituted tryptamines were synthesized from
commercially available indoles as previously described [16, 17]. Benzofuran 49
and benzothiophene 50 derivatives were generated from reduction of the
commercially available nitrile compounds. The pyrrole ethanamine 51 was
synthesized as described [18, 19]. Details of the synthesis by these methods and
compound characterization are located in Appendix A.
2.4 Optimized Secologanin Isolation
Secologanin was isolated from L. tatarica following a modification of a
previously described procedure [20, 21]. Leaves and stems (100 g) from L.
tatarica were ground in a blender with methanol (200 mL). The slurry was
allowed to stand for 50 min and was then filtered over cheesecloth to remove the
solid plant material. This process was repeated until the pulp was a light brown
color. The methanol filtrate (approximately 1 L) was evaporated to dryness
under vacuum and the resulting green syrup was subjected to silica gel column
chromatography (9:1 CH2CI2:CH 30H). Fractions containing secologanin were
pooled, concentrated under vacuum, and the resulting solid was further purified
by C18 column chromatography and eluted with 7:3 water: methanol to yield
purified secologanin (1 g). Proton and carbon NMR and mass spectral data
matched previously reported values [20, 21].
2.5 Activity Assay for Strictosidine Synthase
Strictosidine synthase activity was measured using a modification of a
previously described HPLC assay [22]. Protein (1 pM) was incubated with
tryptamine, secologanin, in 100 mM NaH 2PO4 (pH 6.8) at 300C. An aliquot of the
reaction (20 pL) was directly injected onto the HPLC (Hibar RT 250-4
LiCHrosorb) using a 22 to 67% acetonitrile / aqueous 0.1% trifluoroacetic acid
gradient. The absorbance of tryptamine and strictosidine was monitored at 280
nm. A calibration curve for tryptamine was generated to determine the change in
concentration based on peak area integration. The moles of tryptamine
consumed per minute was plotted and the slope was used to determine the
specific activity of the protein. Kinetic analysis was performed by altering the
substrate concentration under the same assay conditions. Kinetic parameters
were obtained by fitting the rate on the y-axis at various concentrations of
substrate on the x-axis to a logistic curve (equation 1), were A1 is zero, A2 is the
Vmax, p is one, xo is the Km.
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A negative control performed in the absence of enzyme ensured that background
reaction never occurred under assay conditions. Product peaks were collected
and analyzed by electrospray mass spectrometry (ESI-MS). The masses of
product peaks that resulted from the reaction of secologanin and the following
amines were determined by ESI-MS: 3.49 ([M+H] expect. 532.2, obsv. 532.3);
3.48 ([M+H] expect. 548.2, obsv. 548.3); 3a([M+H] expect. 549.2, obsv. 549.2);
3b ([M+H] expect. 549.2, obsv. 549.4); 3c ([M+H] expect. 549.2, obsv. 549.2);
3d ([M+H] expect. 549.2, obsv. 549.2); 3m ([M+H] expect. 545.2, obsv. 545.2);
3n ([M+H] expect. 545.2, obsv. 545.4); 3q ([M+H]' expect. 547.2, obsv. 547.4);
3t ([M+H] expect. 561.2, obsv. 561.3); 3u ([M+H] expect. 561.2, obsv. 561.3);
3x (both diastereomers) ([M+H] expect. 545.2, obsv. 545.3). Synthesis of
authentic racemic standards and determination of chemical reaction rates was
performed by reacting amine and aldehyde substrates (20 mM concentration)
under aqueous conditions (150mM maleic acid, pH 2).
2.6 Activity Assay for Strictosidine-p-Glucosidase
To monitor glucosidase activity, amine substrates were incubated with
secologanin (2), and strictosidine synthase under the conditions described in
section 2.5. Once the strictosidine analogs were formed SGD (luM) was added.
The reaction was quenched with methanol and the disappearance of the starting
strictosidine analog was monitored by HPLC as described above using a 22 to
100% acetonitrile/aqueous 0.1% trifluoroacetic acid gradient. Alternatively, since
cathenamine is not water soluble, the enzymatic reaction was briefly centrifuged,
and the insoluble precipitate was analyzed by ESI-MS to yield a mass consistent
with the cathenamine. Cathenamine 30a ([M+H] expect. 369.4, obsv. 369.5) and
30m ([M+H] expect. 365.4, obsv. 365.5).
3. Results
3.1 Strictosidine Synthase Activity Assay
Enzyme activity was measured by an HPLC assay in which the amine
starting material disappearance and the product formation was monitored by UV
detection. In all cases, product formation was assessed by the appearance of a
new peak on an HPLC chromatogram that co-eluted with a chemically
synthesized (mixture of diastereomers) standard and displayed the correct
molecular weight by ESI mass spectrometry (Figure 2.4A). Kinetic parameters
(Km and kcat) were calculated for a selection of the most active amine substrates
(la-d, 1m-n, lq, lu, and 49; Table 2.1) using STR heterologously expressed in
E. coli and purified by affinity chromatography (Figure 2.3).
3.2 Electron Deficient Substrates for STR
To explore the effect of electron withdrawing groups on catalysis, the
indole ring was substituted with electron-withdrawing substituents at each of the
indole ring positions (Table 2.2, entry i, ii, and iii and Table 2.1). STR converted
4-,5-, 6- and 7-fluorotryptamines (la-d) to the corresponding strictosidine analog
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Figure 2.4: Representative chromatograms illustrating the STR and SGD activity
assay. A) Strictosidine synthase HPLC assay with 4-fluorotryptamine la. B)
Mass chromatogram of deglycosylated 4-fluorostrictosidine 30a.
Table 2.1: Kinetic parameters for selected tryptamine substrates with STR
(mean + se, n=2, * n=1).
Amine substrate Km kcat kca/Km
(p M) (min-') (pMA' s1)
tryptamine 1 7.4 0.90 2000
4-fluorotryptamine la 49 + 1 0.30 + 0.05 100
5-fluorotryptamine lb 18 + 16 0.044 + 0.004 40
6-fluorotryptamine 1c 19 + 14 0.08 + 0.03 72
7-flurorotryptamine* Id 12 0.05 73
benzofuran ethanamine* 49 8 0.01 17
4-methyltryptamine in 75 + 19 0.15 + 0.01 34
5-hydroxytryptamine* iq 1200 0.10 1.3
7-methyItryptamine* In 198 0.23 20
7-methoxytryptamine* 1u 1800 0.22 2.0
Table 2.2: Electron deficient tryptamine substrates for STR.
Strictosidine Analog
la R4 =F, R 5 ,6 ,7 =H R5 R4
1b R 5=F, R4,6 ,7=H R N
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in the presence of secologanin. Kinetic analysis revealed that conversion of
fluorinated tryptamines to strictosidine resulted in a decrease in kcat in each case,
suggesting the enzymatic reaction is inherently dependent on the electron
density of the substrate (Table 2.1). Although the kcat/Km ratios for all fluorinated
derivatives la-1 d are comparable, the Km for 4-fluorotryptamine (la) is
approximately 10 fold higher than the Km value for the other fluorinated
derivatives. However, the kcat for 4-fluorotryptamine la is also significantly higher
than the other fluorotryptamine substrates (1b-1d). Interestingly, the rate of the
chemically catalyzed Pictet-Spengler reaction between 4- or 7-fluorotryptamine
(la and Id, Table 2.3) and secologanin 2 occurred at a slower rate than the
same reaction with 6- or 5-fluorotryptamine (lb and Ic, Table 2.3). These
findings suggest some interesting differences in the reaction catalyzed by STR
compared to the chemically catalyzed reaction. One possible explanation for the
observed decrease in rate with electron withdrawing substitutions is a decrease
in the rate of formation of the cyclized intermediate when fluorine is present at
these positions (Figure 2.1).
Chloro and bromo substitutions on the indole ring were also tested for
formation of strictosidine analogs. No products were produced from 5- and 6-
bromo and chlorotryptamine substrates (Ie-1h) while both 4- and 7-bromo and
chlorotryptamines (1i-11) were processed by the enzyme to yield the
corresponding chloro and bromostrictosidines (3i-31). The bromo and
chlorotryptamine substrates were not fully analyzed kinetically and therefore no
Table 2.3: Relative rate of chemical formation of strictosidine and vincoside
analogs. The values are expressed as percent of the tryptamine control. NR =
no product formation was observed.
Amine substrate Chemical % of control
Reaction Rate
(pM*s -1)
Tryptamine 1 0.51 100
4-fluorotryptamine la 0.06 12
5-fluorotryptamine lb 0.23 45
6-fluorotryptamine 1c 0.28 55
7-fluorotryptamine ld 0.07 13
4-methyltryptamine lm 0.43 85
6-methyltryptamine 1p 0.48 94
7-methyltryptamine 1 n 0.54 106
benzofuran 49 NR
benzothiophene 50 NR
conclusion can be made about the effect of these electron withdrawing
substitutions on the formation of strictosidine by STR.
To further explore the effect of the electronic nature of the indole ring on
the formation of strictosidine, STR catalyzed conversion of the isosteric, electron
deficient heterocyclic derivatives, both the 3-(2-aminoethyl)-benzofuran 49 [23]
and benzothiophene 50 [24] , were assayed. Precedence exists for benzofuran
and benzothiophene heterocycles with interesting biological properties [25, 26].
Both compounds were turned over by STR in the presence of the aldehyde
substrate secologanin 2, and a single diastereomer was observed, indicating that
enantioselective enzymatic catalysis was not compromised (Table 2.2, entry iv).
STR converted the alternate heterocycles (49 and 50) at a diminished rate
relative to the tryptamine 1 substrate. Although the low activity of the
benzothiophene substrate 50 precluded a quantitative comparison of 49 and 50,
it was clear that the rate of reaction of benzothiophene 50 is significantly slower
than benzofuran 49. Notably, no chemical reaction of benzofuran 49 and
benzothiophene 50 occurred at 40 mM concentration of these substrates and
secologanin under acidic conditions demonstrating that the enzyme can catalyze
product formation with relatively chemically inactive substrates with complete
enantioselective control. Since the Pictet-Spengler cyclization is inherently
dependent on an electron rich aminoethylarene substrate [9], the decreased
electron density of the benzofuran and benzothiophene rings is the likely cause
of the slower rate compared to the natural tryptamine substrate. Alternatively,
strictosidine synthase may utilize a specific hydrogen bonding interaction to the
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indole nitrogen. Not surprisingly, the isosteric benzofuran 49 exhibits a Km value
close to that of tryptamine but displays a significantly reduced kcat value,
suggesting that the electron deficient nature of the heterocyclic ring is slowing
catalysis (Table 2.1).
3.3 Sterically Modified Tryptamines as Substrates for STR
Early qualitative studies, performed after STR was first isolated, indicated
that some substitution on the indole ring was tolerated [4]. To rigorously quantify
the effect of indole ring substitution on enzyme catalysis, each position of the
indole ring was systematically substituted with a methyl group (Im-1p), (Table
2.4, entries i and ii) and the kinetic parameters of the active substrates were
measured (Table 2.1). In general, reactivity of substrates with methyl
substitutions in the tryptamine-4-position (1 m) and tryptamine-7-position (1 p)
indole ring positions was significantly higher than substrates with substitutions at
the tryptamine-5-position (In) and tryptamine-6-position (1 o) (Table 2.4, entries i
and ii). The Km value for the 4-methyltryptamine lm was approximately 2-fold
lower than the Km value for 7-methyltryptamine In (Table 2.1), while 5- and 6-
methyltryptamines were completely inactive. This pattern of substrate specificity
is similar to that observed for 5- and 6-chloro and bromotryptamines (1f-1h).
Substitution with a hydroxyl group in the 5-position (1q, Table 2.4, entry iii and
Table 2.1) was converted to the corresponding strictosidine analog by STR with
a Km 60-fold higher then native tryptamine 1 substrate. Therefore, the binding
Table 2.4: Sterically modified tryptamine substrates for STR.
Entry Amine Substrate Strictosidine Analog
i NH lo R5=Me, R6=H No Reaction
R5 N2 lp R6=Me, R=H
N 1v R5=OMe, R6=H
R6 ~H N  w R6=OMe, R5=HH
NR NH 2
R7
R5-s NH2
N
H
lm R4=Me, R7=H
In R7=Me, R4=H
It R4=OMe, R7=H
lu R7=OMe, R4=H
Iq R5=OH, R6=H
R4
i \.N O-Glec
N "H
H 0
H3C0 2 C
No Reaction
e\ N/
N 'H O-GIc
H H
H 3 C0 20
i
pocket of the enzyme can better tolerate a hydrophilic hydroxyl substituent than a
hydrophobic methyl group at the 5-position.
Rates of acid (non-enzymatically) catalyzed Pictet-Spengler reactions with
5-methyltryptamine lo and 5-hydroxytryptamine 1q suggest that the inherent
reactivity of compounds lo and lq are similar (Table 2.3). N-methyl tryptamine
1r (Table 2.4, entry iv) was not a competent substrate, suggesting that the
enzyme tolerates only small steric perturbations at the indole nitrogen. N-w-
methyltryptamine ls (Table 2.4, entry v) was turned over by STR into the
corresponding methylated derivative. In addition, both 4- and 7-
methoxytryptamines (It-u) were converted to strictosidine analogs thereby
confirming the relative promiscuity of the 4-, and 7-positions (Table 2.4, entry ii),
while 5- and 6-methoxytryptamines were not converted by the enzyme (1v-1w,
Table 2.4, entry i). Kinetic analysis of 7-methoxytryptamine 1 u resulted in a Km
250 times that observed for the natural tryptamine 1, while the kcat was of the
same order of magnitude.
3.4 Alternative Heterocycles as Substrates for STR
As mentioned above the isosteric, alternative heterocycles benzofuran 49
and benzothiophene 50 were processed by strictosidine synthase (Table 2.2,
entry iv). The 2-pyrrole-3-ethylamine analog 51 has been shown to undergo a
non-enzymatically catalyzed Pictet-Spengler reaction [27]. Surprisingly, this
smaller substrate along with the isosteric histamine (not shown) were not turned
over by STR, indicating that the benzyl moiety is absolutely required for
recognition by the enzyme (Table 2.5, entry i). Early studies previously
established that tryptophan 25, phenyl ethylamine (not shown) and tyramine 52
are not accepted by strictosidine synthase [4], and since pyrrole substrates are
also not tolerated (Table 2.5, entry ii), we conclude that the basic heterocyclic
framework is required for recognition by this enzyme. Interestingly, the only other
sequenced "Pictet-Spenglerase" (norcoclaurine synthase), which utilizes tyrosine
derived amine and aldehyde substrates, exhibits no sequence homology to
strictosidine synthase [28, 29].
Furthermore, STR proved to have stringent requirements for the side
chain of tryptamine, as evidenced by the lack of turnover exhibited by 3-
methylamine-indole 53 and 3-propylamine-indole 54 (Table 2.5, entry iii) [30].
However, we have found that 2-(1-methyl)-ethylaminoindole (±-a-
methyltryptamine, lx, Table 2.5, entry iv), yielded a small amount of product. No
product formation was observed with the bulkier a-di-methyltryptamine (not
shown). These data indicate that the enzyme has evolved a highly specific
binding pocket for the tryptamine side chain. Perhaps the positioning of this side
chain is essential for correct placement of the imine for attack (Figure 1.1), or
perhaps the enzyme has evolved a selective binding pocket at the side chain to
prevent reaction with the relatively abundant tryptophan 25.
3.5 Turnover of Strictosidine Analogs by Strictosidine Glucosidase
While these initial results suggest that STR can produce a range of
strictosidine analogs, it remains unclear whether the downstream biosynthetic
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Table 2.5: Alternate heterocycles and side-chain modified tryptamine
substrates for STR.
Entry Amine Substrate Strictosidine Analog
a NH2 51 No ReactionNH2
N
H
II 52 No Reaction
HO NH2
iii ( nNH2 53 n=1 No Reaction
i 54 n=3
N
H
iv p lx D,L-3-dimethyl Me
NH2  NH O-Glc
\NGcH O-G
NH
H H3C0 2C
v p 25 L-p-COOH No Reaction
INH 2
H
machinery can process these alternate intermediates to produce novel,
biologically active alkaloids. In the next step of the pathway, a dedicated
glucosidase, strictosidine-P-glucosidase (SGD) hydrolyzes the glycosidic linkage
of strictosidine 3 to reveal a dialdehyde that rearranges in vitro to form
cathenamine 30, an intermediate presumably on pathway for the corynanthe
alkaloids ajmalicine 4 and serpentine 5 (Figure 1.1) [6, 7]. Therefore, the first two
enzymes construct the basic 5-ring framework of the corynanthe alkaloids, and
subsequent enzymes in the terpene indole alkaloid pathways tailor this structure.
To evaluate whether cathenamine 30 derivatives could be enzymatically
produced from the corresponding strictosidine analogs, we incubated all
enzymatically generated strictosidine derivatives (Table 2.2-2.4, column 4) with
SGD. All strictosidine derivatives were processed by SGD as monitored by the
disappearance of the strictosidine derivative peak by HPLC. Additionally, when
the 4-fluorotryptamine and 4-methyltryptamine substrates (la and im) were
incubated in the presence of secologanin 2 with both enzymes, products with the
expected molecular weight were observed when analyzed by mass spectroscopy
(Figure 2.4B). The N-w-methylstrictosidine 3s analog (Table 2.3, entry vi) does
not form an analog of cathenamine 30, but instead as previously reported, and
analog of N-methyl-21-13-hydroxy-mayumbine or 3-isocorreantine is formed [7,
31, 32]. These results suggest that the substrate specificities of STR and SGD
are sufficiently complementary to produce a variety of terpene indole alkaloid
analogs.
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4. Discussion
The initial enzyme in the biosynthesis of all TIA, strictosidine synthase,
catalyzes a stereoselective Pictet-Spengler condensation. Previous studies have
established that this enzyme can tolerate modification to the tryptamine
substrate, though only a limited subset of substrates were tested in early studies
[4]. This study systematically probes the substrate requirements for STR and
establishes a subset of tryptamine analogs, which can be utilized in future work
to generate alkaloid analogs.
The reaction catalyzed by STR demonstrated sensitivity to electronic
perturbations to the indole ring. Specifically, addition of electron withdrawing
fluoro groups to the 4-, 5-, 6-, and 7-positions on the indole ring resulted in
decrease rate of turnover of these analogs. Addition of fluoro group at the 4-
position affected the maximum rate of the reaction the least. Interestingly, the
electron deficient benzofuran 49 and benzothiophene 50 analogs were turned
over by strictosidine synthase suggesting that the enzyme is capable of
catalyzing the Pictet-Spengler reaction with these un-reactive substrates.
Tryptamines substituted at the 4- and 7- positions with methyl (1 m-n),
methoxy (1t-u), chloro (1i-j), and bromo (1 k-1) groups were converted to the
expected strictosidine analogs in the presence of STR. However, 5- and 6-
methyltryptamine (lo-p), 5- and 6-chlorotryptamine (le-g), 5- and 6-
bromotryptamine (Ih-i), 5- and 6-methoxytryptamine (1v-w) were not converted
to the expected strictosidine analog by STR. The use of alternate heterocycles by
STR was limited to substrates with the benzyl ring moiety; pyrrole 51 or
histamine (not shown) derived substrates were completely un-reactive.
Additionally, STR did not convert tryptamines modified at the ethylamine side
chain to the corresponding strictosidine analogs.
Kinetic parameters of strictosidine formation for a sub-set of accepted
tryptamines was determined. Substitution on the indole ring is known to have an
effect on the kinetics many aromatic substitutions reactions. The Hammett
equation is a simple formula that expresses the relationship of the rate or
equilibrium constant for a reaction and the identity of the substitution (equation 2)
[33].
klog = po (2)ko
In this equation, k is the rate or equilibrium constant for a reaction with
substituent X, ko is the rate or equilibrium constant for the unsubstituted reaction,
p is a reaction constant dependent on the reaction mechanism, medium,
temperature, and the distance of the substitution from the site of the reaction,
and a is a constant dependent on the substituent X and its position relative to the
site of the reaction [33]. The a constants determined for substitution of benzene
have been applied to electrophilic aromatic substitution reactions involving indole
substrates [34]. For reaction at the indole-2-position, indole 4-and 6-position
substitutions behave as para position substituents, while 5- and 7-position
substitutions behave as meta position substituents. To determine the effect of
indole substitutions on the Pictet-Spengler reaction catalyzed by STR, the kcat for
the tryptamine analogs tested were plotted based on the Hammett equation
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(Figure 2.5). The o' values used were those determined by Brown for reactions
in which electron donating groups can interact with a developing positive charge
in the transition state [35], this is particularly important for electrophilic aromatic
substitutions such as the Pictet-Spengler reaction analyzed in this study. The
resulting Hammett plot shows the expected correlation between the reaction rate
and the type and position of the substitution made to the tryptamine substrate
(Figure 2.5).
In addition, the substrate specificity for secologanin analogs was explored
using semi-synthetic secologanin derivatives [36, 37]. Two of the key functional
groups of the secologanin substrate were modified to assess the aldehyde
substrate requirements. A streamlined gram-scale isolation protocol of
secologanin from a local source of Lonicera tatarica enabled a semi-synthetic
approach to yield secologanin derivatives. Olefin cross metathesis was used to
introduce a variety of alkyl groups at the vinyl position of secologanin [37].
However, the bulkier groups at the vinyl position completely prevented turnover
by STR. In contrast, trans-esterification at the methyl ester with larger alkyl
groups [37] resulted in secologanin analogs, including a pentynyl ester that could
be further modified by bio-orthogonal copper catalyzed 1,3-dipolar cycloaddition,
which were turned over by the enzyme to yield the corresponding strictosidine
analogues, suggesting that this is a more promising position for derivatization
[36].
After completion of this work the crystal structure for STR from R.
serpentina was solved [38]. The crystal structure of strictosidine synthase co-
0.0-
-0.4-
-0.8-
0
-1.2
-0.4
otryptamine
o4F
7Me o70Me
o4Me
o6F
-0.2 0.0
-I- 0.2
0
0.4
Figure 2.5: Hammett plot for the strictosidine synthase catalyzed Pictet-
Spengler reaction.
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crystallized with the tryptamine substrate identified the active site residues
involved in binding and catalysis of strictosidine formation. The structure
revealed that tryptamine amine coordinated an active site glutamate residue
(Glu-309) (Figure 2.6). Mutation of this glutamate residue resulted in an 890-fold
decrease in the kcat of STR and no change in the Km for the tryptamine substrate.
These results suggest that this active site glutamate residue is involved in the
catalysis of enzymatic strictosidine formation. Additionally, active site residues
near the tryptamine substrate were identified; including tyrosine-151,
phenylalanine-226, and valine-208 (Figure 2.6). The close proximity of valine-
208 (Val-214, C. roseus numbering) to the 5-position of tryptamine, and led
researchers to investigate mutation at this positions to expand the substrate
specificity of strictosidine synthase [39, 40]. Researchers found that mutation of
Val-208 to alanine (R. serpentina) [40] or Val-214 to methionine (C. roseus) [39]
resulted in conversion of 5-methyltryptmaine lo to the corresponding
strictosidine analog. In addition to 5-methyltryptamine lo, 5-chlorotryptamine le
and bromotryptamine 1g were also converted to the corresponding strictosidine
analogs by the C. roseus V214M mutant. Additionally, Phe-232 (C. roseus
numbering, Phe-226 R. serpentina numbering), which is in the proximity of the
ethylamine side chain of tryptamine, to leucine resulted in turnover of D-
tryptophanol to form the corresponding strictosidine analog [39].
Rigorous mechanistic characterization of the C. roseus STR catalyzed
Pictet-Spengler condensation has also been performed and lends insight into
enzymatic strictosidine synthesis [41]. This study revealed that the rate-
Phe-226/232
Val-208/214:
I3.8 Glu-309
NH8  HO.6 O
N r2 2.6
Tyr-151/155'
Figure 2.6: Tryptamine binding site residues in the crystal
structure of strictosidine synthase (R. serpentina). Amino
acids numbering shown is R. serpentina numbering/C.
roseus numbering.
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controlling step, as determined by the observation of a primary kinetic isotope
effect with 2-deuterated tryptamine, was re-aromatization of the positively
charged p-carboline intermediate (Figure 2.7). Although the observation of a
primary kinetic isotope effect was not expected, the results suggest that the
cyclized intermediate can re-aromatize either by deprotonation to form
strictosidine or reformation of the imine intermediate. The reactivity of the
electron deficient substrates with fluoro substitutions on the indole ring or the
electron deficient heterocycle, benzofuran-3-ethanamine, exhibit reduced kcat
relative to the natural substrate tryptamine. Given the mechanism of catalysis
proposed by Maresh and co-workers, one might speculate that the equilibrium
between the positively charged p-carboline and the imine intermediate is
perturbed toward imine formation with electron deficient indoles.
Furthermore, kinetic analysis of strictosidine glucosidase (SGD) with
various strictosidine analogs generated in this study has been performed [42].
This data supports our initial results which indicate that SGD is tolerant of
substitutions to the indole ring [42]. All strictosidine substrates tested had similar
Km and kcat to the natural substrate strictosidine 3.
5. Conclusions
Strictosidine synthase and strictosidine-P-glucosidase are the initial
enzymes in the biosynthesis of TIA in C. roseus. The substrate specificity of
these enzymes was determined and it was found that both strictosidine synthase
and strictosidine glucosidase are able to accept substrates modified on the indole
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Figure 2.7 : Pictet-Spengler reaction catalyzed by STR.
ring. The kinetic analysis of the tryptamine analogs revealed catalytic efficiencies
only an order of magnitude less than the naturally occurring substrate,
suggesting this pathway will be amicable to PDB utilizing this set of tryptamine
substrates. Future work will explore the use of these active substrates for the
production of more complex terpene indole alkaloids in vivo via precursor
directed biosynthesis.
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Chapter 3
Precursor Directed Biosynthesis of Terpene Indole Alkaloids in the Medicinal
Plant Catharanthus roseus
1. Introduction
Natural products are privileged scaffolds, many of which have evolved to
exhibit potent biological activity. Accordingly, natural products provide some of
the most valuable pharmaceutical agents in use today. However, since these
compounds are not produced by the organism to treat human disease, it is not
surprising that modification of the natural product structure often improves the
pharmacological properties of the compound. For example, the toxicity and
insolubility of the topoisomerase I inhibitor camptothecin makes it unsuitable as a
chemotherapy agent [1], the more water soluble semi-synthetically derived
camptothecin analogs, topotecan 17 (Glaxo Smith Kline) and irinotecan 18
(Pfizer) are used clinically for the treatment of certain cancers (Figure 1.3) [2].
An attractive alternative to total or semi-synthesis of new natural product analogs
is the use of the biosynthetic machinery to ferment new "unnatural" compounds
with improved properties. Using this method, termed precursor directed
biosynthesis (PDB) (Figure 3.1), a diverse array of secondary metabolite
derivatives have been produced in microbial cultures [3].
The method of PDB involves several major experimental concerns. PDB
begins by establishment and maintenance of a culture of the desired producing
organism having a known secondary metabolite production profile. In addition, a
fundamental understanding of the biosynthesis of the desired compounds is
necessary to explore appropriate precursors to utilize in the production of
secondary metabolite derivatives. Additionally, in order to perform PDB studies,
A. Natural Product Biosynthesis
EnzA EnzC
Enz B 0 B I
natural product
B. Precursor Directed Biosynthesis
Enz Enz C A A
Enz B
natural product
C natural product natural product
analog
substrate
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C. Experimental Concerns
1. Maintained Culture
2. Well Characterized Biosynthetic Intermediates and Products
3. Analytical System for Detection of Products and Product Analogs
4. Optimization of Product Production
5. Isolation and Characterization of Product Analogs
Figure 3.1: Biosynthetic production of natural product analogs by PDB. A)
Natural product biosynthesis; B) biosynthesis of natural product derivatives
by PDB; C) Experimental concerns for sucessful PDB of natural product
derivatives.
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an analytical system for the detection of both natural and substrate analog
derived products must be established. Once established, variation of timing and
concentration of precursor feeding determines the optimal conditions for
production of the desired derivatives. Finally, after optimization, the desired
metabolites are isolated and characterized to validate the method.
In this study the biosynthetic production of analogs of the terpene indole
alkaloids (TIA) produced by Catharanthus roseus was explored. TIA are plant
natural products with diverse structures and biological activities. A highly
branched biosynthetic pathway is responsible for the production of approximately
130 different alkaloids in Madagascar periwinkle (C. roseus) from a common
biosynthetic intermediate, strictosidine 3 [4]. The most well known of these
alkaloids in the anti-cancer agent vinblastine 15, resulting from the dimerization
of 8 and 9 (Figure 3.2).
Although numerous biosynthetic pathways incorporate analogs of starting
materials to yield novel natural products, it was not clear whether this eukaryotic
TIA pathway could utilize substrate analogs to make new alkaloids. For PDB,
both differentiated C. roseus (seedlings) and hairy root cultures were utilized to
produce alkaloid derivatives (Figure 3.3). Seedlings produce a greater variety of
TIA, while root cultures produce a smaller subset of TIA in greater quantities.
Here we describe feeding tryptamine analogs la-d, li-n, it-w, and 49 and
strictosidine analogs 3e-h, 3o-p, and 3v-w (Figure 3.3) to C. roseus to
demonstrate that the enzymes of this pathway can turnover substrate analogs,
and that the electronic and steric properties of the substrates affect the specific
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Figure 3.3: Experimental procedure for PDB of TIA analogs in C. roseus hairy roots and seedlings.
TIA produced from this highly branched pathway. In this study, high resolution
LCMS (HR-LCMS) was used in conjunction with the extensive knowledge of the
C. roseus metabolome to predict the structures of the analogs produced by this
method. After optimization of precursor feeding timing and concentration,
several of the most abundant alkaloid analogs were isolated and the predicted
structures validated by NMR spectroscopy. Our work demonstrates that the TIA
biosynthetic machinery can produce many novel alkaloid analogs and the
potential of this pathway for future metabolic engineering efforts.
2. Experimental Methods
2.1 Synthesis of Amine Substrate Analogs
Tryptamine analogs were synthesized as described in Chapter 2 and
Appendix A.
2.2 Chemical Synthesis of Strictosidine Analogs
Tryptamine (0.05 mmol) and secologanin (0.1 mmol) were combined and
dissolved in 500 pL of maleic acid (200 mM, pH = 2). The mixture stirred at room
temperature for 24 hours and then purified by preparative HPLC to give 5-10 mg
of product. In vivo studies typically required 20-30 mg of material.
6-Methylstrictosidine 3p
1H NMR (CD3OD) 6 7.81 (1H, s), 7.35 (1H, d, J 8.1), 7.11 (1H, s), 6.9 (1H, d, J
8.0), 5.86 (2H, m), 5.37 (1H, d, J 17.3), 5.28 (1H, d, J 10.7), 4.81 (1H, d, J 7.92),
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4.6 (1H, d, J 11.53), 4.0 (1H, m), 3.80 (3H, s), 3.73 (1H, dt, 12.2, 4.9), 3.67 (1H,
dd, 7.2 and 11.8), 3.47-3.34 (3H, m), 3.24 (1H, d, 3.6), 3.22 (1H, dd, 1.9 and
9.18), 3.1 (3H, m), 2.75 (1H, td, 4.9 and8.34), 2.4 (3H, s), 2.32 (1H, td, ), 2.2 (1H,
td, ). 13C NMR (CD30D) 6 170.8, 156.4, 138.2, 135.0, 132.9, 128.9, 124.9,
121.8, 119.3, 118.3, 111.7, 108.5, 106.5, 99.9, 96.8, 78.4, 77.5, 74.2, 71.2, 62.5,
52.5, 52.1, 44.9, 42.1, 34.3, 32.1, 21.4, 19.1. ESI-MS molecular formula
C28H37N209, [M+H] calculated 545.2499, observed 545.2489.
5-Methylstrictosidine 3o
'H NMR (CD30D) 6 7.81 (1H, s), 7.25 (1H, s), 7.20 (1H, d, J 8.5), 6.99 (1H, d, J
8.5), 5.8 (2H, m), 5.36 (1H, d, J 17.1), 5.29 (1H, d, J 10.9), 4.80 (1H, d, J 7.9),
4.64 (1H, d, J 10.9), 3.98 (1H, m), 3.80 (3H, s), 3.75 (1H, m), 3.65 (1H, dd, J 6.7,
11.6), 3.48-3.33 (3H, m), 3.24 (1H, d, 4.2), 3.22 (1H, dd, 1.9, 9.2) 3.10-3.00 (3H,
m), 2.75 (1H, m), 2.4 (3H, s), 2.35 (1H, td, J 12.8, 2.4), 2.24 (1H, td, 12.2, 3.6).
13C NMR (CD 30D) 6 170.8, 156.4, 136.0, 135.0, 129.7, 129.4, 127.2, 124.6,
119.3, 118.3, 111.5, 108.5, 106.2, 99.0, 96.8, 78.4, 77.5, 74.2. 71.3, 62.5, 52.6,
52.1, 44.9, 42.2, 34.3, 32.1, 21.1, 19.0. ESI-MS molecular formula
C28H37N209, [M+H] calculated 545.2499, observed 545.2521.
6-Methoxystrictosidine 3w
'H NMR (CD30D) 6 7.8 (1H, s), 7.34 (1H, d, J 8.5), 6.83 (1H, d, J 2.4), 6.72 (1H,
dd, J 2.4, 9.1), 5.88 (2H, m), 5.36 (1H, d, J 17.7), 5.28 (1H, d, 10.3), 4.9 (3H, s),
4.80 (1H, d, J 7.9), 4.62 (1H, d, J 10.9), 3.99 (1H, dd, 1.8, 11.5), 3.79 (3H, s),
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3.73 (1H, m), 3.66 (1H, dd, 6.7, 11.6), 3.46-3.34 (3H, m), 3.24 (1H, d, J 5.5), 3.22
(1H, dd, 1.9, 9.2), 3.1-3.0 (2H, m), 2.76 (1H, m), 2.33 (1H, td, J 2.4, 14.6), 2.23
(1H, td, J 3.6 and 11.5). 13C NMR (CD 30D) 6 170.7, 157.87, 156.4, 138.5,
134.9, 128.3, 121.3, 119.3, 119.2, 110.1, 108.5, 106.6, 99.9, 96.8, 95.1, 78.3,
77.5, 74.2, 71.3, 62.5, 55.4, 52.5, 52.1, 44.9, 42.1, 34.4, 32.0, 19.1. ESI-MS
molecular formula C28H37N2010, [M+H] calculated 561.2448, observed
561.2455.
5-Methoxystrictosidine 3v
1H NMR (500 MHz, CD 30D) 6 7.81 (s, 1H), 7.20 (d, J = 9.0, 1H), 6.96 (d, J = 2.3,
1 H), 6.79 (dd, J = 8.8, 2.5, 1 H), 5.94 - 5.75 (m, 2H), 5.35 (dt, J = 17.3, 1.3, 1 H),
5.31 - 5.23 (m, 1H), 4.80 (d, J = 7.9, 2H), 4.71 - 4.51 (m, 2H), 4.03 - 3.92 (m,
1H), 3.80 (s, 3H), 3.80 (s, 3H), 3.72 (s, 1 H), 3.63 (dd, J = 11.8, 7.1, 1H), 3.45 (s,
1H), 3.42 - 3.34 (m, 2H), 3.22 (ddd, J = 9.2, 8.4, 3.2, 3H), 3.06 (dqd, J = 6.6, 2.8,
0.6, 3H), 2.82 - 2.71 (m, 1H), 2.32 (s, 1H), 2.25 - 2.17 (m, 1H). ESI-MS
molecular formula C28H37N2010, [M+H] calculated 561.2448, observed
561.2443.
5-Chlorostrictosidine 3e
1H NMR (500 MHz, CD 30D) 6 7.8 (1H, s), 7.47 (1H, d, J 1.83), 7.29 (1H, d, J
9.2), 7.12 (1H, dd, J 8.5 and 1.8 Hz), 5.89 (2H, m), 5.36 (1H, d, J 17.0 Hz), 5.28
(1H, d, J 10.4 Hz), 4.80 (1H, d, J 7.9 Hz), 4.68 (1H, d, 10.9 Hz), 3.98 (1H, dd,
11.6, 1.8 Hz), 3.80 ( 3H, s), 3.75 (1H, m), 3.65 (1H, m), 3.47 (1H, m), 3.42 (1H, t,
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J 9.2), 3.36 (1H, m), 3.25 (1H, m), 3.1-3.0 (2H, m), 2.75 (1H, m), 2.35 (1H, m),
2.25 (1H, m). ESI-MS molecular formula C27H34N209CI, [M+H] calculated
565.1953, observed 561.1956.
6-Chlorostrictosidine 3f
'H NMR (500 MHz, CD3OD) 6 7.79 (s, 1H), 7.23 (dd, J = 8.1, 0.9, 1H), 7.06 -
6.91 (m, 3H), 5.85 (d, J = 8.7, 2H), 5.43 - 5.24 (m, 5H), 4.79 (d, J = 7.9, 1 H),
4.03 - 3.94 (m, 1 H), 3.93 - 3.81 (m, 2H), 3.81 - 3.77 (m, 2H), 3.76 - 3.70 (m,
1H), 3.64 (tdd, J = 10.7, 6.6, 4.0, 3H), 2.32 (dd, J = 14.1, 7.3, 1H), 2.13 - 2.02
(m, 2H). ESI-MS molecular formula C27H34N209CI, [M+H] calculated
565.1953, observed 565.1936.
5-Bromostrictosidine 3g
'H NMR (600 MHz, CD3OD) 6 7.84 (s, 1H), 7.66 (s, 1H), 7.34 (s, 1H), 7.26 (d, J=
8.0, 2H), 5.87 (d, J = 8.8, 1H), 5.38 (d, J = 17.3, 1H), 5.30 (d, J = 10.7, 1H), 4.82
(d, J = 7.9, 1H), 4.70 (d, J = 12.7, 2H), 4.00 (d, J = 7.3, 6H), 3.78 - 3.61 (m, 5H),
3.44 (d, J = 6.5, 7H), 3.26 - 3.19 (m, 4H), 3.14 - 3.06 (m, 3H), 2.39 - 2.29 (m,
1 H), 2.25 (t, J = 11.6, 1 H).
6-Bromostrictosidine 3h
'H NMR (500 MHz, CD30D) 6 7.84 (s, 1H), 7.47 (dd, J = 7.9, 0.8, 1H), 7.32 (dd,
J = 7.6, 0.8, 1 H), 6.98 (d, J = 7.8, 1 H), 5.96 (d, J = 9.4, 1 H), 5.92 - 5.82 (m, 1 H),
5.34 (dt, J = 17.4, 1.4, 1 H), 5.30 - 5.23 (m, 1 H), 4.80 (d, J = 7.9, 1 H), 4.67 - 4.58
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(m, 1 H), 3.98 (dd, J = 11.8, 2.0, 1 H), 3.81 (s, 3H), 3.74 - 3.66 (m, 1 H), 3.60 (dd,
J = 11.8, 7.4, 1H), 3.47 (d, J = 7.9, 1H), 3.42 - 3.35 (m, 2H), 3.20 (ddd, J = 14.1,
9.5, 8.5, 2H), 3.12 - 3.03 (m, 3H), 2.80 - 2.70 (m, 1H), 2.58 - 2.50 (m, 1H), 2.26
- 2.18 (m, 1H). ESI-MS molecular formula C27H34N209Br, [M+H] calculated
609.1448, observed 609.1453.
2.3 PDB in Seedlings
MS media (pH = 5.7, adjusted with KOH) containing 2 g/L phytogel was
autoclaved and allowed to cool to 60-40 oC. Tryptamine analogs as
hydrochloride salts were dissolved in water (10 mM), syringe filtered through a
0.2 pm filter to sterilize. To the cooled MS media was added MS vitamins (1 mL,
1000x stock per liter) and the sterilized tryptamine analogs to a final
concentration of 1mM. Alternatively, strictosidine analogs were dissolved in
DMSO (100 mM) and added to the MS media with vitamins at 1 mM final
concentration. The media was added to a 6-well plate (5 mL/well) and allowed to
solidify. C. roseus seeds (Horizonherbs) were sterilized for 30 s in ethanol, 10
min in 10% bleach, filtered under vacuum and washed three times with filter
sterilized water. The seeds were then transplanted one at a time to the 6-well
plate (9 seeds per well). Seedlings were grown in the dark for 7 days and then
under incandescent light with 16 h light and 8 h dark for 14 days, yielding
approximately 0.25 g of seedlings per plate. No growth inhibition was seen in the
plates containing analog compared to the control plates. Plant material was
collected and alkaloid material extracted as described below.
105
2.4 PDB in C. roseus Hairy Root Culture
C. roseus hairy root cultures (obtained from the Professor Caroline Lee
Parson's at Northeastern University), were sub-cultured in 14 mL falcon tubes
containing 5 mL of half strength Gamborg's media and vitamins (pH = 5.7) and
grown for 14 days at 26 oC shaking at 50 rpm. Tryptamine analogs (10 mM in
water) were added at day 14 to a final concentration of 0.5 mM. Alternatively,
strictosidine analogs (100 mM in DMSO) were added at day 14 of culture to a
final concentration of 0.5 mM. After 7 days of culture in the presence of the
substrate analogs, the roots were removed from the media, blotted with a paper
towel to remove any remaining media and were extracted as described below.
Hairy root cultures were maintained by sub-culturing in 250 mL flasks containing
50 mL of Gamborg's media with vitamins lacking a tryptamine substrate. The
maintenance cultures were grown for 21 days between each sub-culture. For
substrate concentration studies, the final concentration of tryptamine analog
added at day 14 was varied and sterile water was added to cultures to
standardize the total amount of liquid added. For experiments in which the day
of addition was varied, 0.5 mM tryptamine analog was added on day 2, 4, 8, 10
or 14 of culture growth.
2.5 Hairy root culture for alkaloid analog purification
For large scale alkaloid production, C. roseus hairy root cultures were
cultured in 500 mL flasks containing 100mL of half strength Gamborg's media
and vitamins (pH = 5.7) and grown for 10 days at 26 oC shaking at 50 rpm.
106
Tryptamine analogs (10 mM in water) were added on day 10 to a final
concentration of 0.5 mM. The roots were cultured for an additional 20 days.
Roots were removed from the media and both roots and media were extracted as
described below.
2.6 Seedling Alkaloid Extraction
Fresh seedlings (0.25 g) were ground with a mortar and pestle with
methanol (3 x 8 mL). The methanol extract was filtered and concentrated under
vacuum to yield a yellow solid. This solid was then sonicated for 30 min in 5 mL
3% aqueous HCI. The HCI solution was extracted with hexanes (3 x 8 mL) to
remove hydrophobic material. A saturated solution of NH40H was used to adjust
the pH of the solution to above eight. The basic aqueous solution was extracted
with methylene chloride (3 x 8 mL). The combined methylene chloride fractions
were washed with brine, dried over sodium sulfate and concentrated to yield a
yellow alkaloid extract (2-5 mg/gram of fresh weight plant material). The extract
was dissolved in methanol (1 mL/g of seedlings) for further analysis by HPLC
and LCMS.
2.7 Hairy Root Alkaloid Extraction
Hairy roots were ground in mortar and pestle and extracted with 3 x 8 ml
of methanol per 5mL hairy root culture (approximately 0.25g of fresh roots). The
methanol extract was filtered using a 0.4 pm syringe filter and the methanol was
removed under vacuum. The extract was dissolved in 1.5 mL of methanol,
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transferred to a 1.7 mL centrifuge tube, and dried under vacuum. The resulting
yellow solid was dissolved in 1 mL of methanol per 5 mL culture of hairy roots
extracted and analyzed by LCMS.
2.8 LCMS analysis
The alkaloid mixtures were diluted one to one with water for mass spectral
analysis. The LCMS analysis of samples was performed on a Waters Acquity
UPLC system in line with a diode array detector followed by electrospray
ionization and detection by Micromass LCT Premier TOF Mass Spectrometer.
The LC was run on a Acquity Ultra Performance BEH C18, 1.7pm, 2.1 X 100 mm
column on a gradient of 10-60 % acetonitrile/water 0.1% formic acid over 20
minutes at a flow rate of 0.6 mL/min. The capillary and sample cone voltages
were 2000 and 30 volts respectively. The desolvation and source temperature
were 300 and 100 *C. The cone and desolvation gas flow rates were 20 and 700
L/hour. Analysis was performed with MassLynx 4.1. Accurate mass
measurements and quantification were obtained in W-mode. The spectra were
processed using the Mass Lynx 4.1 mass measure, in which the mass spectrum
of peaks of interest was smoothed and centered with TOF mass correction,
locking on the reference infusion of reserpine (m/z 609.2812, 200 nM solution at
20 tpL/min). Quanlynx was used for quantification of alkaloid peak area.
Standards of commercially available ajmalicine, serpentine, tabersonine and
vindoline were analyzed simultaneously to generate a calibration curve to
determine the total yield of alkaloid per liter of culture or gram of seedlings.
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2.9 Alkaloid Analog Purification by Preparative HPLC and NMR analysis
Alkaloid root extracts were purified on a silica gel column (0.5 in. diameter
column with 50 mL of dry silica gel) with a starting 95:5:1 dichloromethane:
methanol: ammonium hydroxide mobile phase. The methanol and ammonium
hydroxide in the mobile phase was increased to 80:20:1 over 2 L of solvent.
Extracts were collected in 100 mL fractions that were dried down and analyzed
by LCMS. Fractions containing the same compounds were combined and
subjected to further purification by preparative HPLC. Alkaloid fractions were
injected onto a 10 X 20 mm Vydac reverse phase column and run on a gradient
from 20-50% acetonitrilel water (0.1%TFA) over 30 min. The mixture was
monitored at 254 nm and fractions containing the alkaloid analogs of interest
were combined and concentrated. Isolated alkaloids were analyzed by NMR
(proton, COSY, HSQC, and HMBC) on a Bruker AVANCE-600 NMR
spectrometer, a 600 MHz spectrometer equipped with a 5 mm 1H (13 C, 3 1p) cryo-
probe. NMR spectra and tabulation are located in Appendix B.
3. Results
3.1 Precursor Directed Biosynthesis in C. roseus Hairy Roots
3.1.1 Alkaloid Production: Labeled Precursor Incorporation
To definitively identify the subset of alkaloids produced by C. roseus hairy
root cultures, cultures were supplemented with the isotopically labeled tryptamine
precursor ly (Figure 3.2). HR-LCMS spectra of extracts from these hairy root
cultures were compared with spectra from control cultures that were
109
supplemented with natural tryptamine 1. Compounds observed only in cultures
supplemented with ly were assigned as isotopically labeled alkaloids derived
from the exogenous tryptamine substrate. The structures of the alkaloids were
tentatively assigned based on the molecular formula predicted by the high-
resolution mass measurement, retention time, UV-VIS spectra, and the
previously reported structures of alkaloids produced by hairy root culture.
Definitive structural assignment of a particular analog by mass
spectrometry was complicated, since C. roseus hairy root culture produces
numerous alkaloids with identical molecular formulae. For example, control
cultures produce serpentine as the major product with predicted molecular
formula of C21H20N203, as evidenced by co-elution with an authentic
serpentine standard. However, the isomeric diastereomer alstonine was also
produced in small quantities.
Additionally, control hairy root cultures containing tryptamine I or ly
produce four isomers with molecular formula C21H24N203. The major peak
was assigned, based on UVNIS spectral analysis, as lochnericine, which results
from epoxidation of tabersonine. One of the minor compounds was assigned as
ajmalicine 4, a biosynthetic intermediate for serpentine, based on UV analysis
and co-elution with an authentic standard. The third and forth minor compounds
were not assigned and have UV maxima at 334, 291 and 214 nm. A possible
assignment for one of these compounds is pre-akuammicine 21, the precursor to
tabersonine 7, catharanthine 9, and akuammicine 10. However, the low yields in
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the cultures and lack of authentic standards prevented a definitive structural
assignment of these compounds.
Four major isomers with molecular formula C21H24N202 exist in the
control cultures, two of which are assigned as tabersonine 7 and catharanthine 9
based on comparison with authentic standards. The two remaining compounds
were not assigned. They have early retention times suggesting the presence of a
polar group and UV maxima at 294 and 241 nm. Possible assignments include
venalstonine and vindolinine, both known to be produced by C. roseus.
3.1.2 Optimization of Alkaloid Analog Production: Day of Addition
It has been previously established that the subset of alkaloids produced by
C. roseus seedlings change as the seedlings grow. Upon germination formation
of heteroyohimbine alkaloids is first observed (such as ajmalicine 4,
geissoschizine 21), followed by appearance of the strychnos alkaloid
akuammicine 10, then the aspidosperma alkaloid tabersonine 7 and finally the
iboga alkaloid catharanthine 9 [5, 6]. It is therefore reasonable to hypothesize
that the time of addition of the substrate analog could have a dramatic impact on
the alkaloid analogs produced by the culture. To assess the effect that the timing
of addition of the alkaloid analogs had on the production of alkaloid analogs,
isotopically labeled tryptamine ly (0.5 mM) was fed on day 2, 4, 8, 10 and 14 of
subculture. All cultures were cultivated for a total time of 21 days. The alkaloid
analogs derived from the labeled tryptamine fed and the alkaloids derived from
endogenous tryptamine were analyzed by HR-LCMS. The total peak area of the
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alkaloid analogs and the endogenous alkaloids were compared to determine the
effect that day of addition had on the total yield of the alkaloids.
Not surprisingly, the day of addition linearly affects the ratio of natural to
non-natural alkaloids produced (Figure 3.4A). Addition of ly on day 2 of culture
resulted in 90% of the alkaloids produced being derived from the deuterated
substrate, and the percentage of alkaloid analog derived from the exogenous
substrate decreased with later addition times. Interestingly, there was no effect
on the total yield of alkaloid analogs as determined by comparison of the total
peak area of alkaloid analogs produced from cultures fed on different days (not
shown). Differences in the amounts of specific product analogs in these cultures
were also detected. The fraction of the total alkaloid that is tabersonine and
akuammicine increases with increasing day of addition of ly (Figure 3.4B,
akuammicine not shown). The fraction of total alkaloid analog that is serpentine
decreases with increasing the day of addition of ly (Figure 3.4C).
3.1.3 Concentration of ly and Alkaloid Analog Production
Concentration of the alkaloid analog also affects the total yield of the
alkaloid analogs. Increasing the concentration of tryptamine analog ly resulted in
an increase in alkaloids derived from these analogs and a decrease in the natural
alkaloids (Figure 3.5A). However, at tryptamine analog ly concentration of 1 mM
browning and decreased growth were observed, suggesting that high levels of
tryptamine and tryptamine analogs were toxic to the cultures (Figure 3.5B).
Since the maximum fraction of total alkaloid was reached between 0.5 and 1 mM,
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Figure 3.4: Changes in alkaloid production depending on the day of addition of
tryptamine substrate ly. A) Fraction of total alkaloid derived from ly; B) total
tabersonine 7 and 7y production; C) total serpentine 5 and 5y.
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Figure 3.5: Effect of tryptamine analog concentration on the production of
alkaloid analogs. A) Change in total alkaloid derived from ly with increasing
concentration of ly fed on day 14. B) Effect of tryptamine substrate
concentration on the appearance of hairy roots, shown are example hairy roots
from cultures fed 500 jtM and 1000 gIM.
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and there is no significant difference in the total yield of alkaloid analog at these
two concentrations, a concentration of 0.5 mM was used for the remaining
studies. Dramatic differences in the relative amounts of specific analogs
produced in these cultures were also affected by the change in concentration,
and will be discussed in chapter 4.
3.1.4 PDB of Alkaloid Analogs in C. roseus Hairy Roots
To assess the formation of alkaloid analogs in C. roseus, a hairy root
culture was cultivated in liquid media supplemented with the tryptamine analogs
la-d, li-n, it-w, and 49. The incorporation of tryptamine analogs was limited by
the relatively narrow substrate specificity of STR as discussed in Chapter 2 [7].
Therefore, to investigate a wider range of substitutions, strictosidine analogs 3e-
h, 3o-p, and 3v-w were chemically synthesized from tryptamine analogs le-h,
lo-p, and lv-w and secologanin 2. Synthetic precursors la-d, li-n, lt-w, 49,
3e-h, 3o-p, and 3v-w (0.5 mM) were fed on day 14 of culture period. Alkaloids
were extracted from the hairy roots and media after one week of growth and the
extract was analyzed by HR-LCMS.
Analysis of extracts from analog treated cultures and comparison to control
cultures treated with tryptamine 1 revealed novel compounds derived from the
unnatural substrate. HR-LCMS identified alkaloid derivatives with molecular
weights corresponding to the addition of a fluorine, methyl, methoxy, chloro or
bromo group on the indole ring of alkaloids (Appendix B). None of the
compounds assigned as alkaloid analogs were observed in extracts derived from
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cultures incubated with tryptamine 1. Formation of these compounds, therefore,
was strictly dependent on the presence of the specific unnatural substrate
(Figure 3.6).
As previously mentioned, although HR-LCMS data allows assignment of
molecular formula, C. roseus produced numerous isomeric alkaloids with
identical molecular weights and formula. Therefore, NMR analysis was require to
validate structural assignment. Hairy root culture extracts were fractionated by
preparative HPLC and several of the most abundant analogs were purified in
milligram quantities. Representative members of each structural family were
isolated and subjected to NMR analysis (Figure 3.7). Proton NMR spectra were
used to assign 5a-c as fluorinated serpentine analogs, 5n as methylated
serpentine, 5.49 as benzofuran analog of serpentine, and 4a-b fluorinated
ajmalicine analogs (Appendix C).
Interestingly, since yohimbine 6 appeared to be the major product with
molecular formula C21H26N203 in control cultures, as evidenced by co-elution
with an authentic standard, we expected NMR analysis to confirm that the
methylated product with molecular formula C22H28N203 would be a derivative
of 6. However, proton NMR analysis of this methylated analog was instead
consistent with 12-methylsitsirkine 55n. Additionally, analogs of isositsirikine
34.a, 34.m, and 34.49 were isolated and the structure verified by NMR analysis.
An analog with molecular formula C21H23N202F was isolated from
extracts treated with la and identified by NMR to be fluorinated tabersonine 7a,
indicating that the major alkaloid analog in these hairy root cultures with the
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Figure 3.6: Representative LCMS chromatograms for the identification of
alkaloid analogs. A) LCMS traces of serpentine 5 analog labeled with amine
substrate fed and m/z of the extrapolated chromatogram. B) LCMS traces of
akuammicine 10 analogs.
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parent molecular formula C21H22N202 is tabersonine. Product analogs with
parent molecular formula of C20H22N202 correlate to the native alkaloid
akuammicine 10. Akuammicine results from the deformylation of pre-
akuammicine 21, a proposed central intermediate in the formation of vindoline 8
and catharanthine 9. NMR analysis of these compounds verified the structural
assignment as akuammicine 10 analogs; fluorinated 10Of and methylated 10h.
These compounds also had UV spectra and CD spectra corresponding to
analogs of akuammicine [8]. Additionally, reduced dihydroakuammicine 56 and
N-methylakuammicine 57 have been isolated and characterized including
dihydroakuammicine analogs 56c, 56n, and 561 and N-methylakuammicine
analogs 57n. Complete characterization of these alkaloid analogs is located in
Appendix C.
3.1.5 Substrate Specificity of the TIA Pathway in Hairy Roots
In general, all substrate analogs appeared to be incorporated into the
heteroyohimbine alkaloids ajmalicine 4 and serpentine 5 (Figure 3.2). These
results suggested that the putative reductase responsible for ajmalicine synthesis
tolerated substitution on the indole ring similar to the relaxed substrate specificity
observed for strictosidine glucosidase [9].
Additionally, the deglycosylated strictosidine was channeled into a second
pathway branch to form the heteroyohimbine alkaloid geissoschizine 20. After
formation of geissoschizine 20 there is a third (oxidative) branch of TIA
biosynthesis in which the monoterpene unit is rearranged to form pre-
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akuammicine 21. This branch exhibits more substrate specificity; though many
analogs are still channeled into this direction, the relative amounts of these
compounds produced varied significantly depending upon location and type of
substitution. Considering the electronic perturbations that some of these
substituents exert along with the electronic requirements for the rearrangement
to occur, this is not surprising. Akuammicine 10 analogs were observed with
substrates la-d, 1j, Il-m, it, 3e-h, 3o-p, and 3v-w. Putative tabersonine 7
analogs were observed with la-d, Im, It, 3o-p, and 3v-w (Figure 3.2).
3.1.6 Alkaloid Analog Yield from C. roseus Hairy Roots
3.2.6.1 Total Alkaloid Analog Yield Derived from Substrate Analogs
The total incorporation of each alkaloid analog was estimated by
measuring the total peak area of all alkaloid analog peaks detected. Comparison
of these totals for each substrate analog tested provides information about how
well each of the specific substrates was incorporated. Additionally, the total
alkaloid analog was compared to the total alkaloid produced derived from both
the endogenous tryptamine and the substrate fed. This reflects the purity of the
alkaloid analogs produced and the substrates ability to compete with the naturally
occurring substrate and downstream biosynthetic intermediates.
Comparison of the total alkaloid analog, as estimated by total analog peak
area, showed significant effects due to the substitution on the indole ring (p =
<0.0001, Figure 3.8A). Post-hoc analysis revealed that cultures fed 4- and 7-
methyoxytryptamine (It-u), 4-bromo and 4-chlorotryptamine (li, 1k) 5- and 6-
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Figure 3.8: Total alkaloid yield from C. roseus hairy roots; A) total alkaloid
analog produced upon feeding of substrate precursor; B) fraction of total alkaloid
(natural +analog) derived from the fed precursor.
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methoxy, chloro and bromostrictosidine (3e-h, 3v-w), produced significantly less
total methoxylated, brominated or chlorinated alkaloids derived from the fed
substrate when compared to the amount of deuterated alkaloids produced in
cultures supplemented with deuterated tryptamine ly. In contrast, cultures fed
substrate analogs substituted at the 7-position, or with fluoro and methyl groups
at the 4-, 5-, or 6-positions (la-d, 1m-n, and 3o-p) produced alkaloid analogs in
similar amounts to the deuterated tryptamine ly control.
Comparison of the fraction of total alkaloid that is derived from the analog
showed significant effects due to the substitution on the indole ring (p = <0.0001,
Figure 3.8B). Post-hoc analysis revealed that cultures fed 4- and 7-
methoxytryptamine (1t-u), 4-bromotryptamine (1k), and 5- and 6-methoxy, chloro
and bromostrictosidine (3e-h, 3v-w) had significantly smaller fraction of total
alkaloid derived from the fed substrate than from the natural tryptamine produced
in vivo. There were no effects on the fraction of total alkaloid derived from 7-
substituted tryptamines or 4-, 5-, 6-fluoro and methyl substitution or 4-chloro
substitution (la-d, Ii, Im-n, and 3o-p).
Strictosidine synthase is proposed to be a gate-keeping enzyme for the
conversion of tryptamine analogs to the corresponding alkaloid analogs. The
substrate specificity of this enzyme controls the flux of unnatural substrates into
the pathway; once past strictosidine synthase, all substrate analogs are accepted
by the next enzyme in the pathway strictosidine glucosidase [9]. We carefully
analyzed the amount of total unnatural alkaloid derived from the tryptamine or
strictosidine analog. Additionally, the fraction of unnatural alkaloid relative to the
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total alkaloid content (natural + unnatural) was quantified. Several conclusions
could be drawn from these data. In cultures fed 7-chlorotryptamine lj and 7-
bromotryptamine 11II, smaller amounts of unnatural alkaloid derived from the fed
substrate was observed compared to control cultures fed ly. Surprisingly
however, a corresponding decrease in the total natural alkaloid was also
observed. This indicated that the 7-chloro and bromotryptamines (1j, 11) were
also inhibiting biosynthesis of natural alkaloids at an early stage; for example 1j
or 11 could be competing substrates for the strictosidine active site. In contrast, in
the case of 4-bromotyrptamine I k, a decrease in both the formation of analogs
from 1k was observed, while the total amount of natural alkaloid remained
constant. This indicated that 4-bromotryptamine 1k was either a poor substrate
for strictosidine synthase or that it was not properly localized in the vacuole for
conversion by the enzyme.
For many of the strictosidine analogs (5- and 6-methoxy, chloro and
bromostrictosidine 3e-h, 3v-w) fed to hairy root cultures, a decrease in the total
amount of alkaloid analog was noted, while the amount of natural alkaloid
remained constant. These decreases were likely due to a decrease in uptake of
the strictosidine analogs from the media, since no increase in intracellular levels
of the total corresponding strictosidine analog 3e-h, 3v-w in the hairy root extract
was observed. The reason for the decreased uptake is unclear, though
presumably the larger (m/z 531), more polar strictosidine moiety is not able to
passively diffuse through the membrane as readily as tryptamine (m/z 161).
However, not all strictosidine analogs fed were converted to alkaloid analogs at a
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reduced level. The 5- and 6-methylstrictosidines (3o-p) produced total amounts
of alkaloid analogs similar to that observed for the deuterated tryptamine ly
control, which suggests that the decreased incorporation of the methoxy, chloro
or bromostrictosidines (3e-h, 3v-w) was not due to differences in transport of
strictosidine and tryptamine alone.
3.1.6.2 Total Yields of Specific Alkaloid Analogs from C. roseus Hairy Roots
HR-LCMS spectra of alkaloid extracts derived from cultures treated with
tryptamines la-d, li-n, it-w, 49 and strictosidines 3e-h, 3o-p, and 3v-w were
analyzed and specific peaks corresponding to alkaloid analog peaks were
integrated. To obtain an estimate of the total yield of a specific alkaloid analog,
the peak area was converted to a concentration using a calibration curve
generated from dilution of commercially available alkaloid standards. This allows
estimation of the total yield of the alkaloid analog per liter culture. The calculated
yields for tabersonine 7, serpentine 5, and ajmalicine 4 are summarized in Table
3.1.
A general decrease in the total yield of serpentine 5 and an increase in the
yield of ajmalicine 4 was seen as the size of the substitution at all indole ring
positions is increased (Table 3.1). This suggests that the peroxidase that
converts ajmalicine to serpentine does not tolerate steric substitution on the
indole ring (Figure 3.2). Tabersonine 7 analogs derived from 5- and 6-position
substituted strictosidine derivatives (3o-p) were produced in amounts similar to
that found in the control culture ly. However, lower yield of tabersonine 7
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Table 3.1: Total yield of specific alkaloid analogs from C. roseus hairy roots.
* + standard error of the mean (n = 3 or **n=6)
Entry Precursor Tabersonine 18 Serpentine 8 Ajmalicine 7
Fed (mg/L)* (mg/L)* (mg/L)*
ly 0.78 + 0.34 1.54 + 0.33 0.20 + 0.07
la 0.26 + 0.17 1.45 + 0.53 0.58 + 0.24
Im 0.08 + 0.03 0.10 + 0.03 1.04 + 0.28
Iv lb 0.36 + 0.13 2.03 + 0.14 0.57 + 0.20
v 3o** 1.59 + 0.21 0.51 + 0.12 1.97 + 0.23
vi 1c 0.95 + 0.28 2.34 + 0.07 0.17 + 0.07
vii 3p** 1.04 + 0.23 0.41 + 0.08 1.55 + 0.20
ld 0.02 + 0.01 1.23 + 0.17 0.03 + 0.02
ix In 
-- 0.05 + 0.02 0.45+0.22
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analogs were observed with 4 and 7-position substitutions (la, Id, Im, in, Table
3.1). The production of tabersonine is proposed to involve multiple enzymatic
steps, steric modifications at the 4 and 7-position likely hinders one or more of
the enzymes responsible for tabersonine formation. These substituent-dependent
changes in partitioning are discussed in detail in Chapter 4.
3.2 PDB of Alkaloid Analogs Produced in C. roseus Seedlings
3.2.1 PDB of Vindoline Analogs in C. roseus Seedlings
Root cultures do not produce the entire array of TIA found in differentiated
C. roseus plants (Figure 3.2). Most notably, vindoline 8, the precursor of the
pharmaceutically important bis-indole alkaloid vinblastine 15, is not produced in
hairy root culture. To determine if analogs la-d, li-n, it-w, 49, 3e-h, 3o-p, and
3v-w could be incorporated into the vindoline 8 pathway, C. roseus seedlings
were germinated and grown on media containing compounds la-d, li-n, It-w,
49, 3e-h, 3o-p, and 3v-w (Figure 3.2). Although a complex mixture of alkaloids
was observed, HR-LCMS analysis demonstrated that unnatural substrates la-d,
Si-n, it-w, 49, 3e-h, 3o-p, and 3v-w were incorporated into a wide range of
alkaloid structures in these seedlings (Appendix B). The analysis of the seedling
extracts focused on vindoline 8, a pharmaceutically valuable alkaloid that is
unique to differentiated plants.
Several pieces of evidence suggest that seedlings treated with
compounds la-d,lm,lt, 3e-h, and 3o-p produced derivatives of vindoline 8 or
the demethoxyvindoline derivative, vindolidine 48 (Figure 3.2). Molecular formula
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data obtained by HR-LCMS indicate that compounds with molecular formula
consistent with fluorinated, methylated, chlorinated, or brominated derivatives of
8 or 48 were produced in seedlings cultured with analog la-d,1m,lt, 3e-h, and
3o-p (Figure 3.2). Although authentic fluorinated standards of these compounds
are not available, the slightly longer retention times relative to the natural
standard, characteristic UV spectra and correct molecular formulae strongly
supported these assignments. Moreover, no other alkaloid with molecular
formulae matching that of 8 and 48 have been reported to be isolated from C.
roseus, lending support to our proposed assignments evidenced by accurate
mass measurements. Since seedlings produce complex mixtures of alkaloids in
relatively low yields, NMR analysis of seedling extracts was difficult. Therefore,
only one analog, 48c, was purified and analyzed by NMR and the structural
assignment as a fluorinated vindoline analog was validated (Figure 3.7,
Appendix C).
Notably, all analogs which formed a putative tabersonine 7 derivative in
hairy root cultures also formed a derivative of 8 or 48 in seedlings. This suggests
that the enzymatic conversion of tabersonine 7 to vindoline 8 derivatives is highly
promiscuous. However, for the analogs I b-c and 3e-h only analogs of
vindolidine 48 were observed, indicating that the mono-oxygenase which
hydroxylates the 16-position of tabersonine 7 (T16H) exhibits substrate specificity
(Figure 3.9). For analogs substituted at the 6-position Ic, 3f, and 3h this
specificity is due to the substitution at that position preventing the oxidation.
Overall, these data demonstrate that the bottleneck to vindoline 8 production lies
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Figure 3.9: Biosynthesis of vindoline 8 from tabersonine 7. T16H, tabersonine-16-hydroxylase; OMT,
tabersonine-16-O-methyltransferase; NMT, N-methyltransferase; D4H, deacetoxytabersonine-4-hydroxylase;
DAT, deacetyltabersonine-acetyltransferase.
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in the formation of tabersonine 7 and the hydroxylation at the tabersonine-16-
position and not in the specificity of the enzymes which further modify the
tabersonine scaffold.
3.2.2 Total Yields of Specific Alkaloid Analogs from C. roseus Seedlings
In general, seedlings produce a smaller amount of alkaloids per gram of
tissue than hairy root cultures. Additionally, a more complicated mixture of
alkaloids are produced, lowering the yield of each of the specific alkaloids
produced. Serpentine 5, vindoline 8 and vindolidine 48 analog concentrations
were determined by HR-LCMS as described previously and the total yields per
gram of seedlings is listed in Table 3.2.
The total yield of vindoline 8 and vindolidine 48 was dependent on the site
of substitution. Substitution at the 4- and 7-position with fluorine resulted in
yields of vindoline 8 comparable to that observed with natural tryptamine (Table
3.2). Similar to the low yields of tabersonine 7 observed in hairy roots treated
with Im, the total yield of vindoline 8 and vindolidine 48 were detected but were
below the limits of our calibration were observed and could not be quantified. No
vindoline 8 or vindolidine 48 was observed with in treated seedlings, likely due
to the lack of tabersonine 7 formation that was observed in hairy root cultures.
High yields of vindolidine 48 analogs were observed with 5- and 6-position
substitutions. Only vindolidine 48 analogs were observed with substitution at the
6-position since hydroxylation at this site is blocked by the substitution. In
cultures fed 5- substituted analogs, a loss of vindoline 8 production was observed
with increasing substitution size at these positions (Table 3.2, Figure 3.2).
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Table 3.2: Total yield of specific alkaloid analogs from C. roseus seedlings.
* + standard error of the mean (n=6 or **n =3). bl = below limit for quantification.
*** not detected after resuspension, fluorinated vindoline analog was detected in
fresh sample prior to resuspension, the vindoline analog may degrade in
methanol.
Entry Precursor serpentine 8 vindolidine 20 vindoline 19
Fed (pg/g)* (pg/g)* (pg/g)*
ly 0.46 + 0.13 0.87 + 0.15 0.84 + 0.18
i la 2.21 + 0.45 bl 0.90 + 0.12
ii lm 0.74 + 0.17 bl bl
iv lb 1.47 + 0.56 0.34 + 0.14 --
v 30** 1.68 + 1.17 0.16 + 0.05 0.09 + 0.03
vi Ic 2.02 + 0.49 1.67 + 0.18 
--
vii 3p** 2.56 + 1.07 0.39 + 0.22 
--
vi Id 0.70 + 0.27 0.59 + 0.19 1.05 + 0.50
ix In 0.18 + 0.02 -- --
x 3e** 1.49 + 0.29 0.16 + 0.07 
--
xi 3f** 1.18 + 0.01 0.19 + 0.09 
--
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4. Discussion
PDB of natural product derivatives is a powerful method to make natural
product analogs that are not easily accessible via total synthesis. However, at the
outset of this study, it was unclear whether the TIA pathway had the capacity to
generate novel alkaloids. There is very limited precedence for precursor directed
biosynthesis in plants and our understanding of the enzymatic transformations in
the TIA pathway is limited. Our findings reported here demonstrate that PDB in
the medicinal plant C. roseus produces an array of alkaloid analogs. After
feeding of substrate analogs to hairy root and seedling cultures the alkaloid
analogs produced were analyzed by HR-LCMS. The analysis revealed significant
amounts of alkaloid analogs produced from the exogenous precursors. Several
of these alkaloid analogs representing the array of structures were isolated,
purified and the structures validated by NMR. Analogs of alkaloids with known
biological activity including ajmalicine, serpentine, and akuammicine were
isolated in milligram quantities and characterized by NMR. Future work should
aim to evaluate the biological activity of the alkaloid analogs produced in this
study.
The day of culture on which the substrate analog was added and the
extracellular concentration of the substrate analog affected the production of
alkaloid analogs. Feeding of tryptamine substrates on day 2 of culture resulted in
90% of the total alkaloid produced by that culture deriving from the exogenously
fed precursor. The fraction of total alkaloid derived from the fed precursor
decreased when added later in the culture cycle. Moreover, addition of
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substrates on day 2 resulted in decreased production of tabersonine 7 analogs
and increased production of serpentine 5 analogs. This observation suggests a
potential way to generate only the specific alkaloid analog of interest. For
instance if production of serpentine analogs is desired, then feeding on day 2 of
culture would be most effective. However, if tabersonine analogs are desired,
feeding of the substrate later in the culture cycle is optimal.
The concentration of the tryptamine substrate fed also affected the total
yield of alkaloid analog. As expected, increasing the extracellular concentration
of tryptamine analogs results in increased production of alkaloid analogs
compared to the total alkaloid produced. The total yield of alkaloid analogs
produced from the precursor was dependent on the precursor fed. This likely
reflects specificity of strictosidine synthase for that substrate and the substrate
specificity of enzymes further downstream in the biosynthesis of TIA.
Many of the tryptamine or strictosidine analogs fed produced alkaloid
analogs in amounts similar to the natural alkaloids observed in the control
cultures. The total yield of the specific alkaloid analogs produced was also
dependent on the precursor analog fed. Elevated yields of ajmalicine 4 analogs
were generated when steric modifications were introduced at all positions,
demonstrating that PDB is a good method for production of ajmalicine analogs.
Additionally, higher production of akuammicine 10 analogs were obtained in
cultures fed 6- and 7-position substituted tryptamines and increased amounts of
isositsirikine 34 analogs were produced in cultures fed 4-substituted tryptamines
and the electron deficient benzofuran-3-ethanamine.
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Although the dimeric alkaloid vinblastine is not produced in C. roseus
seedlings or hairy roots, analogs of the biosynthetic precursor, vindoline 8, were
produced upon precursor directed biosynthesis in seedlings. The results indicate
that the biosynthesis of vindoline 8 from tabersonine 7 is tolerant to modifications
on the indole ring, since all substrates that produced tabersonine 7 analogs
produced analogs of vindoline 8. Putative catharanthine 9 analogs were
generated. However, the low yields prevented structural characterization. Other
cultures that produced higher total yields of catharanthine 9 should be explored
for the production of catharanthine derivatives.
In addition to the compounds tested in this study, several new tryptamine
and secologanin analogs generate TIA analogs by the method of PDB. Cultures
fed 4-, 5- and 6-azidostricotisdine and 7-azidotryptamine resulted in production of
azide analogs of TIA [10]. Secologanin analogs harboring a pentynyl ester were
also incorporated into alkaloid analogs in C. roseus hairy root cultures [11]. After
isolation these compounds were chemically modified by a copper catalyzed 1,3-
dipolar cycloaddition reaction between the alkyne and biotin-azide and purified
from the natural alkaloids by elution from a streptavidin resin [11]. The
conversion of these substrate analogs to alkaloid analogs in vivo represents the
foundation for future use of these analogs as photo-reactive probes for TIA
biosynthetic enzymes as described in Chapter 5.
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5. Conclusions
This study demonstrates that precursor directed biosynthesis is a valid
method for the production of an array of analogs of these complex alkaloid
structures. PDB is a unique tool for the generation of alkaloid analogs not easily
synthesized by total synthesis or semi-synthesis. The total yield of alkaloid
analogs produced is comparable to the control cultures tested validating this
method of natural product analog production in useful quantities. The analysis
revealed that each substrate analog tested generated a unique set of C. roseus
TIA analogs. Quantitative analysis of the substrate specific alkaloid profiles may
provide insight into the mechanism of their formation.
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Chapter 4
Metabolomic Analysis of Substrate Specific Alkaloid Analog Profiles Upon Precursor
Directed Biosynthesis in Catharanthus roseus
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1. Introduction
Plants produce some of the most structurally complex and medicinally
important compounds observed in nature. Monoterpene indole alkaloids (TIA) are
plant derived natural products with diverse structures and biological activities
(Figure 4.1) [1]. A highly branched biosynthetic pathway is responsible for the
production of over 130 different TIA in Madagascar periwinkle (Catharanthus
roseus) that arise from a common biosynthetic intermediate (Figure 4.1) [2].
The biosynthesis of these compounds begins with the condensation of
tryptamine 1 and secologanin 2 to form strictosidine 3, catalyzed by the enzyme
strictosidine synthase (STR, Figure 4.2) [3-5]. Strictosidine 3 is then
deglycosylated by a dedicated glucosidase, strictosidine glucosidase (SGD) [6-
11]. The strictosidine aglucone rearranges by reacting with the secondary amine
to form a tetra-cyclic aldehyde, which most likely exists in equilibrium between
multiple isomers (28-30) (Figure 4.2) [12-15]. Although the enzymes that
catalyze the steps following deglycosylation remain unidentified on a genetic
level, partially purified proteins isolated from C. roseus convert the
deglycosylated intermediate cathenamine 30 to ajmalicine 4 in the presence of
NADPH (Figure 4.2) [15-17]. Reduction of the deglycosylated intermediate, 4,21-
dehydrogeissoschizine 29, yields geissoschizine 20, thereby shuttling the
deglycosylated intermediate down the second branch of the proposed pathway
for TIA biosynthesis in C. roseus (Figure 4.2). An NADP+ dependent
dehydrogenase isolated from C. roseus cultures specifically converts
geissoschizine 20 to ajmalicine 4, linking the two branches of TIA biosynthesis
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Figure 4.1: Example terpene indole alkaloids derived from strictosidine 3. Representative examples
of the various structural classes of TIA produced by plants and the variety of medicinal applications.
through the proposed intermediates 4,21-dehydrogeissoschizine 29 and
cathenamine 30 (Figure 4.2) [18, 19]. These enzymes represent the only alkaloid
biosynthetic enzyme activities immediately following strictosidine glucosidase
(SGD) reproducibly observed in partially purified extracts of C. roseus cultures.
The remaining C. roseus TIA are generated from ajmalicine 4 and geissoschizine
20 intermediates. Ajmalicine is transported to the vacuole for storage, where it is
further oxidized by an uncharacterized peroxidase to form serpentine 5, which
accumulates in the vacuole (Figure 4.2) [20].
In addition to the corynanthe alkaloid ajmalicine 4 and its diastereomers,
labeled geissoschizine 20 was shown to be incorporated into akuammicine 10,
tabersonine 7, and catharanthine 9, members of the strychnos, aspidosperma,
and iboga family of alkaloids, respectively (Figure 4.2) [21]. Biosynthesis of the
more complex strychnos, aspidosperma and iboga classes remains cryptic. A
chemically logical pathway entails an oxidative rearrangement of geissoschizine
20, followed by reduction to form pre-akuammicine 21 (Figure 4.2).
Furthermore, geissoschizine 20 was reduced to form isositsirikine 34 by an
NADPH dependent reductase [22]. Several possible mechanisms have been
proposed for the formation of pre-akuammicine 21 from geissoschizine 20 [23].
Pre-akuammicine 21 isolated from C. roseus rapidly deformylates at room
temperature to yield akuammicine 10, an alkaloid with the strychnos structure
[23]. Reduced pre-akuammicine 21, stemmadenine 22, has been isolated from
TIA producing cultures, and various experimental studies suggest that
stemmadenine 22 is a potential link between the corynanthe and
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aspidosperma/iboga alkaloids (Figure 4.2) [24, 25]. The conversion of
stemmadenine 22 to cathenamine 9 and tabersonine 7 through a dihydropyridine
acrylic ester, dehydrosecodine 41, is experimentally supported by bio-mimetic
synthetic studies (Figure 4.2) [26-31].
As described in Chapter 3, the TIA biosynthetic pathway can be hijacked
to produce novel structures by precursor directed biosynthesis [32]. Precursor
directed biosynthesis of TIA in C. roseus with tryptamine analogs (la-d, li-n, It-
w, 49) and strictosidine analogs (3e-h, 3o-p, 3v-w) resulted in the production of
alkaloid analogs in both C. roseus hairy root cultures and seedlings. In addition to
the production of high levels of the expected alkaloid analogs (serpentine,
ajmalicine and tabersonine), many of the substrate analogs resulted in high
yields of alkaloid analogs that had little or no natural counterpart in control
cultures fed tryptamine 1.
In this work, the conversion of these 22 tryptamine 1 or strictosidine 3
analogs (Figure 4.3) into the branches of the TIA biosynthetic pathway to form
alkaloid analogs in hairy root cultures was quantified, thereby revealing the steric
and electronic effects of these substitutions on the formation of TIA in vivo. The
substrate specific alkaloid analogs produced allows examination of enzymatic
steps, which have previously not been examined. A bottleneck in the production
of alkaloids in the oxidative branch of the TIA pathway was observed, and
potential new intermediates in the pathway were identified. Time and
concentration dependent studies support these findings and highlight factors
involved in the production of TIA analogs. In this chapter the scope and
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limitations of using the TIA biosynthetic pathway within the context of the plant
cell for production of novel compounds and sets the stage for a host of future
metabolic and genetic engineering efforts in C. roseus.
2. Experimental
2.1 Tryptamine Analog Synthesis
Tryptamine analogs were synthesized as described in Chapter 2 and
Appendix A.
2.2 Strictosidine Analog Synthesis
Strictosidine analogs were synthesized as described in Chapter 3.
2.3 PDB in Hairy Root Cultures
C. roseus hairy root cultures (obtained from the Parson's Lab at
Northeastern University), were sub-cultured in 14 mL falcon tubes containing 5
mL of half strength Gamborg's media and vitamins (pH = 5.7) and grown for 14
days at 260C shaking at 50 rpm. Tryptamine hydrochloride analogs (10 mM in
water) were added to the media at day 14 to a final concentration of 0.5 mM. The
roots were grown for an additional 7 days. Roots were removed from the media
and were extracted as described in Chapter 3. Hairy root cultures were
maintained by sub-culturing as described in Chapter 3. For concentration studies
the final concentration (1 mM, 0.5 mM, 0.2 mM and 0.08 or 0.04 mM) of
tryptamine analog added at day 14 was altered and sterile water was added to
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cultures to standardize the amount of total liquid added. For time course
experiments, 0.5 mM tryptamine analogs were added to multiple cultures at the
same time, and cultures were extracted in triplicate at each time point to obtain
the time course data.
2.4 Statistical Analysis
Analysis of Variance was performed on the peak area or fraction of
total peak area for the alkaloid analogs produced. For the concentration study,
the alkaloid analogs and naturally derived alkaloids for each substrate fed were
analyzed separately with concentration as an independent variable. Post-hoc
analysis was preformed using the Bonferroni-Dunn test for multiple comparisons.
3. Results
3.1 Alkaloid Analog Assignment
A Catharanthus roseus hairy root culture, which yields a relatively limited
profile of monoterpene indole alkaloids (TIA) compared to the whole plant
(Figure 4.2) [33], was cultivated in the presence of tryptamine analogs (1a-d, 1i-
n, it-w, 49) (Figure 4.3). Since tryptamine analogs le-h, lo-p, and lv-w are
blocked from entering the pathway at an early stage [34], strictosidine analogs
3e-h, 3o-p, and 3v-w were used to assess the incorporation of substrates having
substituents at the 5- and 6-position of the indole (Figure 4.3). Tryptamine and
strictosidine analogs substituted with fluoro, chloro, bromo, methyl and methoxy
on the indole ring were used to systematically probe the effect of substituent size
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and electronic properties on incorporation into the pathway. Additionally, the
isosteric, electron-deficient alternative heterocycle benzofuran-3-ethanamine 49
was fed.
To identify compounds derived from the cultures supplemented with la-d,
li-n, it-w, 49, 3e-h, 3o-p, and 3v-w, HR-LCMS spectra of extracts from analog
treated hairy roots were compared with spectra from control cultures that were
supplemented with endogenous tryptamine 1, isotopically labeled ly, or cultures
in which an amine substrate was not included. As described in Chapter 3,
compounds observed only in analog supplemented cultures were assigned as
alkaloid analogs. Alkaloid analogs were assigned to a specific structural class
based on the observed molecular formula, UV spectrum, retention time, and, for
select analogs, NMR spectra (Appendix D).
To simplify the alkaloid profile further, each compound was grouped based
on the major structural classes produced in C. roseus hairy roots; analogs of
tabersonine 7 (aspidosperma), analogs of akuammicine 10 (strychnos), and
analogs of ajmalicine 4, serpentine 5, and isositsirikine 34 (corynanthe). The
categorized alkaloids were plotted as pie charts to graphically illustrate the
substrate specific profiles for each substrate analog (Figure 4.4). A detailed
table for each tryptamine or strictosidine analog fed listing the retention time,
experimental molecular mass, the assigned molecular formula, the observed UV
maxima, and the structural class to which this compound was assigned is located
in Appendix B. Clearly, as illustrated in Figure 4.4, the profile of products formed
is highly dependent on the identity of the substrate analog fed.
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Figure 4.4: Alkaloid analog profiles produced upon feeding tryptamine and
strictosidine analogs to Catharanthus roseus hairy root cultures. Alkaloid
analogs produced are color coded; strictosidine (red), ajmalicine (blue),
serpentine (light blue), isositsirikine (green), akuammicine (orange), tabersonine
(pink). All other substrate analog derived alkaloids are categorized as other
(black).
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3.2 Pattern of Incorporation
3.2.1 Substitution at the Tryptamine-4-Position
Strictosidine synthase turns over tryptamine analogs with various
substitutions at the 4-position, indicating that these compounds can enter into the
pathway from the earliest stage [34]. The profiles resulting from feeding of
tryptamine analogs with substitution at the 4-positions of the indole ring (1a, i, k,
m, and t) to hairy root cultures on day 14 of growth are illustrated in Figure 4.4.
All cultures produced significantly higher amounts of compounds with parent
molecular formula of C21H26N202, which is consistent with the known parent
alkaloids isositsirikine 34, sitsirikine 55 and yohimbine 6 (p = <0.0001). The major
compound corresponding to this molecular formula was isolated from cultures fed
with la and 1m and determined to be an analog of isositsirikine (34a or 34m).
Universally, all substitutions at position four resulted in increased production in
relative amounts of isositsirikine 34 analog when compared to the control
cultures, where isositsirikine 34 levels were low. Further analysis revealed that
4-chloro and bromotryptamine (li, 1k) produced significantly higher levels of
isositsirikine then was produced in cultures fed with 4-methyl, fluoro and
methoxytryptamine (la, lm, it, p(i,a)=<0.0001, p(i,m)=<0.0001, p(i,t)=<0.0001,
p(k,a)=<0.0001, p(k,m)=<0.0001, p(k,t)=<0.000 1).
Akuammicine 10 production was also dramatically affected by substitution
at the 4-position (p=<0.0001). The fraction of total alkaloid analog assigned as
akuammicine 10 in cultures fed 4-fluoro and 4-methyltryptamine (Ia, Im) was
significantly higher then the amount of deuterated akuammicine 10y that was
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produced in cultures fed ly (p(y,a)=0.0005, p(y,m)=<0.0001) (Figure 4.3). The
fraction of total alkaloid analog assigned as akuammicine 10i in cultures fed 4-
bromotryptamine li was significantly lower than the fraction of deuterated
akuammicine 10y produced in cultures fed ly (p(y,i)=0.0027). The fraction of
akuammicine analogs (10k, 10t) produced in cultures fed 4-chloro and 4-
methoxytryptamine (1k, It) did not differ significantly from the fraction of
akuammicine 10y produced in control cultures fed ly (Figure 4.3). In addition,
the amount of methylated akuammicine 10m produced in cultures treated with 4-
methyltryptamine 1m was significantly higher than the fraction of the
corresponding akuammicine 10 analog produced in cultures fed 4-fluoro, 4-
chloro, 4-bromo and 4-methoxytyrptamine (la, 1k, li, It, p(m,a)=<0.0001,
p(m,k)=<0.0001, p(m,i)=<0.0001, p(m,t)=<0.0001).
Tabersonine analog production was also significantly affected by the
substitution at the 4-position (p=<0.0001). No tabersonine 7 analog production
was observed in cultures fed 4-methoxy, 4-chloro, and 4-bromotryptamine (It,
1k, and ii). The total fraction of tabersonine 7 analog in cultures fed 4-fluoro and
4-methyltryptamine (la, 1 m) was significantly lower then the fraction of
deuterated tabersonine 7y observed in control cultures fed ly (p(a, y)=<0.0001,
p(m, y)=<0.0001).
These data indicate that substitution at the 4-position with electron
withdrawing groups (fluoro, bromo, and chloro), which result in a more electron
deficient indole ring, causes a decrease in the formation of alkaloid analogs in
the oxidative branch of the TIA pathway (tabersonine 7 and akuammicine 10).
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Instead, the potential precursor to pre-akuammicine 21, isositsirikine 34,
accumulates. Although all substitutions at the 4-position produced significantly
higher yields of isositsirikine 34 analog than the control culture, both 4-chloro and
4-bromotryptamine (1 k, li) cultures produced a higher fraction of isositsirikine
analogs (34k, 341i) than the fraction of isositsirikine analogs (34m, 34t) derived
from 4-methy and methoxy tryptamine (lm, It). Taken with the high yields of
akuammicine produced in 4-methyltryptamine lm fed cultures, these results
indicate that the increased production of isositsirikine 34 and decreased
production of akuammicine 10 is observed upon feeding of precursors with
substitutions at the 4-position that are deactivating (F, CI, Br). Additionally,
although 4-methyltrypamine Im is converted to pre-akuammicine 21m, as
evidence by formation of akuammicine 10m, production of tabersonine 7m was
limited. This indicates that the enzymes responsible for conversion of pre-
akuammicine 21 to tabersonine 7 are not tolerant of steric substitutions at this
position.
Serpentine 5 and ajmalicine 4 analog production are also dependent on
substitution at the 4-position. As the size of the substitution at the 4-position is
increased, serpentine 5 analog production decreases and ajmalicine 4 analog
production increases. For example, the total yield of ajmalicine derived alkaloids
(4 and 5) in 4-methyltryptamine Im treated roots is about half that observed for
4-fluorotryptamine la treated hairy roots (0.7 + 0.1 mg/L and 2.0 + 0.3 mg/L
culture, respectively). However, the serpentine analog 5m accounts for only 9
percent of the total ajmalicine derived analogs (4m and 5m) in hairy roots treated
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with 4-methyltryptamine lm, but serpentine 5a accounts for 80 percent of the
ajmalicine derived product (4a and 5a) in hairy roots fed 4-fluorotryptamine la.
This suggests that the peroxidase responsible for oxidation of ajmalicine 4 to
serpentine 5 is sensitive to steric substitutions at this position. Notably, ajmalicine
4 must be transported into the vacuole where this peroxidation reaction is
proposed to occur [20]. It is unlikely that the differences in ajmalicine to
serpentine ratios are due to decreased transport of ajmalicine across the
membrane, since ajmalicine is not actively transported across the vacuolar
membrane. The subtle structural differences would have a limited impact on the
rate of passive diffusion across the membrane.
Cultures fed 4-substituted tryptamine analogs produced significant
amounts of derivatives of two compounds with parent molecular formula of
C21H22N203, which would correspond to analogs of deglycosylated
strictosidine, cathenamine 30 or 4,21-dehydrogeissoschizine 29. Deglycosylated
strictosidine synthesized in vitro formed one product peak, with a distinctive
broad line shape. The compounds observed in vivo lack this peak shape,
suggesting that they fall into another, unidentified structural class. No reported
natural alkaloid from C. roseus, besides deglycosylated strictosidine, was
reported to have this molecular weight [1]. These new compounds were
observed in cultures incubated with 4-chlorotryptamine 1k, 4-fluorotryptamine la,
and 4-methyltryptamine 1m treated hairy roots but not in 4-bromotryptamine li or
4-methoxytryptamine It treated hairy roots. They accounted for less then 1% of
the total alkaloid and were included in the category "other" for the purposes of
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this analysis. Additionally, 4-methoxytryptamine It fed hairy roots produced a
compound with molecular formula C21H22N202, which was expected to be a
derivative of tabersonine. However, the UV-VIS spectrum and retention time
were not consistent with this assignment and therefore the compound was
categorized as "other".
3.2.2 Substitution at the Tryptamine-7-Position
Tryptamine analogs Id, j, I, n, and u substituted at the 7-position (Figure
4.3) were added to hairy root cultures after 14 days of growth. A dramatic
increase in the fraction of analogs of akuammicine 10 was observed with fluoro
Id, chloro lj, bromo 11 and methyl In substitutions at the 7-positions, compared
to control cultures fed with deuterated tryptamine ly (p(d,y)= <0.0001, p(j,y)=
<0.0001, p(l,y)= <0.0001, p(n,y)= <0.0001, Figure 4.4). For this analysis, analogs
of akuammicine 10 reduced at the vinyl group 56 or N-methylated 57 were
combined with unmodified akuammicine 10. Similar akuammicine production was
detected in cultures fed 7-methoxytryptamine lu and the control tryptamine ly.
Instead, 7-methoxytryptamine lu fed cultures accumulated a significantly higher
fraction of isositsirikine 34u (p(u,y)=<0.0001), similar to the profile observed with
deactivating substitutions at the 4-position. Feeding of all other 7-position
substituted analogs (Id, Ij, 11, and In) to hairy root cultures did not result in a
significant increase in production of isositsirikine 34 analogs.
Pre-akuammicine 21 is the proposed biosynthetic precursor for both
akuammicine 10 and tabersonine 7. Although in the 7-fluoro, chloro, bromo, and
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methyltryptamine (ld, 1j, 11II, and In) fed cultures a significant increase in the
fraction of akuammicine 10 analogs were observed, only 7-flourotryptamine ld
was able to form the corresponding fluorinated tabersonine analog 7d. One
explanation is that steric substitutions at the 7-position are not tolerated by at
least one of the enzymes responsible for the conversion of pre-akuammicine 21
to tabersonine 7 resulting in exclusive production of akuammicine 10 from the
pre-akuammicine 21 intermediate. It should be noted that pre-akuammicine 21 is
known to degrade at room temperature to akuammicine 10, and whether the
akuammicine 10 observed is generated in vivo or during the alkaloid extraction
procedure is not known [23].
Serpentine 5 and ajmalicine 4 analog production was also dependent on
substitution at the 7-position. As observed with the 4-substituted series,
serpentine analog production decreases and ajmalicine analog production
increases with increasing size of the substitution at the 7-position. For example,
the total ajmalicine and serpentine analog content is the same for 7-
methyltryptamine 1 n and 7-fluorotryptamine Id treated hairy root cultures (1.4 +
0.4 and 1.3 + 0.1 mg/L, respectively). However, serpentine analogs 8n and 8d
make up 13 and 95 percent of that total respectively. This suggests that the
peroxidase responsible for oxidation of ajmalicine to serpentine is sensitive to the
size of the substitution at the 7-position.
Cultures fed 7-substituted tryptamine analogs also produced significant
amounts of derivatives of two compounds with parent molecular formula of
C21H22N203, which would correspond to analogs of deglycosylated
153
strictosidine, cathenamine 30 or 4,21 -dehydrogeissoschizine 29. These products
are similar to the compounds observed upon feeding of tryptamine analogs
substituted at the 4-position. These new compounds were observed in cultures
incubated with 7-bromotryptamine 1j, 7-chlorotryptamine 11, 7-fluorotryptamine
id, and 7-methyltryptamine In treated hairy roots but not in 7-methoxytryptamine
lu treated hairy roots. They accounted for 3 to 14 percent of the total alkaloid
and were included in the category "other" for the purposes of this analysis.
3.2.3 Substitution at the Tryptamine-5- Position
Unlike 4- and 7- substituted tryptamines, most substituents on the 5- and
6- positions are not accepted by strictosidine synthase. Only 5- and 6-
fluorotryptamine (lb and Ic) are turned over by strictosidine synthase [34].
Therefore 5- and 6-chlorostrictosidine (3e, 3f), 5- and 6-bromostrictosidine (3g,
3h) and 5- and 6-methylstrictosidine (3o, 3p) and 5- and 6-methoxystrictosidine
(3v, 3w) analogs were synthesized chemically and supplemented in C. roseus
hairy root culture media to explore incorporation into the pathway past the
bottleneck of strictosidine synthase.
Strictosidine analogs 3e, 3g, 3o, and 3v and 5-fluorotryptamine analog lb
were added to hairy root cultures after 14 days of growth to explore the effect
that substitution at the 5-position of the indole ring had on alkaloid production.
The fraction of alkaloid analogs derived from the oxidative branch of the pathway
(tabersonine 7 and akuammicine 10) was significantly affected by substitutions at
the tryptamine-5-position. The fraction of tabersonine 7 analog derived from the
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supplemented substrate decreased in cultures fed tryptamines with deactivating
substitutions (fluoro lb, chloro 3e, and bromo 3g) at the 5-position compared to
the fraction of tabersonine 7 produced in 5-methylstrictosidine 3o and
tetradeuterated tryptamine ly fed cultures (p(b, y) =<0.0001, p(e, y)=0.0003, p(g,
y)=<0.0001, p(b, o) =<0.0001, p(e, o)=<0.0001, p(g, o)=<0.0001, Figure 4.4).
The production of akuammicine was significantly less in all 5-position substituted
analogs (lb, 3e, 3g, 3o, 3v) compared to the deuterated control ly (p=<0.0001).
A general trend in reduction of akuammicine with deactivating substitutions at the
tryptamine-5-position was observed. However, the fraction of methylated
akuammicine 10o produced in cultures fed 5-methylstrictosidine 3o was only
significantly higher then the amount of brominated akuammicine 10g produced in
culture fed 5-bromostrictosidine 3g (p(g,o)=0.0002). Therefore, deactivating
substitutions at the 5-position cause a decrease in production of alkaloid analogs
derived from the oxidative branch of the TIA pathway, similar to that observed
with deactivating substitutions at the 4-position.
Significant increases in the fraction of isositsirikine 34 were also observed
in 5-bromo, chloro, methyl and methoxystrictosidine (3e, g, o, v) fed cultures,
while 5-fluorotryptamine lb fed cultures did not display particularly elevated
levels of isositsirikine 34 analog relative to control cultures fed deuterated
tryptamine ly (p(e,y)= <0.0001, p(g,y)= <0.0001, p(o,y)=0.0003, p(v,y)=
<0.0001). This trend is similar to that observed for 4-position substitutions.
Significant increases in ajmalicine 4 and serpentine 5 were observed with
varying substitution at the tryptamine-5-position. The fraction of ajmalicine 4
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analog increased relative to cultures incubated with deuterotryptamine ly in
cultures supplemented with sterically modified 5-chlorostrictosidine 3e, 5-
bromostrictosidine 3g, 5-methylstrictosidine 3o and 5-methoxystrictosidine 3v
(p(e, y)=0.001, p(g,y)=<0.0001, p(o,y)=<0.0001, p(v,y)=<0.0001). A significant
increase in the fraction of fluorinated serpentine 5b relative to deuterated
serpentine 5y produced in control cultures was observed in 5-fluorotryptamine lb
fed cultures (p(y,b)=0.0003). Additionally, in cultures treated with 5-
fluorotryptmaine Ib and 5-methylstrictosidine 3o, the extracts contained 1.2 + 0.2
and 1.0 + 0.3 mg/L total serpentine 5 and ajmalicine 4, with 85 and 21 percent of
that total being serpentine respectively. This is consistent with observations
made in the 4- and 7- substituted series that suggested that the peroxidase
responsible for serpentine biosynthesis is sensitive to larger steric perturbations
on the indole ring.
3.2.4 Substitution at theTryptamine-6-Position
Strictosidine analogs 3f, 3h, 3p and 3w and 6-fluorotryptamine analog 1c
were added to hairy root cultures after 14 days of growth to assess the effect of
substitutions in the 6-position of the indole ring. As with the 7-substituted series,
the most striking effect was that cultures fed 6-methyl, chloro, bromostrictosidine
(3p, 3f and 3h) and 6-fluorotryptamine 1c resulted in high amounts of
akuammicine analogs 10c, 10Op, 10Of and 10Oh (Figure 4.4). Feeding of 6-
methoxystrictosidine 3w did not produce a higher fraction of
methoxyakuammicine 10w then the fraction of deuterated akuammicine 10y
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formed in the control culture supplemented with deuterated tryptamine ly.
However, 6-methoxystrictosidine 3w supplemented cultures also contained
significantly higher fraction of isositsirikine analog 34w compared to the control
cultures fed ly (p(w, y)=0.0002) as was observed in cultures fed analogs with
deactivating substitution (fluoro, chloro and bromo) at the 4-position.
In contrast to analogs with substitutions at the 7-position, formation of
tabersonine 7 analogs derived from 6-substituted 1c, 3p, 3f, 3h and 3w were
observed. A significantly smaller fraction of tabersonine 7 analog in 6-
fluorotryptamine Ic and 6-methoxy, 6-bromo and 6-chlorostrictosidine (3w, 3h,
3f) treated cultures was observed compared to the control cultures fed ly
(p(c,y)=0.0005, p(w,y)=<0.0001, p(f,y)=<0.0001, p(h,y)=<0.0001). Additionally, a
significantly smaller fraction of 6-chlorostrictosidine 3f was converted to
tabersonine 7f compared to the conversion of 6-methylstrictosidine 3p to
tabersonine 7p (p(p,f)=<0.0001) suggesting that this decrease in tabersonine 7
production is not due to steric perturbations alone. These data suggest that
electronic perturbations (fluoro, chloro and bromo) at the 6-position affect the
production of tabersonine 7. In short, for deactivating substitutions at the
tryptamine-6-position, there was an increase in the formation of akuammicine 10,
but a decreased conversion to tabersonine 7 was observed. With methoxy
substitution at the 6-position 3w, there was a decrease in both akuammicine 10w
and tabersonine 7w analog, and a corresponding increase in the fraction of
isositsirikine 34w analog suggests that the enzyme responsible for pre-
akuammicine 21 formation has a decreased reactivity with the methoxy-
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substituted intermediate. Feeding of 6-methylstrictosidine 3p resulted in a
significant increase in the fraction of akuammicine 10p, however had not effect
on the total amount of tabersonine 7p produced.
Serpentine 5 analog and ajmalicine 4 analog production was also
dependent on substitution at the 6-position. As observed with all other substrate
analogs, serpentine 5 analog production decreases and ajmalicine 4 analog
production increases as the size of the substitution at the 6-position was
increased. For example there was significantly more ajmalicine 4p and less
serpentine 5p in 6-methylstricotosidine 3p fed cultures then in the deuterium
control however, the ratio of these compounds in cultures treated with 6-
fluorotrytamine 1c was similar to the deuterium control cultures fed ly. The
peroxidase appears to be less sensitive to substitution at the 6-position since no
significant decrease in the fraction of serpentine 5f derived from 6-
chlorostrictosisidine 3f was observed.
3.2.5 Benzofuran ethanamine
Electronic characteristics of tryptamine can be dramatically altered with an
isosteric heterocyclic substitution. Benzofuran ethanamine 49 was added to hairy
root cultures after 14 days of growth. The major product produced was isolated
and identified as an analog of isositsirikine 34 (Figure 4.4). Serpentine 5 analog
was also produced with a total yield of 0.43 + 0.02 mg/L. No other alkaloid
analogs derived from the benzofuran ethanamine 49 were observed in the hairy
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root extracts, indicating that the indole has a profound impact on the biosynthetic
steps.
The electron deficient heterocycle did not form any alkaloid analogs with a
rearranged monoterpene unit. This suggests that the biosynthesis of benzofuran
ethanamine 49 derived alkaloid analogs is blocked at the oxidative branch of the
biosynthetic pathway similar to that observed with deactivating substitutions at
the 4-position.
3.3 Changes in Natural Alkaloid Production
The profile of alkaloid analogs produced varied dependent on the
precursor fed. However, the profile of the natural alkaloid compounds derived
from the endogenously produced tryptamine 1 was also be affected upon
addition of the alkaloid analogs. When looking at the alkaloids of interest in this
study (ajmalicine 4, serpentine 5, isositsirikine 34, tabersonine 7 and
akuammicine 10) there were no significant changes in the fraction of these
compounds produced dependent on the specific analog fed.
However, there were changes in production levels of compounds with
unknown structural assignments (categorized as "other"). There are six
compounds with molecular formula C21H24N202, two of which co-elute with
either tabersonine 7 or catharanthine 9. The remaining four compound identities
are unknown. Two of these unknown compounds did not change as the
concentration of the substrate was altered. Given the early retention times of
these compounds, it was speculated that they are derivatives of the polar
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alkaloids venalstonine or vindolinine. The remaining two compounds are not
produced in high yields in the control cultures (no amine or tryptamine ly fed).
However, in cultures that were fed 7-chlorotryptamine and 4-chlorotryptamine (li,
1j), there was a significant increase in the production of these two compounds.
The mass spectral data clearly indicates that these compounds do not contain a
chlorine atom, and are therefore not derived from the exogenous substrate.
Notably, cultures incubated with 7-chlorotryptamine and 4-chlorotryptamine (li,
1j) show some of the most dramatically altered alkaloid profiles when compared
to cultures incubated with natural tryptamines 1 or ly. Tryptamine 1j, 7-
chlorotryptamine, is largely incorporated into derivatives of akuammicine 10 and
the 4-chlorotryptamine Ii is largely incorporated into derivatives of isositsirikine
34, both intermediates to the oxidative branch of the TIA biosynthetic pathway.
Whether the novel natural compounds produced are the result of blocking of the
oxidative branch of the pathway is not known. Several possible assignments
including N-methylakuammicine 57 and dehydrosecodine 41, but further analysis
of these compounds is necessary to gain insight into the identity and reason for
their increased production when fed these specific substrates.
Additionally, significant increases in a compound with the molecular
formula C21H24N203 was also observed in cultures fed 4-methyltryptamine lm
and 7-chlorotryptamine lj. The compound exhibited a UV maximum at 330 nm,
consistent with an assignment is pre-akuammicine 21. More structural
characterization is required for definitive identification of this compound.
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3.4 Concentration Dependent Changes in Alkaloid Profiles
Dramatically varied profiles of alkaloid analogs resulted from small
perturbations to the tryptamine precursor structure, as shown in Figure 4.4. It
was also shown that addition of the substrate analogs, particularly certain 4- and
7-position substituted tryptamine analogs, change the production of natural
alkaloids. It is possible that the substrate analogs themselves or one of the
corresponding biosynthetic intermediates are causing changes in alkaloid
production by inhibiting enzymes or enzyme expression. To determine the
mechanism by which these substrate dependent changes in profile are occurring,
the dependence of the alkaloid profile on tryptamine substrate concentration was
investigated. Limited data for describing the effect of substrate concentration on
alkaloid profile is available in the literature. In one study, tryptamine
concentration was increased by increasing the activity of anthranilate synthase,
and resulted in decreased production of tabersonine 7 [35-38]. To test the effect
of precursor feeding on the production of alkaloid analogs, three representative
tryptamine analogs were fed over a range of concentrations and both the alkaloid
analog and natural alkaloid profiles were quantified.
To 14 day old hairy root cultures was added 1, 0.5, 0.2 and 0.08 or 0.04
mM tetradeuterated tryptamine ly, 6-fluorotryptamine 1c, or 7-methyltryptamine
In. These substrate analogs each generated distinct alkaloid profiles. Further
analysis of other tryptamine analogs would greatly benefit the understanding of
the mechanism for controlling other profile changes, but is outside the scope of
this initial study. The cultures were extracted after 7 days of incubation for
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analysis by HR-LCMS. The alkaloids derived from ly, 1c, In or the endogenous
tryptamine 1 were analyzed as a function of the concentration of the tryptamine
analogs fed.
As expected, the concentration of alkaloids derived from ly, Ic or in
increased and the concentration of natural alkaloid decreased with increasing
concentration of the tryptamine analog. To quantify changes in the profile (or
fraction of total alkaloid) of both the natural alkaloids derived from endogenous
tryptamine 1 and the alkaloid analogs derived from either ly, 1c or in, the
specific alkaloid or alkaloid analog was expressed as a fraction of the total
alkaloid derived from the endogenous precursor or total alkaloid analog for this
analysis. Several significant effects of tryptamine concentration on the relative
production of the specific alkaloid analogs and natural alkaloids were observed
(Table 4.1, Figure 4.5). Additionally, many of these changes appeared to be
dependent on the specific tryptamine substrate.
3.4.1 Deuterated Tryptamine Concentration Effects on Alkaloid Profile
Increasing the concentration of ly added to the cultures resulted in a
significant increase in production of deuterated akuammicine 10y (p = 0.0002).
Increasing the concentration of ly also resulted in a significant decrease in the
fraction of serpentine 5y and isositsirikine 34y produced (p = 0.0059 and 0.0065).
Increasing the concentration of ly also had significant effects on the profile of
alkaloids derived from the endogenous tryptamine 1 produced in vivo. Increasing
the concentration of ly resulted in an increase in production of serpentine 5 and
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Table 4.1: Summary of results of increasing concentration of substrates on alkaloid profile. Red arrows are changes
in corresponding alkaloid analog derived from the tryptamine analog fed (column 1). Black arrows are changes in
corresponding natural analog derived from endogenous tryptamine dependent on the tyrptamine analog fed.
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Figure 4.5: Changes in the alkaloids A) tabersonine 7 and B) akuammicine 10,
derived from the endogenous precursor tryptamine 1, upon feeding increasing
concentration of tryptamine analogs; 7-methyltryptamine In (0), a,c,3,P-
deuterotryptamine ly (U), 6-fluorotryptamine 1c (*).
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a decrease in the production of strictosidine 3 (p =0.0045 and 0.0108, Table 4.1).
Since the fraction of the akuammicine 10y analog increases while the fraction of
serpentine 5y analog decreases, excess biosynthetic intermediate such as
geissoschizine 20y appear to be converted to akuammicine 10y. The observed
increase in natural serpentine 5 is likely due to a corresponding decrease in the
fraction of natural akuammicine 10; presumably, the supplemented substrates,
when present in large amounts, are competing with the natural substrate on this
akuammicine 10 branch of the pathway.
3.4.2 Concentration Effects of 6-Fluorotryptamine on Alkaloid Profile
Increasing the concentration of 6-fluorotryptamine 1c resulted in a
significant increase in the production of akuammicine 10c (p= 0.0002) and a
decrease in the production of isositsirikine 34c and tabersonine 7c (p = 0.0003
and 0.0230). The levels of alkaloids derived from endogenous tryptamine 1 also
changes with increasing concentration of 6-fluorotryptamine 1c. Increasing the
concentration of Ic resulted in a significant increase in the production of natural
serpentine 5 (p = 0.0009) and a significant decrease in the production of natural
tabersonine 7 and strictosidine 3 (p= 0.0002 and 0.0060,Table 4.1 and Figure
4.5).
Comparison of these results with those observed in cultures treated with
deuterated tryptamine ly revealed very similar concentration-dependent changes
in the production of alkaloids. Cultures treated with high amounts of either ly or
1c resulted in an increased production of akuammicine analogs (10y or 10c,
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respectively) and a decreased production of isositsirikine (34y or 34c,
respectively). This suggests that excess amounts of exogenous substrate
partition toward the oxidative akuammicine pathway branch. Increasing substrate
ly and 1c concentration also both resulted in an increased fraction of natural
serpentine 5 and a decreased fraction of natural strictosidine 3. In cultures
treated with ly, a significant reduction of alkaloid analog serpentine 5y was also
noted. However, 11-fluoroserpentine 5c levels decreased only very modestly in
cultures treated with Ic. In cultures treated with 1c a significant reduction in both
7c and 7 was observed, but this trend was not observed in ly treated cells and
suggests it is a specific effect unique to cultures treated with 6-fluoroserpentine
1c. It could be hypothesized that Ic, or an intermediate derived from 1c, is an
inhibitor of one of the steps between the formation of pre-akuammicine 21 and
tabersonine 7 (Figure 4.2).
3.4.3 Concentration Effects 7-Methyltryptamine on Alkaloid Profile
Increasing the concentration of 7-methyltryptamine In resulted in a
significant increase in the production strictosidine 3n (p =0.0050), as well as a
significant increase in the fraction of natural alkaloids serpentine 5, isositsirikine
34 and akuammicine 10 (p = 0.0004, 0.0002, and 0.0002 respectively).
Significant decreases in the production of natural tabersonine 7 were also
observed with increasing concentrations of In (p = 0.0009, Figure 4.5).
Comparison of these results to those observed upon feeding of ly or 1c
revealed several significant differences. As in cultures treated with ly or ic,
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increasing the concentration of In also resulted in an increase in the fraction of
serpentine 5 derived from the endogenous tryptamine 1. Similar to 6-
fluorotryptamine 1c, there was also a decrease in tabersonine 7 production with
increasing concentration of in, suggesting that Ic and in is an inhibitor of
tabersonine synthesis (Figure 4.5A). In contrast to cultures fed ly and Ic,
however, 7-methyltryptamine in results in an increase in production of natural
akuammicine 10 (Figure 4.5B). Since both tabersonine 7 and akuammicine 10
are derived from pre-akuammicine 21, 7-methyltryptamine in may be inhibiting a
biosynthetic step immediately following the formation of pre-akuammicine 21
formation, while 6-fluorotryptamine 1c may inhibit a biosynthetic step further
downstream in the production of tabersonine 7, and therefore does not result in
accumulation of pre-akuammicine 21.
3.5 Temporal Analysis of Precursor Directed Alkaloid Analog Biosynthesis
In addition to the potential effect the substrate analog has on the
biosynthesis of natural alkaloids, there may also be a decrease in the rate of
biosynthesis due to the chemical properties of a non-natural intermediate. Small
perturbations have resulted in significant changes in the alkaloid profile and
temporal studies may identify the build up of biosynthetic intermediates not
observed in the final profile. Therefore, the rate of uptake and conversion of
tryptamine analogs to alkaloid analogs was next examined by culturing hairy
roots at day 14 in the presence of 0.5 mM tryptamine analog and extracting the
roots at various time points. Five tryptamine substrates (la, Ib, c, In and lz)
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were utilized in this study. Representing a range of profiles and substitutions at
all ring positions, tryptamine analogs, 4-, 5, and 6-fluorotryptamines (la, Ib, Ic)
and 7-methyltryptamine 1n, were tested in this time course study. Each
substrate was extracted at 1, 5, 10, 24, 48, 72, and 96 hours after feeding. The
extracts were analyzed by HR-LCMS to quantify the amount of alkaloid analogs
produced.
All tryptamine analogs were observed intracellularly after 1 hour of
incubation, and a maximum level of tryptamine and strictosidine analogs,
produced by the action of STR in vivo, was reached after 24 hours. The
concentration of tryptamines la-c, in and 1z and strictosidine analogs 3a-c, 3n
and 3z observed intracellularly did not vary dependent upon the individual analog
tested, suggesting that the uptake of tryptamine analogs is not dependent on
substitution (not shown). In control cultures fed with deuterated tryptamine
analog 1z, formation of tabersonine 7z was first observed after 5 hours and
continued to increase over the course of the experiment (Figure 4.6). Similar
increases in tabersonine analog production were observed with cultures fed lb
and Ic. However, feeding of la formed tabersonine analog 7a at a slower rate
and had a final concentration at 96 hours that was only 30% of that observed for
the lz control. No tabersonine is observed in cultures fed In, consistent with the
results reported in section 3.2.2.
In the control cultures supplemented with 1z, the formation of ajmalicine
4z and serpentine 5z production was first observed after 24 hours (Figure 4.6).
This order in formation of analogs is similar to what was observed in a study in
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which labeled tryptamine was fed to 9 day old seedlings [39]. No substrate
dependent changes in ajmalicine 4 and serpentine 5 analog production was
observed, with the exception of 1 n treated cultures in which no 5n was formed
over the course of this experiment. This was consistent with the observation that
serpentine production is reduced when steric perturbations are added to the
indole ring as discussed in section 3.2.
The formation of akuammicine 10z is observed after 24 hours of
incubation in cultures supplemented with deuterated tryptamine 1z (Figure 4.6).
Comparatively, there are significant increases in akuammicine analog production
in cultures treated with both In and Ic, which is consistent with the results found
in the final profiles discussed in section 3.2.2 and 3.2.3. In hairy roots treated
with In, the formation of akuammicine 10n occurs much earlier- after 9 hours-
and reaches a final level 40 times the level of akuammicine 10z in the 1z control
after 96 hours. In hairy roots treated with Ic, akuammicine 10c is produced after
24 hours and increases to 30 times the concentration of akuammicine 10z in
control cultures after 96 hours. Formation of akuammicine 10a and 10b in the la
and I b treated hairy roots did not differ significantly from the control.
Little isositsirikine 34z is generated in control cultures supplemented with
1z over the course of this experiment (Figure 4.6). A significant production of
isositsirikine 34a occurs in cultures treated with la at 48 hours and levels of 34a
steadily increased to 20 times the amount found in the control culture at the 96
hour time point.
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Interestingly, the profile of alkaloid analogs produced after 96 hours is
nearly identical to the profile observed in the final cultures after 7 days, as
discussed in section 3.2 (Figure 4.4). After addition of each exogenous substrate
lz, Ib, and Ic, there is an initial burst of tabersonine formation. However, in
cultures supplemented with la and in, where tabersonine 7 analog is not
present or is produced at a slower rate, the production of either akuammicine
10n, in the case of In, or isositsirikine 34a, in the case of la, occurs.
Isositsirikine 34 is a potential precursor to pre-akuammicine 21 while
akuammicine 10 is the product of deformylation of pre-akuammicine 21 (Figure
4.2). These results provide additional support the differences in alkaloid analog
profiles as discussed in section 3.2 (Figure 4.4).
4. Discussion
In this hairy root culture system, we explored the biosynthesis of TIA
analogs from variants of the starting materials tryptamine or strictosidine.
Substitutions made to the tryptamine or strictosidine starting materials greatly
affected the resulting alkaloid analog profile (Figure 4.4). These changes identify
bottlenecks to the production of various TIA analogs, which are important
findings for the future of metabolic engineering of this biosynthetic pathway.
Furthermore, these changes also provide insight into the chemistry of currently
unknown enzymes involved in the biosynthesis of TIA.
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4.1 Biosynthesis of Ajmalicine and Serpentine
Serpentine 5 is believed to be directly formed from ajmalicine 4 via an
enzymatic peroxidation reaction. Ajmalicine 4 or serpentine 5 was formed from all
tryptamine analogs tested. The level of ajmalicine 4 and serpentine 5 produced
varied depending on the substitution to the indole ring of the substrate fed. In
control cultures supplemented with deuterated tryptamine ly, relatively low
ajmalicine 4y levels were observed, and instead high levels of serpentine 5y
were formed. The amount of ajmalicine 4 increased and the amount of
serpentine 5 decreased with increasing size of substitution at all positions on the
indole ring (Figure 4.4). The isosteric benzofuran ethanamine 49 partitioned
exclusively into serpentine 5, with no ajmalicine 4 accumulating, similar to what is
found for control cultures fed deuterated tryptamine ly.
Ajmalicine 4 is likely synthesized from the iminium form of cathenamine 30
by an NADPH dependent reductase located in the cytosol (Figure 4.7) [17].
Ajmalicine 4 then enters the vacuole and is converted to serpentine 5, which is
then trapped in this organelle, since the positively charged serpentine 5 cannot
pass through the vacuolar membrane [20]. These results clearly indicate that the
reductive enzyme responsible for the formation of ajmalicine 4 from
deglycosylated strictosidine is promiscuous and exhibits little specificity for
substitutions on the indole ring. However, the peroxidase responsible for
oxidation of ajmalicine 4 to serpentine 5 is not tolerant of large, steric
perturbation at any position on the indole ring. The electronic characteristics of
these substitutions do not appear to play a major role for recognition by this
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peroxidase enzyme. It is unlikely that the reason for decrease in serpentine
production is due to differences in transport into the vacuole since it is not
thought to be transported by an active mechanism by rather by diffusion across
the membrane and storage as serpentine by an ion trap mechanism [20].
However, the effects of transport on the reduction of serpentine 5 levels can not
be definitively ruled out.
4.2 Central Role of Geissoschizine in Isositsirikine and Akuammicine
Biosynthesis
Certain tryptamine derivatives produced a profile of alkaloid analogs that
deviated significantly from the deuterated alkaloid profile that resulted from
cultures supplemented with isotopically labeled tryptamine substrate ly (Figure
4.4). The most dramatic deviations involved the accumulation of akuammicine 10
and isositsirikine 34 analogs. Although akuammicine 10 and isositsirikine 34
normally exist as minor components of a C. roseus alkaloid extract, cultures fed
certain un-natural tryptamine analogs produced large amounts of 10 and 34
analogs. Indole substitution therefore has a profound impact on how the
substrate analog partitions in this branch of the TIA biosynthetic pathway.
These data provide insight into the mechanism of biosynthesis and the
intricate interrelationship among these structurally diverse alkaloids.
Akuammicine 10, tabersonine 7 and isositsirikine 34 are each proposed to be
derived from the intermediate geissoschizine 20 (Figure 4.8) [21], as evidenced
by feeding of labeled geissoschizine 20 to C. roseus and observing incorporation
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of the label into 10, 7 and 34 [21, 22]. Geissoschizine 20 can be reduced to form
isositsirikine 34, or rearranged to form the biosynthetic intermediate pre-
akuammicine 21, the proposed precursor for both akuammicine 10 and
tabersonine 7 (Figure 4.8).
Pre-akuammicine 21 has never been isolated and rigorously characterized
due to its extreme lability [40]. Several mechanisms for pre-akuammicine 21
biosynthesis from geissoschizine 20 have been proposed [41]. Two reasonable
hypotheses for the formation of pre-akuammicine 21 both begin by oxidation at
the indole-3-position (geissoschizine-7-position, Figure 4.9).
In the first proposed pathway, addition of water to the p-hydroxyindolenine
35 generates geissoschizine-oxindole intermediate 36. Conversion of 36 to an
imino ether 37 promotes reaction with the enol form of the methyl ester and after
reduction of the aldehyde generates pre-akuammicine 21 (Figure 4.9) [40]. This
mechanism is supported by feeding studies in C. roseus that resulted in
incorporation of labeled geissoschizine-oxindole 36 into akuammicine 10 (0.55%)
and tabersonine 7 (0.05%) [40]. However, the synthesis and characterization of
the labeled geissoschizine-oxindole 36 used in this report was not provided and
this data was never subjected to peer review. Bio-mimetic synthesis of
akuammicine through an oxindole intermediate, generated by oxidation of
deformyl geissoschizine 20.1, resulted in formation of only 3-R-
deformylgeissoschizine-oxindoles 36.1, which do not have the correct
stereochemistry to form akuammicine 10 [42, 43]. This stereoselectivity is
believed to be due to steric clash between the methyl ester and vinyl group of
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deformylgeissoschizine-oxindole 36.1. Whether the same diastereoselectivity
would be observed with geissoschizine-oxindole 36 was not addressed.
The alternative hypothesis for the formation of pre-akuammicine 21 via a
P-hydroxyindolenine intermediate 35 begins with reaction with the enol form of
the methyl ester to generate of 16-formylstrictamine 39 (rhazinaline), a natural
product that is commonly found in the TIA producing plant Rhaza stricta [44]. Bio-
mimetic studies indicate that this is a valid mechanism for the formation of
akuammicine 10 from deformylgeissoschizine 20.1, through a strictamine 39.1
intermediate [42, 43]. These contrasting results leave doubt to the mechanism
through which geissoschizine 20 rearranges to form pre-akuammicine 21 and
further investigation to identify valid intermediates remains necessary to confirm
either hypothesis.
In light of our results, a third mechanistic hypothesis is proposed. In this
method, geissoschizine 21 is reduced to form isositsirikine 34 followed by
oxidation, through either an oxindole or strictamine intermediate, to form pre-
akuammicine 21. No feeding studies with isositsirikine 34 have been performed
to eliminate this mechanism. The proposed intermediate strictamine analog 39.2
has been isolated from Catharanthus roseus cultures [45], while none of the
other proposed intermediates have been detected in this plant. Future studies
should aim to assess if C. roseus converts isositsirikine 34 to the oxidized
products (akuammicine 10, tabersonine 7, and catharanthine 9).
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4.3 Rationale for Favoring Isositsirikine
The results of alkaloid analog incorporation can be interpreted in the
context of these mechanistic possibilities. First, deactivating substitutions at the
4-position greatly inhibit formation of pre-akuammicine 21 derived compounds
and instead favor accumulation of isositsirikine 34 analogs. This same pattern of
incorporation is also observed with the isosteric, electron deficient benzofuran
ethanamine substrate 49, further illustrating that the electronic nature of the
indole plays a key role in pre-akuammicine 21 biosynthesis. Studies of the
reactivity of un-substituted benzofuran suggest that it is more reactive at the 2-
position than the 3-position, which provides a possible explanation for the
decrease in formation of the desired oxidative product. The analog feeding
results support a mechanism invoking oxidation at the indole-3-position, but can
not definitively eliminate either the oxindole 36 or 16-formylstrictamine 39 as a
biosynthetic intermediate involved in pre-akuammicine 21 biosynthesis. The
oxidation at the indole-3-position would be affected by the presence of
deactivating substitutions at the 4-position. Therefore the formation of the P-
hydroxyindolenine intermediate 35 would be blocked and it would be at this initial
oxidation step that the biosynthesis of pre-akuammicine is inhibited (Figure 4.9).
The formation of isositsirikine 34 as the major product in cultures
supplemented with 4-substituted indoles and benzofuran ethanamine 49 is
consistent with reduction to isositsirikine 34 prior to oxidation. No time dependent
increase of a putative geissoschizine 20 intermediate (parent m/z = 353) occurs
in the time course analysis of 4-fluorotryptamine la treated hairy roots, while an
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increased rate of formation of isositsirikine 34 does occur with these analogs.
Substitution at the indole-5-position with electron withdrawing substitutions
results in a similar increase in isositsirikine 34 analog production.
Substitutions on the indole ring have effects on the electrophilic aromatic
substitution reaction that is proposed to in the oxidative rearrangement of
geissoschizine 20 to form pre-akuammicine 21 (Figure 4.9). Many aromatic
substitution reactions are influenced by both inductive and resonance effects of
the substitution. Although the substitution with fluorine has the strongest electron
withdrawing effect of the halogen series, it is also able to donate its electrons
through resonance. Therefore, fluorine substitutions para to the site of reaction
have a diminished net deactivation effect. Extensive studies of reactions with
benzene substrates clearly indicated that the position of the substitution relative
to the site of the reaction is essential for assessing reactivity [46]. A simple
formula
k
log = po (1)kO
where k is the rate constant or equilibrium constant for the reaction with
substituent X, ko is the rate constant or equilibrium constant for the unsubstituted
reaction, p is a reaction constant dependent on the reaction mechanism,
medium, temperature, and the distance of the substitution from the site of the
reaction, and a is a constant dependent on the substituent X and its position
relative to the site of the reaction [46]. The a constants determined for
substitution of benzene have been applied to electrophilic aromatic substitution
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reactions involving indole substrates [47]. For reaction at the indole-3-position,
indole positions 4 and 6 behave as meta position substituents, while 5 and 7
position substitutions behave as para substituents. Pre-akuammicine 21 is
derived from the oxidation of geissoschizine 20 at the indole-3-position
(geissoschizine 7-position, Figure 4.9). Analysis of the total peak area for
alkaloids derived from pre-akuammicine 21 (tabersonine 7 and akuammicine 10)
in cultures fed with tryptamine substituted at the 4- and 5- positions correlate with
the a constants determined for benzene meta and para substitutions respectively
(Figure 4.10). However, with substitution at the 6- and 7- positions this same
correlation was not observed (not shown). With these substitutions unusually
high amounts of oxidative products are present. The reason for this is not clear
with substrates substituted at the 6- and 7-positions. Geissoschizine is
substituted at both the indole-2-and 3-position. Studies of electrophilic aromatic
substitution of 2,3-disubstituted indoles could not be found and it is possible that
the indole reactivity is varied when multiple substitutions are present. Another
explanation is that the formation of akuammicine with substitutions at the 6- and
7-position is through a different mechanism. Also, the effect of the substitution
may not be felt at the oxidation step due to the distance from the site of reaction
but the effect may be observed at a step later in the formation of akuammicine
such as the reaction with the enol ester (Figure 4.9). A similar correlation was
observed when comparing the rate of formation of akuammicine and tabersonine
in the time course analysis of alkaloid analog production. The C constant
correlated well with the rate of formation of akuammicine and tabersonine
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analogs in cultures fed 4-fluorotryptamine la, 5-fluorotryptamine Ib, deuterated
tryptamine lz, and 7-methyltryptamine In. However, the rate of formation of 6-
fluorotryptamine lc did not follow this same trend (Figure 4.10C). These results
indicate that substitutions at indole- 6- and 7-position do not react in the same
manner as is observed with 4- and 5-position substituted intermediates.
Complete analysis of the profiles that result from feeding of precursors la-
d, li-n, it-w, 49, 3e-h, 3o-p, and 3v-w uncovered interesting trends in the
biosynthesis of akuammicine 10 and isositsirikine 34 analogs. First, placement of
electron withdrawing (deactivating) substituents (F, CI, Br) at the 4- and 5-
position of tryptamine resulted in an increase in the formation of isositsirikine 34
analogs and a decrease in the "oxidized" alkaloids derived from pre-akuammicine
21 (specifically akuammicine 10 and tabersonine 7). This trend was observed
with substituents at both 4- and 5-positions, but the effect was more dramatic
with 4-position substituents, similar to what would be expected based on the
Hammett constant a (Figure 4.10). Placement of methyl and methoxy
substituents at the 4- and 5-position also resulted in increased formation of
isositsirikine 34 though at levels significantly less then that observed with chloro
and bromo substitutions. Furthermore, unlike chloro and bromo analogs, the
formation of akuammicine 10 was observed with methyl and methoxy
substitution.
Conversely, the presence of substituents at the 6- and 7-position resulted
in an increase in the formation of akuammicine 10, the deformylation product of
pre-akuammicine. The formation of high amounts of akuammicine was
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independent of the type of substitution on the indole ring, suggesting that the
partitioning to form akuammicine is due to steric effects of the modification at the
6- and 7- positions of the indole ring (Section 4.5).
4.5 Rational for Favoring Akuammicine Production
The formation of akuammicine with tryptamine substrates having 6- and 7-
position substitutions does not follow the expected trend for the proposed indole-
3-position oxidation in the formation of akuammicine. As briefly discussed
above, the abnormally high yields of akuammicine 10 analogs produced upon
feeding of 7- and 6-substituted tryptamine analogs could be due to the following
four factors. First, the reactivity of 2,3-disubstituted indoles may not be affected
by substitutions at the 6- and 7-position. Second, 6- and 7-substituted indoles
may form pre-akuammicine through a different mechanism. Third, tabersonine 7
biosynthesis may be blocked, resulting in pre-akuammicine 21 accumulation and
degradation to akuammicine 10. Finally, the incorrect diastereomer of pre-
akuammicine 21 may be formed from these tryptamine analogs resulting in
increased accumulation of a pre-akuammicine 21 isomer that can not be
converted to tabersonine 7 (Figure 4.11).
Explanation one requires further study of the oxidative reactivity of 2,3-
disubstituted indoles. If the substitutions at the 6-and 7-position do not result in
decreased rate of electrophilic aromatic substitution then this would be a likely
explanation for the lack of inhibition of the oxidation step with deactivating
substitutions at this position. Explanation two suggests that the reaction pathway
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for 6- and 7-position substituted indoles is different from 4-and 5-position
substituted indoles. One hypothesis might be that due to the distance from the
site of the reaction, 6-and 7-position substitutions do not affect the oxidation step
as dramatically and instead increase the rate of the second step in the reaction,
attack by the enol form of the methyl ester. Explanation three would predict that
little or no tabersonine analog derived from 6 or 7-susbtituted tryptamine analogs
would be formed. However, cultures fed with 6-fluorotryptamine 1c and 6-
methylstrictosidine 3p produced a similar total yield of tabersonine when
compared to the control culture fed with deuterated tryptamine ly. Explanation
three is therefore not likely the sole cause for the increase in akuammicine 10
observed in the case of 6-position substitutions, although it may be partially
contributing the overall yield of this product. Explanation four invokes the
capacity of pre-akuammicine 21 to equilibrate between multiple diastereomers
such as condylocarpine (Figure 4.11, Figure 4.12). Substitutions on the ring
could disfavor formation of the correct diastereomer which can be productively
processed to form tabersonine 7, thereby blocking subsequent biosynthetic
steps. The pre-akuammicine 21 would then simply deformylate to form
akuammicine 10. Previous synthetic work has shown that oxindole formation
and isomerization is sensitive to the size of substitution at the 7-position, but not
at the 5-position (the 6-position was not examined) [48]. In this study the ratio of
diastereomers was altered and steric substitution at the 7-position resulted in
10:1 ratio of diastereomers compared to the 1:1 ratio observed with 5-position
substitutions. It is possible that a non-productive oxindole/pre-akuammicine
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diastereomer is formed from the 6- and 7-position substituted tryptamine analogs
which lack the proper stereochemistry for turnover by subsequent enzymes.
Instead, this "incorrect" diastereomer would be deformylated to akuammicine 10.
CD spectra of 7-methylakuammicine 10n, 6-fluoroakuammicine 10c, and
akuammicine 10 each had similar CD spectra, consistent with spectra observed
for akuammicine 10 previously (Figure 4.13) [49]. However, since the
stereochemistry of the "productive" pre-akuammicine 21 is not known, it is not
clear whether the accumulated akuammicine 10 matches the correct
stereochemistry.
The effects of substrate concentration on alkaloid profile also provide
clues for the reasons behind increased accumulation of akuammicine 10. In
cultures fed high concentration of tetradeuterotryptamine ly or 6-fluorotryptamine
1c, increased amounts of akuammicine analogs 10y and 10c were observed. A
decreased amount of natural akuammicine 10 was observed, suggesting that the
substrate analog effectively "competes" for the akuammicine 10 biosynthetic
machinery over the natural substrate and that excess intermediates are
commonly converted to akuammicine 10. In contrast, as 7-methyltryptamine In
concentration was increased, the amount of both akuammicine analog 10n and
natural akuammicine 10 product increased. This suggested that 7-
methyltryptamine 1n or an intermediate derived from 7-methyltryptamine 1 n
inhibits the processing of both natural and analog derived pre-akuammicine 21
by the plant. Since tabersonine 7 production was also decreased, the step
immediately following the formation of pre-akuammicine 21 is likely inhibited.
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Whether this decrease in tabersonine 7 formation is the sole explanation for the
increased formation of akuammicine 10 is unclear and must be investigated
further to draw conclusions about the observed effects.
Temporal analysis of the production of akuammicine 10 also revealed that
the timing of akuammicine analog 10n and 10c production in 7-methyltryptamine
In and 6-fluorotryptamine 1c supplemented cultures correlates with the timing of
tabersonine 7z formation in the control cultures fed 1z. Again, this suggests that
these analogs may be blocked in formation of tabersonine 7, and the excess pre-
akuammicine 21 intermediate, since it cannot be converted to tabersonine 7, is
instead deformylated to akuammicine 10. It appears that although these pre-
akuammicine analogs are not processed by the "tabersonine synthase" enzyme
they might be inhibitors of this enzyme as indicated by reduced amounts of
natural tabersonine observed with increasing concentrations of 7-
methyltryptamine In and 6-fluorotryptamine 1c.
4.7 Biosynthesis of Tabersonine
The biosynthesis of tabersonine 7 from pre-akuammicine 21 is poorly
understood. Feeding the reduced form of pre-akuammicine, stemmadenine 22, to
C. roseus cell suspension cultures increases the formation of tabersonine 7 and
catharanthine 9, in addition to the isomer of akuammicine, condylocarpine 40
(Figure 4.8) [50]. Many researchers propose dehydrosecodine 41 as an
intermediate in the biosynthesis of tabersonine 7 from pre-akuammicine 21 [26,
27, 29, 30, 51, 52]. Although dehydrosecodine 41 is too reactive for definitive
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feeding studies, feeding of the reduced form, secodine 42, to C. roseus culture
resulted in low but definite incorporation into vindoline 8 (a derivatized form of
tabersonine 7) suggesting that secodine 42 or dehydrosecodine 41 may be a
precursor to the aspidosperma alkaloids [28, 31]. The poor incorporation may be
due to the low efficiency of re-oxidation of secodine 42 to dehydrosecodine 41. A
direct link between dehydrosecodine 41 and the iboga alkaloid catharanthine 9
remains unverified in vivo and is proposed based on bio-mimetic studies [26, 29,
30].
Analysis of the alkaloid analog metabolome reveals that the most
substrate specificity occurs in the conversion of pre-akuammicine 21 to
tabersonine 7. Only steric and electronic perturbations at the 5- and 6-position of
the indole ring are permitted, but even many of these analogs are only produced
in low overall yields. Direct analysis of the effect of substitutions on the formation
of tabersonine 7 is complicated due to the intermediacy and specificity in the
formation of pre-akuammicine 21 discussed in the previous section.
The mechanism of formation of tabersonine from dehydrosecodine 41 is
proposed to occur via either extended Mannich chemistry or a 4+2 cyclo-addition.
The formation of tabersonine appears to be reversible based on the formation of
catharanthine 9 from labeled tabersonine 7 in vivo [25]. Future work should more
carefully examine this process with the aim to identify the intermediate between
tabersonine 7 and catharanthine 9, and to determine the mechanism by which
each compound forms. Compounds that might correspond to a dehydrosecodine
41 or secodine 42 intermediate were observed in cultures treated with 4-
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methoxytryptamine lt and 5-methoxystrictosidine 3v respectively. However,
these compounds were not isolated in this study and future work should fully
characterize these compounds to determine if they are non-productive
intermediates to the formation of tabersonine.
The formation of pre-akuammicine 21 does not occur with many
tryptamine-4-position substituted substrates, therefore it is impossible to assess
the effect these substitutions have on the formation of tabersonine 7. It remains
unclear whether 4-chloro or 4-bromo pre-akuammicine 21 analogs would form
tabersonine 7 analogs if they were generated in vivo. Comparison of the
akuammicine 10 and tabersonine 7 analog yield in 4-fluorotryptamine la and 4-
methyltryptamine Im fed hairy root cultures suggests that the formation of
tabersonine 7 is sensitive to steric perturbations at the 4-position (Figure 4.4).
Substitution of flouro, chloro, and bromo groups at the 5-position results in
a decrease in the fraction of both akuammicine 10 and tabersonine 7 analogs
formed. It appears that placement of deactivating groups at the 5-position does
not affect the ratio of akuammicine 10 to tabersonine 7 in these cultures
suggesting there is little effect of either size nor electronic nature of the 5-position
substitution on the formation of tabersonine 7 from the pre-akuammicine 21
intermediate (Figure 4.4). The high amounts of methylated tabersonine 7o
produced in cultures fed 5-methylstrictosidine 3o suggests that there is little
effect of steric substitutions at the 5-position on tabersonine synthesis.
Substitution of electron withdrawing groups at the tryptamine-6-position
results in high amounts of akuammicine 10 analogs and decreased tabersonine 7
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analog when compared to the control cultures fed the electron donating 6-
methylstrictosidine 3p. These results suggest that the electronic natural of the
substitution at the 6-position may affect tabersonine 7 analog production.
Of all the 7-substituted analogs, only 7-fluorotryptamine Id fed hairy roots
produced analogs of tabersonine 7d. This could be due to either the electronic
nature of the substitution or biosynthesis of tabersonine 7 may be particularly
sensitive to steric perturbations at this position, and a conclusion can not be
drawn from this study due to the limited number of tabersonine analogs produced
upon substitution at this position.
5. Conclusions
Dramatic changes in the alkaloid profile were produced by introducing only
minor changes to the starting materials. Utilization of these alternative tryptamine
substrates could be an excellent way to increase yield of certain alkaloid analogs
such as ajmalicine 4, akuammicine 10, and isositsirikine 34. These compounds
are not produced in high yields in C. roseus cultures but have potentially useful
bioactivities. Ajmalicine 4 is a known anti-hypertensive agent that is clinically
used in a combination treatment for rehabilitation following a stroke [53].
Akuammicine 10 has been shown to have opioid activity and to bind to opioid
receptors with varied affinity, but is currently not used in the clinic [54]. These
results suggest that production of higher yields of these potentially useful natural
products is possible using directed biosynthesis.
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In addition to producing compounds not normally produced in high
amounts in natural cultures, this study highlights the specificity of enzymes,
which have yet to be identified on an enzymatic or genetic level. We found that
the enzyme responsible for the oxidation of geissoschizine 20 is sensitive to
electron withdrawing substitutions at the 4 and 5-postiion of the indole ring. The
yet unidentified enzymes responsible for tabersonine 7 formation are also
sensitive to substitutions at the 4- 6- and 7-positions of the indole ring, while it is
less sensitive to substitution at the 5-positions. Future work should aim to identify
the enzymes responsible for these conversions. Identification of these enzymes
and rigorous analysis of their substrate specificity can give further insight into the
various profiles observed with substitution to the indole ring. Furthermore, the
substrate scope for these enzymes could be expanded through protein
engineering techniques for the generation of additional alkaloid analogs.
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Chapter 5
Photo-affinity Labeling of C. roseus TIA Biosynthetic Enzymes
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1. Introduction
Terpene indole alkaloids (TIA) are a group of plant natural products
displaying diverse medicinal activities [1]. The lack of identified biosynthetic
enzymes at important branch points in the pathway hinders the study of this
highly branched natural product biosynthetic pathway. Although several of the
enzyme activities are observed in partially purified protein extracts [2], the
enzymes that immediately follow the first two steps in this biosynthetic pathway
have not been identified on a genetic level.
Functional proteomic methods, such as activity based protein profiling,
have recently emerged to identify enzymes of specific functional class [3]. The
method involves development of a chemical probe with both a reactive group for
chemical labeling of the enzyme of interest and a second functional group for the
attachment of the reporter tag to identify the labeled proteins (Figure 5.1). There
are two general types of reactive groups employed in the labeling of enzymes;
photo-reactive groups, which modify active site residues upon irradiation with UV
light and electrophilic groups, which modify active site nucleophiles.
Photo-affinity labeling of proteins has led to the identification of proteins
that bind photo-reactive substrates [4]. Several photo-reactive groups are
commonly used for labeling of proteins including diazirines, benzophenones, and
aryl azides (Figure 5.1) [5]. The aryl azides and diazirines are ideal in systems
where steric modification of a ligand might inhibit the protein-ligand interaction of
interest. Previously, several indole-azides specifically labeled proteins of interest
[6-15]. For example 6-azidotryptophan labeled tryptophan synthase [11] and
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Figure 5.1: Affinity based protein labeling. Ligand is modified with a reactive
group (red), and a chemical handle such as an acetylene. After protein
labeling with the reactive group the ligand can be coupled to a tag such as
rhodamine or biotin. Representative reactive groups are shown.
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azido-indole acetic acid, a phytohormone, labeled and identified its protein
binding partners[10]. No precedence exists for the use of diazirine analogs of
indoles to modify protein targets.
In addition to photo-affinity labels, activity based probes that react with
active site nucleophiles have been developed to identify proteins based on the
mechanism of enzymatic catalysis and utilized as probes for active enzymes [3].
These probes generally contain a reactive group, which covalently modifies the
enzymes active site nucleophiles as mechanism based inhibitor [3]. Recently aryl
alkynes have been used as suicide inhibitors of P450 enzymes (Figure 5.1) [16].
Additionally, aryl alkynes with a second alkyl alkyne as a bio-orthogonal handle
were used to label P450 enzymes in cell free extracts in an activity dependent
manner [17]. Several of the steps in the biosynthesis of TIA may require the
activity of P450 and therefore a similar probe for TIA biosynthesis would be
useful in the identification of these enzymes.
Typically, the proteins of interest are not tolerant of large modifications to
the substrate, such as the addition of a biotin or fluorophore label for detection.
Enzyme photo-active substrates or covalent inhibitors modified with bio-
orthogonal groups, including alkyl azides or alkynes, allows facile covalent
modification with labels for detection after the protein modification reaction has
occurred. Attachment of an appropriately modified biotin or fluorophore can be
performed by a bio-orthogonal copper catalyzed Huisgen-Sharpless 1,3-dipolar
cycloaddition reaction between an alkyl azide and alkyne (Figure 5.1) [18]. A
secologanin analog, modified by transesterification of the methyl ester to add an
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alkyne functionality [19], was processed by strictosidine synthase, and upon
feeding to C. roseus hairy root cultures was converted to ajmalicine, serpentine
and isositsirikine analogs containing the alkyne functionality [20, 21].
With these proof-of-concept experiments, I envisioned that strictosidine
analogs generated by coupling tryptamine- modified with either photo-reactive
(diazirine or azide) or electrophilic (alkyne) moieties- and the secologanin analog
containing a pentynyl ester- for attachment of a reporter tag- could be utilized to
identify enzymes involved in TIA biosynthesis (Figure 5.2). Attempts to
synthesize diazirine and alkyne tryptamine analogs failed. However, 4, 5, 6 and
7-azidotryptamines are known to be accepted by strictosidine synthase and
downstream enzymes when fed to C. roseus hairy root cultures [22]. In this study
the bi-functional strictosidine analogs, generated by condensation of 4-,5-,6- and
7-azidotryptamines and secologanin pentynyl ester, were used to label the
proteins in a cell free extract containing proteins to which the substrate bound.
After modification of the alkyne with biotin- or rhodamine-azides (Figure 5.1), the
labeled proteins were identified by 2-dimensional SDS-PAGE or western blot
analysis. The identified proteins were sequenced by mass spectrometry. Since
the genome of C. roseus has not been sequenced, the peptides identified by
mass spectrometry were used to search the C. roseus EST database and
potential candidates for the yet unidentified biosynthetic enzymes were identified.
As an alternative to these functional proteomic based methods for
identification of C. roseus enzymes, label transfer reagents capable of identifying
protein-protein interactions were explored. SGD, when purified from C. roseus,
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Figure 5.2: Synthesis of 4-, 5-, 6- and 7- azidostrictosidine pentynyl ester aglucones from the
corresponding tryptamine-azides and secologanin pentynyl ester.
existed as a insoluble multi-enzyme complex [23, 24]. To explore whether SGD
is forming protein interactions with downstream enzymes in the biosynthesis of
TIA, a commercially available label transfer reagent (Pierce Biotechnology, cat #
33083) was tested to identify proteins that interact with SGD. The reagent
labeled several enzymes, which were sequenced and the corresponding C.
roseus EST sequences were identified.
2. Experimental Methods
2.1 Synthetic Methodology
2.1.1 Rhodamine-azide Synthesis
5(6)-Carboxy-X-rhodamine N-succinimidyl ester (Sigma cat # 21966, 6.6
mg, 0.0125 mmol) was dissolved in methanol (0.25 mL). 11-Azido-3,6,9-
trioxaundecan-l-amine technical (Sigma cat # 17758, 0.1 mol) and triethylamine
(10 pL ) was added and the solution was stirred at room temperature for 4 hours.
The solvent was removed and the product was purified by silica gel
chromatography in 1:1 DCM/Hexanes.
2.1.2 Synthesis of 5-ethynyltryptamine
2.1.2.1 5-Ethynylindole-3-carbaldehyde
5-Bromoindole-3-carbaldehyde (0.3571 g, 1.59 mmol), copper iodide (30.9
mg), triphenylphosphine (43.7 mg), bis(triphenylphosphine)palladium(ll)
dichloride (56.2 mg) were suspended in DMF (0.8 mL) and to this solution was
added trimethylsilyl acetylene (0.44 mL). After four hours the reaction was
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quenched by addition of water (3 mL) and ethyl acetate (3 mL). The product was
extracted into ethanol, washed with brine, filtered over celite, dried over
anhydrous sodium sulfate. The solvent was removed under vacuum to give a
brown product. The brown product was purified over silica gel chromatography
to yield 5-ethynylindole-3-carbaldehyde (259 mg).
2.1.2.2 5-ethynylindole-3-nitroethylene
5-Ethynylindole-3-carbaldehyde (0.279 g, 1.64 mmol) was dissolved in 8
mL of nitromethane with ammonium acetate (.065 g) and refluxed for 4 hours.
The solvent was removed under vacuum and the product was purified by silica
gel chromatography in 20% acetone in hexanes to yield 55 mg of 5-
ethynylindole-3-nitroethylene (0.259 mmol, 16%). 1H NMR (300 MHz, d6-
acetone) 6 ppm 8.39 (d, J = 13.56 Hz, 1H), 8.23 (s, 1H), 8.15 (dd, J = 1.34, 0.70
Hz, 1H), 8.01 (d, J = 13.53 Hz, 1H), 7.59 (dd, J = 8.44, 0.73 Hz, 1H), 7.41 (dd, J
= 8.44, 1.46 Hz, 1H), 3.60 (s, 1H). 13C NMR (500 MHz, d6-acetone) 6 ppm
137.417, 134.907, 134.581, 129.016, 126.263, 117.654, 114.828, 86.176,
78.639.
2.1.2.3 5-Ethynyltryptamine
5-Ethynylindole-3-nitroethylene (0.259 mmol, 55 mg) was dissolved in 1,4-
dioxane and added to 2.5 mL of 1M LAH in THF. The solution was refluxed form
2 hours and quenched by addition of 5 mL of 50% 1,4-dioxane in waster. The
solution was filtered over celite and the solvent was removed under vacuum.
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The product was purified by silica gel chromatography; 95:5:1
dichloromethane/methanol/ammonium hydroxide to elute impurities and 90:10:1
dichloromethane/methanol/ammonium hydroxide to elute the product (12.1 mg,
0.069 mmol, 30% yield). 1H NMR (500 MHz, CD 30D) 6 7.72 (dd, J = 1.4, 0.7,
1H), 7.30 (dd, J = 8.4, 0.7, 1H), 7.20 (dd, J = 8.4, 1.5, 1H), 7.14 (s, 1H), 4.72 (s,
1 H), 3.07 - 2.95 (m, 3H), 2.95 - 2.86 (m, 3H). 13C NMR (126 MHz, CD 30D) 6
127.71, 125.56, 124.28, 123.02, 112.92, 112.45, 111.74, 85.75, 74.70, 73.69,
70.77, 42.00, 27.57.
2.1.3 Synthesis of 5-Acetyltryptamine
2.1.3.1 5-Acetylindole-3-nitroethylene
5-Acetylindole (0.3826 g, 2.4 mmol) and 1-dimethylamino-2-nitroethylene
(0.27 g) were dissolved in 3 mL of TFA and stirred at room temperature under
nitrogen for 30 minutes. The resulting product was quenched by pouring the
solution into 4 equivalents of saturated sodium bicarbonate in water. The
resulting yellow product was extracted into ethyl acetate and the organic fractions
were collected and solvent removed under vacuum. The product was purified by
silica gel chromatography (23.3 mg, 0.105 mmol, 16% yield). 1HNMR (d6-
acetone) 6 8.649 (1H, m), 8.43 (1H, d, J =13.6 Hz), 8.289 (1H, d, J = 2.9 Hz),
8.03 (1H, d, J = 13.6 Hz), 7.97 (1H, dd, J = 8.6 and 1.6 Hz), 7.67 (1H, dd, J = 0.7
and 8.6 Hz), 2.712 (3H, s).
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2.1.3.2 5-Etheleneketalindole-3-nitroethylene
5-Acethylindole-3-nitroethylene was dissolved in benzene with p-toluene
sulfonic acid and ethylene glycol and refluxed for 2 hours. The product was
extracted with benzene and the solvent was removed under vacuum the product
was purified by silica gel chromatography 20% acetone in hexanes (72 mg, 0.26
mmol). 'H NMR (300 MHz, CD 30D) 6 8.40 (1 H, d, J = 13.49 Hz), 8.20-8.18 ( 1
H, m), 7.98-7.95 ( 1 H, m), 7.91 ( 1 H, d, J = 13.55 Hz), 7.56 ( 1 H, dd, J = 8.63,
0.61 Hz), 7.43 ( 1 H, dd, J = 8.53, 1.54 Hz), 4.07-4.01 ( 2 H, m), 3.82-3.75 ( 2 H,
m), 1.66 ( 3 H, s)
2.1.3.3 5-Ethethelenketaltryptamine
5-Etheleneketalindole-3-nitroethylene (72 mg, 0.26 mmol) was dissolved
in 1,4-dioxane and added to 2.6 mL of 1M LAH in THF. The mixture was
refluxed for 2 hours and quenched by the addition of wet dioxane. The solution
was filtered over celite and the solvent removed under vacuum. The product was
purified by silica gel chromatography; 95:5:1 dichloromethane/l methanol/
ammonium hydroxide to elute impurity and 90:10:1 dichloromethanel methanol/
ammonium hydroxide to elute the product (23.5mg). 1H NMR (500 MHz, CD 30D)
6 9.90 (s, 1H), 9.41 (d, J = 10.4, 1H), 9.01 (d, J = 11.7, 1H), 8.97 - 8.92 (m, 1 H),
8.87 (s, 1H).
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2.1.4 Azidostrictosidine Synthesis
Proto-reactive substrates, 4-,5-, 6- and 7-azidostrictosidine pentynyl esters
and 7-azidostrictosidine, were synthesized either chemically in 200 mM maleic
acid with 40 mM each azidotryptamine and secologanin pentynyl ester, or
enzymatically by addition of 1 mM of 7-azidotryptamine, 1 mM secologanin or
secologanin pentynyl ester in assay buffer (pH 6.8 sodium phosphate dibasic)
with 1 VpM strictosidine synthase which was expressed and purified from E. coli
as a C-terminal HIS tag using a construct provided by Bill Hillmann The
strictosidines were purified by preparative HPLC using 25-50% acetonitrile: 0.1%
trifluoroacetic acid in water over 15 minutes on Denali C18 10 um, 22 x 250.
2.1.4.1 4-Azidostrictosidine Pentynyl Ester
1H NMR (600 MHz, CD 3CN) 6 10.21 (s, 1H), 10.13 (s, 1H), 7.84 (s, 1H), 7.64 (s,
1H), 7.55 (s, 1H), 7.28 - 7.15 (m, 5H), 6.93 (d, J = 6.4, 2H), 5.93 - 5.76 (m, 2H),
5.70 (dd, J = 64.8, 8.2, 2H), 5.43 - 5.25 (m, 5H), 4.76 (d, J = 7.9, 1 H), 4.71 (d, J
= 7.9, 3H), 4.57 (d, J = 7.5, 1H), 4.28 (t, J = 6.2, 2H), 4.17 - 4.10 (m, 1H), 4.04 -
3.98 (m, 1H), 3.98 (s, 1H), 3.81 (ddd, J= 12.0, 5.7, 2.4, 2H), 3.63 (ddd, J= 18.4,
12.0, 6.2, 4H), 3.36 (dt, J = 14.2, 7.5, 7H), 3.29 (s, 5H), 3.25 (dd, J = 20.5, 9.4,
3H), 3.21 - 3.12 (m, 7H), 3.08 (dd, J = 12.5, 6.6, 1H), 3.02 (dt, J = 11.7, 4.4, 1H),
2.81 - 2.70 (m, 2H), 2.25 (dd, J = 8.9, 6.3, 8H), 2.19 (tt, J = 8.6, 4.4, 4H), 1.90 (p,
J = 6.8, 2H), 1.75 - 1.65 (m, 2H). ESI MS (C31 H38N509, m/z calc. 624.2670,
obs. 624.2670)
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2.1.4.2 5-Azidostrictosidine Pentynyl Ester
'H NMR (600 MHz, CD 3CN) 6 10.07 (d, J = 2.2, 1H), 10.04 - 10.00 (m, 1H), 7.85
(s, 1H), 7.64 (s, 6H), 7.57 (s, 1H), 7.43 (dd, J = 22.9, 8.7, 2H), 7.25 (d, J = 1.8,
2H), 6.93 (ddd, J = 8.6, 3.5, 2.2, 2H), 5.96 - 5.86 (m, 1H), 5.85 - 5.77 (m, 1 H),
5.76 (d, J = 8.9, 1 H), 5.64 (d, J = 7.7, 1 H), 5.35 (ddd, J = 44.3, 18.0, 9.5, 5H),
4.76 (d, J = 7.9, 1 H), 4.74 - 4.68 (m, 3H), 4.28 (t, J = 5.9, 3H), 4.17 - 4.03 (m,
2H), 4.00 (dd, J = 11.3, 6.3, 1H), 3.98 (s, 3H), 3.91 - 3.77 (m, 6H), 3.70 - 3.55
(m, 3H), 3.43 - 3.31 (m, 7H), 3.29 (d, J = 9.0, 14H), 3.15 (td, J = 8.6, 3.8, 1H),
3.07 - 2.96 (m, 5H), 2.81 - 2.69 (m, 2H), 1.70 (dq, J = 13.2, 6.8, 2H). ESI MS
(C31H38N509, m/z calc. 624.2670, obs. 624.2671)
2.1.4.3 6-Azidostrictosidine Pentynyl Ester
'H NMR (600 MHz, CD 3CN) 6 10.03 (s, 1H), 9.99 (s, 1H), 7.85 (s, 1H), 7.64 (s,
4H), 7.58 (s, 1H), 7.52 (d, J = 8.4, 2H), 7.12 (d, J= 17.4, 2H), 6.87 (d, J = 6.4,
2H), 5.90 (ddd, J = 17.5, 10.4, 8.5, 1 H), 5.85 - 5.77 (m, 1H), 5.75 (d, J = 8.8,
1H), 5.63 (d, J= 7.6, 1H), 5.43 (s, 1H), 5.37 (d, J= 11.6, 2H), 5.29 (d, J = 10.9,
1 H), 4.76 (d, J = 7.9, 1 H), 4.72 (d, J = 7.9, 2H), 4.61 - 4.54 (m, 1 H), 4.28 (t, J =
6.2, 2H), 4.12 (s, 1H), 4.10 - 4.04 (m, OH), 4.01 (s, 1H), 3.98 (s, 2H), 3.83 (s,
2H), 3.65 (s, 3H), 3.43 - 3.32 (m, 6H), 3.29 (s, 12H), 3.26 (d, J = 9.3, 2H), 3.15
(s, 2H), 3.00 (s, 6H), 2.77 (dd, J = 23.3, 10.3, 2H), 1.94 - 1.86 (m, 6H), 1.76 -
1.65 (m, 2H), 1.29 (s, 18H). ESI MS (C31H38N509, m/z calc. 624.2670, obs.
624.2659)
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2.1.4.4 7-Azidostrictosidine Pentynyl Ester
'H NMR (600 MHz, CD 3CN) 6 9.95 (s, 1H), 7.85 (s, 1H), 7.64 (s, 2H), 7.33 (d, J =
7.9, 1H), 7.16 (t, J = 7.7, 1H), 7.07 (d, J = 7.6, 1H), 5.87 - 5.78 (m, 1H), 5.77 (d,
J = 8.9, 1H), 5.48 (s, 3H), 5.36 (d, J = 17.4, 1H), 5.28 (d, J = 10.7, 1H), 4.77 (d, J
= 7.9, 1 H), 4.27 (t, J = 6.2, 2H), 4.08 (dd, J = 11.3, 4.4, 1 H), 4.03 - 3.97 (m, 2H),
3.98 (s, 1H), 3.89 (d, J = 38.2, 3H), 3.80 (s, 1H), 3.61 (d, J = 37.8, 2H), 3.52 -
3.39 (m, 1H), 3.39 - 3.33 (m, 2H), 3.29 (d, J = 5.3, 15H), 3.26 (dd, J = 9.4, 4.2,
1H), 3.14 (s, 1H), 3.00 (d, J = 12.0, 3H), 2.72 (d, J = 30.7, 1H), 1.93 - 1.88 (m,
2H), 1.34 (d, J = 60.9, 20H), 0.91 (t, J = 7.0, 3H). ESI MS (C31H38N509, m/z
calc. 624.2670, obs. 624.2664)
2.1.4.5 7-Azidostrictosidine
1H NMR (600 MHz, CD 3CN) 6 9.47 (s, 1H), 7.81 (s, 1H), 7.62 (s, 1H), 7.35 (d, J=
7.9, 1H), 7.18 (t, J = 7.8, 1H), 7.09 (d, J = 7.6, 1H), 5.86 - 5.76 (m, 1H), 5.76 (d,
J = 8.8, 1H), 5.48 (s, OH), 5.36 (d, J = 17.3, 1H), 5.27 (d, J = 10.6, 1H), 4.77 (d, J
= 7.9, 1H), 4.62 (s, 1H), 3.82 (dd, J = 12.1, 2.5, 1H), 3.79 (s, 3H), 3.76 (s, 1 H),
3.63 (dd, J = 12.0, 6.2, 1H), 3.43 - 3.33 (m, 3H), 3.27 (dd, J = 19.2, 9.9, 1H),
3.19 - 3.14 (m, 1H), 3.04 (ddd, J = 25.0, 18.3, 13.9, 3H), 2.80 - 2.71 (m, 1H).
ESI MS (C27H34N509, m/z calc. 572.2357, obs. 572.2330)
2.2 UV Degradation of Tryptamine and Strictosidine Azides
The UV spectrum from 220-350 nm for 7-azidotryptamine 100 pM in 0.1
mM phosphate buffer in a 1 cm UV cuvette was monitored after irradiation under
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302 nm UV light for 0-3 minutes. Irradiation was performed by placing the
cuvette 3 inches under an inverted DNA lamp at 302 nm for the designated time.
The amount of 7-azidotryptamine remaining was determined by analysis of the
absorbance at 247 nm.
2.3 Strictosidine Synthase Inhibition with 4-azidotryptamine
4-Azidotryptamine (0-1 mM) was added to a strictosidine synthase activity
assay containing 0.02 mM tryptamine, 0.5 mM secologanin and 100 nM STR in
100 mM NaH 2PO 4 (pH =6.8) in a 0.1 mL total reaction volume. The reaction was
quenched by the addition of 0.4 mL of methanol, containing 500 nM yohimbine
as an internal standard, at various time points and diluted with 1 mL of water.
Strictosidine and yohimbine were separated from the starting materials
secologanin and tryptamine by isocratic elution on a Waters Acquity UPLC
system of 20% acetonitrile in 0.1% formic acid water at a flow rate of 0.6 ml/min
on a Waters UPLC BEH C18, 1.7 um, 2.1x100 mm column. The product was
detected by ESI-TOF MS on a Waters LCT Premier spectrometer. The ionization
parameters were a capillary and sample cone voltage 3000 and 20 respectively;
source and capillary temperatures were 100 and 300 0C respectively; and cone
and desolvation gas flow rates of 20 and 700 L/hr. The resulting LCMS
chromatograms were integrated and standardized to yohimbine. The enzymatic
rate was determined by plotting the standardized strictosidine peak area against
the time of quench.
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2.4 Strictosidine Synthase Inactivation with Tryptamine Azides
Strictosidine synthase (10 pL) was incubated with 4-,6- and 7-
azidotryptamines (250 M) was diluted to a final volume of 100 PIL with assay
buffer (0.1 M sodium phosphate dibasic, pH 6.8), and 250 mM sucrose). The
reaction was irradiated for 2 minutes at 302 nm under an inverted DNA gel lamp
placing the assay solution three inches from the light source. The control
reactions were irradiated in the absence of 4-, 6- or 7-azidotryptamines, were not
irradiated but contained 4-, 6- or 7-azidotryptamines, or untreated strictosidine
synthase.
Strictosidine synthase (10 pL of irradiated assay or controls) was added to
500 pL reaction mixture containing 300 [tM tryptamine, 500 pM secologanin in
0.1 M NaH 2PO 4 (pH=6.8) at room temperature. The reaction was quenched by
adding 100 pL of reaction mixture to 400 pL of methanol containing 500 nM
yohimbine as an internal standard. The resulting solution was further diluted with
1 mL of water and analyzed by LCMS. Strictosidine and yohimbine were
separated from the starting materials secologanin and tryptamine by isocratic
elution on a Waters Acquity UPLC system of 20% acetonitrile in 0.1% formic acid
water at a flow rate of 0.6 mL/min on a Waters UPLC BEH C18, 1.7 pm, 2.1x100
mm column. The product was detected by ESI-TOF MS on a Waters LCT
Premier spectrometer. The ionization parameters were a capillary and sample
cone voltage 3000 and 20 respectively; source and capillary temperatures were
100 and 300 0C respectively; and cone and desolvation gas flow rates of 20 and
700 L/hr. The resulting LCMS chromatograms were integrated and standardized
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to yohimbine. The enzymatic rate was determined by plotting the standardized
strictosidine peak area against the time of quench. These rates were then
compared to the control in which strictosidine synthase was added to the 4-,6- or
7-azidotryptamines sample after irradiation. No loss in STS activity was
observed for samples irradiated in the absence of 4-,6- or 7-azidotryptamines.
2.5 Formation of Azidostrictosidine Aglucone
Purified 4-, 5-, 6-, and 7-azidostrictosidine pentynyl ester were dissolved in
DMSO to a final concentration of 100 mM. For each azidostrictosidine, 1 PL was
added to a 1.7 mL centrifuge tube and diluted to 15 pIL with 14 pL of 0.1 mM
sodium phosphate buffer (pH 7). SGD (5 pL of a 1 mg/mL solution, SOC
construct) was added to the solution and vortexed and briefly centrifuged and
incubated at room temperature for one hour covered in aluminum foil to protect
from light. After one hour the reaction was checked for complete conversion to
the aglucone. This was done by LCMS analysis using an Acquity UPLC
equipped with an Acuity BEH C18 column (1.7 pLm, 2.1x100 mm). The sample
was eluted on a 25-80% acetonitrile/ 0.1% formic acid in water gradient over 5
min. The product was detected using the LCT Premier mass spectrometer in
positive V mode. The aglucone was identified by extrapolation of m/z 444 and
the absence of starting material (m/z 624) was verified. For 4- and 5-
azidostrictosidine, complete loss of starting material was not observed since it
was a mixture of diastereomers.
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2.6 Cell Free Conversion of Strictosidine Azide Pentynyl Ester
First, 4-,5-,6-and 7-azidostrictosidine pentynyl esters (1 iL of 2 mM) were
incubated with strictosidine glucosidase (SGD, 5 gL, 1 M) for 1 hour at room
temperature in assay buffer (pH 6.8 NaH 2PO 4 and 250 mM sucrose). The
"ajmalicine synthase" protein preparation (84 gL) prepared by Nancy Yerkes, and
1 mM NADPH (10 pL of 10 mM stock solution). The reaction was incubated for
30 min. Control lacking the "ajmalicine synthase" preparation were used as
controls. The reaction was quenched after 15 and 30 min and the samples were
analyzed by LCMS by separation on an Acquity UPLC equipped with an Acuity
BEH C18 column (1.7 gm, 2.1x100 mm). The sample was eluted on a 25-80%
acetonitrile/ 0.1% formic acid in water gradient over 5 min. The product was
detected using the LCT Premier mass spectrometer in positive V mode
extrapolating for the mass of the reduced product (m/z 446). No product
formation was observed in the control lacking the "ajmalicine synthase"
preparation.
2.7 Inactivation of "Ajmalicine Synthase" Activity with Strictosidine Azide
To a cell free protein extract with "ajmalicine synthase" (10 gtL) activity 1
gL of 10 mM 7-azidostrictosidine was added. Strictosidine glucosidase (10 jL)
and 1 tL of 1 mM NADPH was added and irradiated for 2 min under a 302 nm
UV lamp. After 2 min of irradiation an additional 10 ItL of 7-azidostrictosidine and
irradiated another 2 min. The resulting protein sample was then tested
"ajmalicine synthase" activity by adding 10 tL of extract, 1 gL of NADPH, 10 iL
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of d4-strictosidine (0.1 mM) and 10 pL of SGS. The reaction was quenched at
various time points. The samples were analyzed as determined by an LCMS
based assay. Labeled ajmalicine and yohimbine were separated from
deglycosylated labeled strictosidine by isocratic elution on a Waters Acquity
UPLC system of 20% acetonitrile in 0.1% formic acid water at a flow rate of 0.6
mL/min on a Waters UPLC BEH C18, 1.7 pm, 2.1x100 mm column. The product
was detected by ESI-TOF MS on a Waters LCT Premier spectrometer. The
ionization parameters were a capillary and sample cone voltage 3000 and 20
respectively; source and capillary temperatures were 100 and 300 *C
respectively; and cone and desolvation gas flow rates of 20 and 700 L/hr. The
resulting LCMS chromatograms were integrated and standardized to yohimbine.
The enzymatic rate was determined by plotting the standardized labeled
ajmalicine peak area against the time of quench. These rates were then
compared to the control in which no 7-azidostrictosidine or no UV at 302 nm in
the presence of 7-azidostrictosidine. No loss in "ajmalicine synthase" activity
was observed for samples irradiated in the absence of 7-azidostrictosidine or
without UV irradiation at 302 nm.
2.8 Biotinylation of Cross-linked Proteins
After irradiation the pentynyl ester of the cross-linked compound was
biotinylated through a 1,3-Huisgen cycloaddition reaction. The reaction
consisted of 1 mM TCEP, 1 mM CuSO4, 1 mM biotin, 1 mM ligand, 5% t-butanol
and 1% SDS. The reaction was carried out wrapped in aluminum foil at room
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temperature for 1 hour. After incubation, the protein was purified using the
perfect focus protein clean up kit (G-biosciences) following the manufacturer's
protocol.
2.9 Detection of Biotin Labeled Proteins
7-Azidostrictosidine pentynyl ester (10 pL, 1 mM) was added to 100 pL of
extract with 2 pL of 1 mM NADPH and 10 L of SGS and 60 gL of pH 7 buffer
containing 100 mM NaH 2PO 4 and 250 mM sucrose. The sample was irradiated
for 5 min at 302 nm (or not for the control). The two samples were then
conjugated to biotin by addition of 8 tL of tris(2-carboxyethyl)phosphine (TCEP,
25 mM), 4 jL of CuSO 4 (50 mM), 12 IL of tris-(benzyltriazolylmethyl)amine
(TBTA, 17 mM), and 1 tL of biotin (60 mM). The reaction was carried out for 1
hour at room temperature then the proteins were precipitated with methanol:
chloroform precipitation. These protein samples were then analyzed utilizing a
UV based biotin detection kit (Pierce biotechnology) using the standard protocol.
2.10 UV Cross-linking of Proteins for 2-Dimensional Western Blot
To the preformed azidostrictosidine pentynyl ester aglucone was added
185 tL of protein extract from Catharanthus roseus cultures (1.4 mg/mL total
protein). Following the addition of 1 tL of NADPH (100 mM) the solution was
vortexed and centrifuged briefly. The reaction was wrapped in aluminum foil and
incubated at room temperature for 15 min to allow formation of enzyme-substrate
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complex. The reaction was then irradiated under an inverted DNA gel lamp 5
min at 302 nm and a distance of 3 inches.
2.11 2-Dimensional Western Blot Analysis
The protein sample was dissolved in 200 pl of rehydration buffer (Bio-Rad)
and vortexed to dissolve the protein pellet followed by centrifugation for 5
minutes at 17 rpm to pellet debris. The protein solution (190 pl) was loaded onto
the protein IEF tray (Bio-rad). A pH 4-7 IPG strip with plastic backing removed
was then placed gel side down to the tray well insuring that no air bubbles were
trapped below the strip. After 15 minutes of hydration 2 ml of mineral oil was
placed in each well. The focusing tray was then attached to the protein IEF
system (Bio-rad) and programmed using the preset method for rehydration and
linear isoelectric focusing. Once the focusing was complete the strips were
removed from the mineral oil overlay and the oil was allowed to drip off the strip,
followed by gentle wicking away of the remaining oil with a Kim wipe. The strip
was then placed gel side up into a rehydration tray. The tray was wrapped in
saran wrap and placed in the -80 C freezer for up to one day. Strips were
removed in sets of two for running in the second dimension.
2.12 Label Transfer from SGD to "Ajmalicine Synthase" Protein Preparation
SGD purified from E. coli as a N-terminal His tagged fusion protein was
modified by the Pierce Biotechnology Mts-Atf-LC-Biotin label transfer reagent
(Pierce Biotechnology, cat # 33083) following the manufacturer's protocol. The
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resulting SGD was purified from excess reagent by nickel affinity
chromatography. The resulting protein (10 pL of a 30 pM stock solution) was
added to 80 pL of the "ajmalicine synthase" protein preparation followed by
addition of NADPH (5 VL of a 10 mM stock solution) and strictosidine (5 gpL of a 5
mM stock solution). The solution was allowed to incubate for 30 minutes at room
temperature and was then irradiated under 302 nm UV light for 5 minutes. To
the sample was added SDS-PAGE loading buffer and the proteins were loaded
onto a 12% SDS-PAGE gel after heating at 95 C for 5 minutes. For 2-
dimensional analysis, irradiated proteins were precipitated using the Perfect-
Focus 2D protein purification kit (G-biosciences). The sample was solubilized in
rehydration buffer (Bio-Rad) and loaded onto a 3-10 NL strip and the proteins
were separated as described above.
3. Results
3.1 Synthesis of Tryptamine Analogs
Previously, 4-,5-,6- and 7-azidotryptamines were synthesized [22] (Figure
5.2) and similar indole-azides are known to be photo-active and capable of
labeling enzyme active sites [6, 8-15]. However, it was unclear if tryptamine
analogs harboring a diazirine or alkyne functionality could be synthesized. Indole-
alkynes have previously been synthesized from the corresponding 5-iodoindole
via a palladium catalyzed cross-coupling reaction, to give 5-ethenylindole [25].
Although 5-iodoindole is commercially available, our initial attempts at synthesis
utilized 5-bromoindole-3-carbaldehyde, which was more readily available. First
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5-ethynylindole-3-carbaldehyde was synthesized by a palladium catalyzed cross-
coupling reaction (Figure 5.3A). The resulting aldehyde was converted to 5-
ethynyl-3-nitroethylene by the Henry reaction. Upon reduction of 5-ethynyl-3-
nitroethylene by LAH 5-ethenyltryptamine was produced. Attempts to synthesize
the corresponding 10-ethynylstrictosidine analog with STR or with the V214M
STR mutant [26], previously shown to convert tryptamine analogs with steric
substitutions at the indole-5-position, failed to yield the desired product.
Additionally, attempts to couple 5-ethynyltryptamine with secologanin under
acidic conditions resulted in rapid degradation of the 5-ethynyltryptamine starting
material and no strictosidine product formation. Therefore, the 5-
ethynyltryptamine was determined to be too unstable for practical use and was
not explored as an electrophilic probe for C. roseus enzymes.
It was anticipated that diazirine analogs could be synthesized from the
corresponding 5-acetyltryptamines by methods described for other acetylated
benzyl compounds [27, 28]. 5-acetyltryptamine was synthesized from the
corresponding 5-acetylindole (Figure 5.3B). First 5-acetylindole was converted
to the corresponding 5-acetylindole-3-nitroethylene by an acid catalyzed reaction
with N,N-dimethylamino-3-nitroethylene. The resulting product was protected
and reduced with LAH and deprotected to yield 5-acetyltryptamine. The reaction
was low yielding and not pursued for production of this photo-reactive analog.
Synthesis of 5-(trifluoromethyl)acetyltryptamines from the corresponding 5-
bromotryptamine was successfully achieved in our lab by Aimee Usera [28],
however the conversion to the corresponding diazirine failed. Therefore, these
220
A Synthesis of 5-ethynyltryptamine
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B Synthesis of 5-acetyltryptamine
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Figure 5.3: A. Synthesis of 5-ethynyltrypatmine. i) [Pd(CI12)(PPh3)2, Cul,
PPh 3, TMS-acetylene, CH 3CN; ii) NaOH, MeOH; iii) nitromethane, sodium
acetate; iv) LAH, 1,4-dioxane; v) strictosidine synthase, secologanin, pH 7
phosphate buffer; vi) maleic acid pH 2, secologanin. B. Synthesis of 5-
diazirine tryptamine. i) dimethylamino-2-nitroethylene, TFA, room
temperature, 30 minutes; ii) ethylene glycol (5eq), p-toluene sulfonic acid
(0.1eq), benzen, reflux; iii) LAH (10eq), 1,4-dioxane, reflux 3hours; iv) 1M
HCI, THF 30 minutes.
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studies to identify enzymes utilized exclusively tryptamine-azide analogs as
photo-affinity labels for TIA biosynthetic enzymes.
3.2 Inhibition of Strictosidine Synthase with Tryptamine Azides
It has been established that 7-azidotryptamine laz7 is a substrate for
strictosidine synthase, while the 4-,5-, and 6-azidotryptamines laz4-6 when
incubated with STR and secologanin do not yield azidostrictosidine analogs [22].
Although these tryptamine analogs do not form strictosidine analogs, they may
bind to the STR active site in non-productive conformations (Anne Friedrich,
personal communication). To establish whether the tryptamine-azides are
inhibitors of STR activity an inhibition assay was performed for inhibition by 4-
azidotryptamine laz4. Increasing the concentration of laz4 reduced STR activity
demonstrating that laz4 inhibits STR with an IC50 of 130 + 30 pM (Figure 5.4).
3.3 UV Degradation of Tryptamine- and Strictosidine-Azides
To further characterize the photo-physical properties of the tryptamine-
azides and strictosidine-azides, the degradation of the azide substrates upon UV
irradiation was quantified. Tryptamine-azides, laz6 and laz7, and strictosidine-
azide, 3az7b, were irradiated under 302 nm UV light for various times and the
reduction in absorbance at 247 nm was quantified as previously described
(Figure 5.5) [11]. The maximum loss of absorbance was achieved after 300 s (5
min) of UV exposure. This irradiation time was used for future studies of UV
cross-linking to alkaloid biosynthetic enzymes.
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Rate
(peak areals)
IIC 50 = 0.13 + 0.03 mM
0.0 0.2 0.4 0.6 0.8 1.0
[4-azidotryptamine] (mM)
Figure 5.4: Inhibition of STR activity by 4-azidotryptamine. The reported IC50 is
average of two independent sets of assays.
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Figure 5.5: UV degradation of tryptamine and strictosidine azides. Absorption
spectrum of 7-azidotryptamine in which 7-azidotryptamine (0.10 mM in 0.1 M
Phosphate buffer, pH 6.8) was irradiated and the cuvette was removed at time
incruments to record the spectrum: spectrum 1 (t =0); spectrum 2 (t = 20 s);
spectrum 3 (t = 60 s); spectrum 4 (t = 3 min). The inset shows the fraction of
absorbanse remaining as a function of the time of irradiation. The fraction
remaining is determined by the following relationship: (A247 at t =X- A247 at t
=3 min)/(A247 at t =0 - A247 at t =3 min).
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3.4 Photo-chemical Inhibition of STR
Irradiation of STR in the presence of laz4, laz5, and laz7 did result in
irradiation dependent inhibition of STR activity, suggestive of photochemical
cross-linking. Initial studies with 4-azidotryptamine and 6-azidotryptamine (laz4
and laz6) indicated that irradiation of STR in the absence of laz4 or laz6 results
in a significant reduction in STR activity, which is commonly observed with UV
irradiation of enzymes at 302 nm. To overcome this issue, 250 mM sucrose was
added to the enzyme buffer prior to irradiation to protect the enzyme against
degradation, thereby maintaining a greater percent of enzyme activity upon
irradiation. We determined the percentage inhibition of STR activity upon
irradiation in the presence of 4-,6-, and 7-azidotryptamine (Table 5.1).
3.3 Photo-affinity Labeling of Cell Free Extracts with Strictosidine Azides
With establishment that tryptamine-azides (1az4-7) are active photo-
affinity labels for STR, the photochemical labeling with strictosidine-azides of cell
free extracts containing NADPH dependent "ajmalicine synthase" activity,
prepared and provided by Nancy Yerkes, was examined. The 7-
azidostrictosidine (3az7) analog was incubated with a cell free extract containing
"ajmalicine synthase" activity, SGD and NADPH followed by UV irradiation. The
resulting protein solution was assayed for "ajmalicine synthase" activity and
compared to controls lacking 3az7, containing 3az7 without irradiation, and
untreated protein extracts (Table 5.2). The control reactions, which contained no
3az7 with irradiation or 3az7 without irradiation, had 93 and 101% activity
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Table 5.1: Inhibition of strictosidine synthase (STS) activity upon irradiation in
the presence of 4-azidotryptamine laz4, 6-azidotryptamine laz6, and 7-
azidotryptamine laz7. *Activity remaining is R/R(0) x 100 where R is the initial
rate after 1 minute of irradiation at 302nm and R(0) is the rate without irradiation.
** Relative activity is (1-A/A(0))*100 where A is the activity remaining at 0.25mM
and A(0) is the activity remaining at 0 mM.*** Buffer contained 250 mM sucrose
which decreased the loss of activity upon irradiation at 302nm in the absence of
the tryptamine azide.
Activity RelativeCompound Concentration (mM) Activity Relative
remaining* activity"
laz4 0.25 7 + 1 75 + 5%
laz4 0 29 + 3
laz6 0.25 28 + 7 34 + 11%
laz6 0 43 + 4
l az7*** 0.25 70 + 1 33 + 7%
laz7*** 0 105 + 6
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Table 5.2: Inhibition of "ajmalicine synthase" activity with 7-azidostrictosidine
7-azidostrictosidine (3az7) UV 302 nm % Activit
0 pM 4 minutes 93
100 uM 0 minutes 101
100 pM 4 minutes 60
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compared to untreated control reductase fraction, respectively (Table 5.2). The
assay which was irradiated in the presence of 7-azidostrictosidine (3az7) had
60% activity compared to the assay with no irradiation in the presence of 3az7
(Table 5.2). These data suggest that the 7-azidostrictosidine (3az7) is capable
of labeling of the "ajmalicine synthase" present in these cell free enzyme
preparations.
It has previously been established that the pentynyl ester of secologanin
(2b) can be formed and is processed by strictosidine synthase [20]. Feeding of
the secologanin pentynyl ester to C. roseus hairy root cultures resulted in the
accumulation of large amounts of the corresponding strictosidine pentynyl ester
in addition to small amounts of pentynyl ester analogs of serpentine 5, ajmalicine
4, and isositsirikine 34 [21] . Likely explanations for accumulation of 3b are
either the decrease activity with strictosidine glucosidase [29] or decreased
efficiency of transport of 3b out of the vacuole for processing by strictosidine
glucosidase.
To test the ability of this cell free "ajmalicine synthase" preparation to
process the 4-, 5-, 6- and 7-azidostrictosidine pentynyl esters (3az4b-7b), the
compounds were synthesized either chemically or enzymatically from the
appropriate 4-, 5-, 6- or 7-azidotryptmaine (laz4-7) and the secologanin
pentynyl ester 2b (Figure 5.2). The resulting 4-, 5-, 6- and 7-azidostrictosidine
analogs (3az4b-7b) were incubated with SGS to form the corresponding
deglycosylated intermediate (30az4b-7b). The resulting aglucone was then
incubated with the cell free enzyme preparation in the presence of NADPH. The
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formation of a reduced product was monitored by LCMS. Incubation of the
"ajmalicine synthase" extract with all four azidostrictosidine pentynyl ester
aglucones (30az4b-7b) resulted in the formation of a peak corresponding to the
expected reduction product. After establishing that these substrates were
converted to the desired reduction products, we next aimed to specifically label
the protein extract after photo-chemical cross-linking of the 4- , 5- , 6- or 7-
azidostrictosidine pentynyl ester analogs (3az4b-7b) to the enzymes in the
extract. For the initial studies, 7-azidostrictosidine pentynyl ester (3az7b) was
used due to its facile enzymatic synthesis catalyzed by STR.
In the initial study, 7-azidostrictosidne pentynyl ester aglucone (30az7b)
was generated in vitro by addition of SGD to the strictosidine substrate. The
reaction was then incubated in the presence of the cell free enzyme preparation
and NADPH, and irradiated under 302 nm UV light for five minutes. Controls
which contained no 7-azidostrictosidine pentynyl ester aglucone (30az7b) and
which contained 30az7b but were not irradiated were also examined. The
resulting labeled extracts were biotinylated via a Huisgen-Sharpless 1,3-dipolar
cycloaddition with a biotin-azide (58), synthesized as previously described [21].
After labeling, the protein was precipitated to separate the total protein
preparation from un-reacted biotin-azide. The protein was then analyzed for the
presence of biotin using a biotin detection kit (Pierce biotechnology). The
analysis revealed that only in the presence of 30az7b and upon UV irradiation
was biotinylation of the cell free protein extract observed (Table 5.3, Figure 5.6).
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Table 5.3: Biotin detection of precipitated reductase fraction proteins using
Pierce biotin quantification kit (cat# 28005). The absorbance of HABA reagent at
500 nm decreases in the presence of biotin.
Protein sample Biotin-azide Absorbance (500nm)
7 az + UV + extract Yes 0.6939
7 az + UV + extract No 0.7325
7 az + extract Yes 0.7523
HRP-Biotin control -- 0.5956
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Figure 5.6: Detection of proteins labeled with 7-azidostrictosidine pentynyl ester
following copper catalyzed coupling with biotin-azide. A. Western blot with
streptavidin-horse radish peroxidase conjugate to detect for biotin. Biotin labeled
proteins are detected using Pierce Biotechnology ECL substrate. B. SDS-PAGE
detection of proteins with sypro-ruby. Lane M, protein standards (Bio-Rad
precision plus dual color); Lane 1, complete assay containing 7-azidostrictosidine
pentynyl ester, UV irradiation, "ajmalicine synthase" protein preparation, biotin-
azide; Lane 2, no biotin-azide added; Lane 3, no UV irradiation; Lane 4, no
"ajmalicine synthase" protein preparation; Lane 5, no 7-azidostrictosidine
pentynyl ester. C. Labeling of "ajmalicine synthase" protein preparation by 7-
azidostrictosidine pentynyl ester in the presence and absence of strictosidine.
Reduced labeling of the protein preparation with the bi-functional probe, 7-
azidostrictosidine pentynyl ester, is observed in with the addition of strictosidine.
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To identify the specific proteins labeled by 7-azidostrictosidine pentynyl
ester aglucone (30az7b), the biotin labeled enzymes were separated by SDS-
PAGE, transferred to PVDF membrane and detected by western blot using a
streptavidin-HRP (horse radish peroxidase) conjugate for biotin detection. Only
in cultures treated with both 7-azidostrictosidine pentynyl ester aglucone
(30az7b) and UV irradiation was biotin labeling of the proteins detected (Figure
5.6A). To further support that strictosidine aglucone was specifically labeling the
desired biosynthetic enzymes, after addition of strictosidine (3) to the labeling
reaction a reduction of the biotinylation was observed, suggesting that the
strictosidine substrate was competing at the site of labeling (Figure 5.6B). Due
to the number of proteins of the cell free enzyme preparation, 1D SDS-PAGE
was not optimal for protein identification. Therefore, 2-dimensional separation of
labeled proteins and western blot analysis was performed to obtain pure protein
spots that could be more accurately identified by mass spectrometry methods.
Cell free enzyme preparations were labeled with 4-, 5-, 6- and 7-
azidostrictosidine pentynyl ester aglucones (30az4b-7b) by irradiation at 302 nm.
Following irradiation, the protein samples were biotinylated and purified for
separation by 2-dimensional SDS-PAGE. The resulting gels were transferred to
PVDF membranes and detected by streptavidin-HRP conjugate (Figure 5.7,
Appendix D). The blots were aligned with the control SDS-PAGE gel. Several of
the labeled spots were excised from the gel for sequencing. The proteins were
sequenced by mass spectrometry following in gel trypsin digestion (Leslie Hicks,
Danforth Center).
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Figure 5.7: Western blot of 4-azidostrictosidine labeled "ajmalicine synthase"
protein preparation modified with biotin-azide and detected with a streptavidin-
HRP probe and ECL. The numbered spots were picked for mass spectral
peptide sequencing, sequences are summarized in Table 5.4 and Appendix D.
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Alignment of the western blots with the corresponding gel is complicated
by the lack of markers for alignment. A solution to this is the use of alternative
labels to biotin for detection of the photo-cross-linked proteins directly in the
SDS-PAGE gel. Therefore, a rhodamine-azide (59) label was utilized to label
enzymes from the cell free enzyme preparation. This experiment was
preformed by irradiation of the "ajmalicine synthase" preparation in the presence
of 6-azidostrictosidine pentynyl ester aglucone (30az6b). After modification with
rhodamine-azide by the copper catalyzed 1,3-dipolar cycloaddition reaction,
rhodamine labeled proteins were detected under UV light (Figure 5.8). The
fluorescently labeled proteins were excised directly from the 2-dimensional SDS-
PAGE gel for sequencing.
3.4 Label Transfer Reagents to Identify SGD Binding Proteins
SGD is isolated from C. roseus cultures as a multi-enzyme complex [23,
24], however the identify of the enzymes has never been explored. To identify
the proteins that interact directly with SGD, a commercially available label
transfer reagent containing a thiol reactive group and a trifluorophenyl azide
photo-affinity label was employed. The reagent reacts with surface exposed
cysteine residues on the bait protein, SGD, to form a disulfide bond (Figure 5.9).
Then, upon UV irradiation in the presence of prey proteins that bind to the bait
protein, the trifluorophenyl-azide covalently modifies nearby protein residues.
Addition of disulfide reducing agents, such as those found in the SDS-PAGE
loading buffer, reduces the disulfide bound linking the biotin label to the bait
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Figure 5.8: Protein preparations with "ajmalicine synthase" activity chemically
labeled with 6-azidostrictosidine pentynyl ester and modified with rhodamine-
azide (59). Rhodamine labeled proteins were directly detected under a UV
transilluminator. Numbered spots were excised directly from gel for sequencing
by mass spectroscopy.
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Figure 5.9: Pierce Biotechnology Mts-Atf-LC-Biotin label transfer reagent. A sulfhydryl-directed biotin label
transfer reagent (product # 33083) containing a UV light activated perfluorophenylazide (Atf), biotin and a
sulfuhydryl reactive methanthiosulfonate (MTS). MTS reacts with cysteine residues on the bait protein, in this
case SGS, at pH 7. The resulting protein conjugated to the Atf and biotin by a disulfide bond is then
incubated with the prey protein, in this experiment an "ajmalicine synthase protein preparation. Upon UV
irradiation the Atf covalently modifies the prey protein. After preparation for protein analysis by addition of 50
mM DTT the disulfide bond is broken and only the prey proteins are labeled with biotin.
protein, and only the protein binding partner proteins are labeled. These proteins
are then detected by western blot with streptavidin-HRP detection. The biotin
transfer reagent was incorporated into SGD, which was heterologously
expressed and purified from E. coli. SGD from R. serpentina has been
crystallized and the structure contains three surface exposed cysteine residues
[30]. SGD was modified through these surface exposed cysteine residues with
the label transfer reagent to yield a labeled SGD (SGD-ss-x). Upon incubation
with the "ajmalicine synthase" protein extract (containing the prey proteins),
irradiation with UV light (302nm) and analysis by western blot, the label was
transferred to proteins in the protein extract (Figure 5.10). The assay was
performed in the presence of strictosidine and NADPH, strictosidine alone,
NADPH alone, no NADPH or strictosidine, no UV irradiation and no "ajmalicine
synthase" extract. Interestingly, in the presence of both strictosidine substrate
and NADPH, less labeling of proteins in the cell lysate was observed. No
labeling was observed without irradiation at 302 nm and no labeled proteins were
detected in the absence of the bait protein (SGD-ss-x), showing that labeling is
occurring to the protein extract and that it is dependent on irradiation. Since 1-
dimensional SDS-PAGE does not provide the separation necessary for isolation
of pure proteins, the assay containing no strictosidine or NADPH was analyzed
by 2-dimesional SDS-PAGE followed by western blot for detection of the biotin
labeled proteins (Figure 5.11). The labeled proteins detected by western blot
were excised from SDS-PAGE control gels for identification by mass spectral
peptide sequencing.
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SGD-ss-x x x x x x
NADPH - x x x x x
Strictosidine x x x - x x
Extract x x - x x x
UV light x x x x - x
Figure 5.10: Label transfer reaction between SGD and "ajmalicine synthase"
protein preparation. A. Western blot analysis with Streptavidin-HRP probe protein
and ECL detection, B. SDS-PAGE with SyproRuby (Invitrogen) protein detection.
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Figure 5.11: Label transfer 2-dimensional western blot analysis. The numbers
correspond to the peaks chosen for sequencing by mass spectrometry.
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3.5 Protein Sequencing and Identification of Putative Enzymes from C. roseus
EST Libraries
Sequencing and database searching was performed by Leslie Hicks and
the proteomics facility staff at the Danforth Center. The genome for C. roseus
has not been sequenced, however several expressed sequence tag (EST)
libraries generated from C. roseus have been sequenced. The NCBI database of
known C. roseus EST (approximately 20,000) was searched for genes matching
the peptide fragments identified from protein sequencing. Our results identified
several ESTs that displayed sequence identity that is consistent with putative
alkaloid biosynthetic enzymes (Table 5.4). A complete list of peptides and EST
identified is located in Appendix D.
4. Discussion
Both small molecule photo-active substrates and label transfer reagents
successfully labeled proteins in a cell free C. roseus system. The resulting
proteins were sequenced by mass spectrometry and compared to the NCBI
database of C. roseus EST to identify the gene sequences for the labeled
proteins. Current work to clone and characterize these proteins using the
identified EST sequences is underway.
The predicted function of the EST sequences identified suggested that
these proteins may be involved in the missing steps in alkaloid biosynthesis.
Several dehydrogenases, including sequences with homology to malate
dehydrogenase, aldehyde dehydrogenase, and alcohol dehydrogenase were
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NCBI predicted # of
Spot GI # for EST protein function species peptides
Bi-2 116656081 Malate dehydrogenase Zea Mays 5
Bi-36 116655042 fructose-bisphosphate Solanum 6
164552554 aldolase tuberosum
164558997
164559800
Bi-8 164559297 cytosolic ascorbate Nicotiana 6
164559645 peroxidase tabacum
164560995
Rh-3 164559965 enolase-like Solanum 9
tuberosum
Rh-4 116658794 aldehyde dehydrogenase Nicotiana 4
(NAD+) tabacum
Rh-5 164558700 alcohol dehydrogenase Dimocarpus 6
Iongan
Rh-7 116660546 protein S Catharanthus 7
roseus
SG-1 116653644 Protein disulfide Elaeis 5
isomerase 2 precursor guineensis
SG-2 164560015 adenosine kinase isoform Nicotiana 6
2S tabacum
SG-7 164558212 20S proteasome Vitis vinifera 10
regulatory subunit
alpha
Table 5.4: Selected mass spectral peptide sequencing results. Column 1,
protein spot analyzed with 2 letter code for the method by which the spot was
obtained and number corresponding to the protein labeled in the western blot or
protein gel figure. Bi, biotin labeled western figure 5; Rh, rhodamine labeled gel
figure 6; SG, label transfer biotin labeled wetern figure 11. Column 2 is the NCBI
GI number for the C. roseus EST match. Column 3 predicted protein function
based on sequence homology. Column 4 the species of the protein identified in
column 3. Column 5 number of unique peptides matched to the C. roseus EST.
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identified. A dehydrogenase responsible for the conversion of geissoschizine to
ajmalicine was previously identified in cell free extracts but not cloned [31].
Additionally, proteins with homology to the glycolytic enzyme fructose-1,6-
bisphosphate aldolase (FBPA) was also identified in several labeling
experiments. Cloning of the identified EST and functional analysis of these
enzymes in the biosynthesis of C. roseus alkaloids is underway.
A known C. roseus protein, protein S, with homology to the alP-hydrolase
superfamily was identified as one of the proteins labeled in this study [32]. The
al/-hydrolase superfamily has diverse functions all containing a conserved
catalytic triad (Asp, Ser, His). Members of this family include lyases, esterases,
and lipases. Protein S expression has been previously shown to be associated
with alkaloid production in C. roseus cells and contains homology to a known TIA
biosynthetic enzyme, polyneuridine aldehyde esterase (PNAE), which is involved
in early steps in ajmaline synthesis in R. serpentine [33]. Although the reaction
catalyzed by PNAE is not directly implicated in the biosynthesis of TIA produced
in C. roseus, the labeling of the C. roseus protein with the photo-reactive
strictosidine probes indicates that it may likely involved in the biosynthesis of C.
roseus TIA.
Other proteins sequenced had homology to enolase-like proteins [34]. The
reactions catalyzed by enzymes in the enolase superfamily are all initiated by
abstraction of the a-proton of a carboxylic acid to form an enolic intermediate.
Although no carboxylic acids are proposed in the biosynthesis of C. roseus TIA
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the biosynthesis of pre-akuammicine 21 requires enolization of the
geissoschizine 20 methyl ester.
Proteins with homology to plant cytosolic ascorbate peroxidases were
identified. Ascorbate peroxidases have been shown to oxidize aromatic
substrates in addition to the physiological substrate ascorbate [35]. Peroxidases
are implicated in several steps in the biosynthesis of C. roseus alkaloids
including the oxidation of ajmalicine 4 to serpentine 5 and the oxidation of
geissoschizine 20 to pre-akuammicine 21.
The proteins identified from the label transfer reagent were proteasome
subunits, a protein disulfide isomerase and several biosynthetic enzymes. The
proteasome has been implicated in the regulation of biosynthesis by degradation
of biosynthetic enzymes [36, 37]. Additionally the proteasome functions to
degrade mis-folded proteins. Whether the proteasome has a role in the
regulation of alkaloid biosynthesis or in the degradation of mis-folded SGD, or
whether this is simply an abundant protein that gets non-specifically labeled
cannot be concluded from these studies. Protein disulfide isomerase (PDI)
catalyzes the formation and breakage of disulfide bonds in proteins [38]. The
label transfer reagent modifies SGD at surface exposed cysteine residues
forming a disulfide bond. It is likely that PDI may be actively isomerizing SGD
surface exposed disulfide bonds. In addition, transfer of the biotin label to
several biosynthetic enzymes was observed; such as FBPA, malate
dehydrogenase, CXE carboxylesterase, ascorbate peroxidase and dienolactone-
hydrolase, a member of the alp-hydrolase superfamily (Appendix C).
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5. Conclusions
Substrate based photo-affinity labels were used to successfully identify
potential C. roseus biosynthetic enzymes in a cell free protein preparation. The
3' EST sequences corresponding to the labeled proteins showed homology to a
diverse set of enzymes including dehydrogenases, hydrolases, esterases,
enolases, peroxidase, and aldolases. Future studies to clone the corresponding
full-length genes from C. roseus and screen for biosynthetic activity are
underway.
6. Acknowledgments
I acknowledge Nancy Yerkes for generously donating "ajmalicine
synthase" protein preparations. I acknowledge Dr. Anne Friedrich for synthesis
of 4-, 5-, 6-, and 7-azidotryptamines, Dr. M. Carmen Galan for generous
donation of Biotin-Azide, Joe Gregg for synthesis of Secologanin Pentynyl Ester.
I acknowledge Sarah Sinnett for assistance in the optimization of photo-labeling
of strictosidine synthase. A special thanks to Lesley Hicks for useful discussions
regarding optimization of 2-dimensional separation and identification of labeled
proteins. Funding for this research was provided by the David Koch Research
Fund (2740198) and the NIH (RO1-GM074820-01).
244
7. References
1. Van der Heijden, R., et al., The Catharanthus alkaloids: pharmacognosy
and biotechnology. Curr. Med. Chem., 2004. 11(5): p. 607-628.
2. Hemscheidt, T. and M.H. Zenk, Partial-Purification and Characterization of
a Nadph Dependent Tetrahydroalstonine Synthase from Catharanthus-
Roseus Cell-Suspension Cultures. Plant Cell Reports, 1985. 4(4): p. 216-
219.
3. Cravatt, B.F., A.T. Wright, and J.W. Kozarich, Activity-based protein
profiling: from enzyme chemistry to proteomic chemistry. Annu Rev
Biochem, 2008. 77: p. 383-414.
4. Chowdhry, V. and F.H. Westheimer, Photoaffinity labeling of biological
systems. Annu Rev Biochem, 1979. 48: p. 293-325.
5. Sadakane, Y. and Y. Hatanaka, Photochemical fishing approaches for
identifying target proteins and elucidating the structure of a ligand-binding
region using carbene-generating photoreactive probes. Anal Sci, 2006.
22(2): p. 209-18.
6. Fischer-lglesias, C., et al., Auxin distribution and transport during
embryonic pattern formation in wheat. Plant J, 2001. 26(2): p. 115-29.
7. Tian, H., D. Klambt, and A.M. Jones, Auxin-binding protein I does not
bind auxin within the endoplasmic reticulum despite this being the
predominant subcellular location for this hormone receptor. J Biol Chem,
1995. 270(45): p. 26962-26969.
8. Brown, J.C. and A.M. Jones, Mapping the auxin-binding site of auxin-
binding protein 1. J Biol Chem, 1994. 269(33): p. 21136-40.
9. Jones, A.M., Location of Transported Auxin in Etiolated Maize Shoots
Using 5-Azidoindole-3-Acetic Acid. Plant Physiol, 1990. 93(3): p. 1154-
1161.
10. Jones, A.M. and M.A. Venis, Photoaffinity labeling of indole-3-acetic acid-
binding proteins in maize. Proc Natl Acad Sci U S A, 1989. 86(16): p.
6153-6156.
11. Miles, E.W. and R.S. Phillips, Photoinactivation and photoaffinity labeling
of tryptophan synthase alpha 2 beta 2 complex by the product analogue 6-
azido-L-tryptophan. Biochemistry, 1985. 24(17): p. 4694-703.
12. Jones, A.M., et al., Azido Auxins : Photoaffinity Labeling of Auxin-Binding
Proteins in Maize Coleoptile with Tritiated 5-Azidoindole-3-Acetic Acid.
Plant Physiol, 1984. 75(4): p. 1111-1116.
13. Jones, A.M., et al., Azido Auxins: Quantitative Binding Data in Maize.
Plant Physiol, 1984. 74(2): p. 295-301.
14. Melhado, L.L., et al., Azido Auxins : Photolysis in Solution and Covalent
Binding to Soybean. Plant Physiol, 1984. 74(2): p. 289-294.
15. Brock, P.W., Jr., et al., Photoaffinity labeling of the indole sites on the
Escherichia coli tryptophan synthase alpha-subunit. Arch Biochem
Biophys, 1983. 220(2): p. 435-43.
245
16. Foroozesh, M., et al., Aryl acetylenes as mechanism-based inhibitors of
cytochrome P450-dependent monooxygenase enzymes. Chem. Res.
Toxicol., 1997. 10(1): p. 91-102.
17. Wright, A.T. and B.F. Cravatt, Chemical proteomic probes for profiling
cytochrome p450 activities and drug interactions in vivo. Chem Biol, 2007.
14(9): p. 1043-51.
18. Agard, N.J., et al., A comparative study of bioorthogonal reactions with
azides. ACS Chem Biol, 2006. 1(10): p. 644-8.
19. Galan, M.C. and S.E. O'Connor, Semi-synthesis of secologanin
analogues. Tetrahedron Lett., 2006. 47(10): p. 1563-1565.
20. McCoy, E., M.C. Galan, and S.E. O'Connor, Substrate specificity of
strictosidine synthase. Bioorg. Med. Chem. Lett., 2006. 16(9): p. 2475-8.
21. Galan, M.C., E. McCoy, and S.E. O'Connor, Chemoselective derivatization
of alkaloids in periwinkle. Chem Commun 2007(31): p. 3249-51.
22. Friedrich, A., S. Brise, and S.E. O'Connor, Synthesis of 4-, 5-, 6-, and 7-
azidotryptamines. Tetrahedron Lett., 2008: p.
doi:10.1016/j.tetlet.2008.10.091 (in press).
23. Luijendijk, T.J.C., A. Nowak, and R. Verpoorte, Strictosidine glucosidase
from suspension cultured cells of Tabernaemontana divaricata.
Phytochemistry 1996. 41(6): p. 1451-6.
24. Luijendijk, T.J.C.S., Luc H.; Verpoorte, Robert., Purification and
characterization of strictosidine b-D-glucosidase from Catharanthus
roseus cell suspension cultures. Plant Physiology and Biochemistry, 1998.
36(6): p. 419-425.
25. H6nona, H., et al., Synthesis and biological evaluation of new
dipyrrolo[3, 4-a:3, 4-c]carbazole- 1,3, 4, 6-tetraones, substituted with various
saturated and unsaturated side chains via palladium catalyzed cross-
coupling reactions. Bioorganic & Medicinal Chemistry, 2006. 14(11): p.
3825-3834.
26. Bernhardt, P., E. McCoy, and S.E. O'Connor, Rapid identification of
enzyme variants for reengineered alkaloid biosynthesis in periwinkle.
Chem Biol, 2007. 14(8): p. 888-97.
27. Abelt, C.J. and J.M. Pleier, .beta.-Cyclodextrin as a molecular reaction
vessel:reactions of included phenylmethyldiazirine. J Org Chem, 1988.
53(10): p. 2159-2162.
28. Wiegand, M. and T.K. Lindhorst, Synthesis of Photoactive a-Mannosides
and Mannosyl Peptides and Their Evaluation for Lectin Labeling. Eur. J.
Org. Chem., 2006(21): p. 4841-4851.
29. Yerkes, N., et al., Substrate specificity and diastereoselectivity of
strictosidine glucosidase, a key enzyme in monoterpene indole alkaloid
biosynthesis. Bioorg. Med. Chem. Lett., 2008. 18(10): p. 3095-3098.
30. Barleben, L., et al., Molecular architecture of strictosidine glucosidase: the
gateway to the biosynthesis of the monoterpenoid indole alkaloid family.
Plant Cell, 2007. 19(9): p. 2886-97.
246
31. Pfitzner, A. and J. Stoeckigt, Partial purification and characterization of
geissoschizine dehydrogenase from suspension cultures of Catharanthus
roseus. Phytochemistry, 1982. 21(7): p. 1585-1588.
32. Lemenager, D., et al., Purification, molecular cloning, and cell-specific
gene expression of the alkaloid-accumulation associated protein CrPS in
Catharanthus roseus. J Exp Bot, 2005. 56(414): p. 1221-8.
33. Dogru, E., et al., The gene encoding polyneuridine aldehyde esterase of
monoterpenoid indole alkaloid biosynthesis in plants is an ortholog of the
a/b hydrolase super family. Eur. J. Biochem., 2000. 267(5): p. 1397-1406.
34. Babbitt, P.C., et al., The enolase superfamily: a general strategy for
enzyme-catalyzed abstraction of the alpha-protons of carboxylic acids.
Biochemistry, 1996. 35(51): p. 16489-16501.
35. Raven, E.L., Understanding functional diversity and substrate specificity in
haem peroxidases: what can we learn from ascorbate peroxidase? Nat
Prod Rep, 2003. 20(4): p. 367-81.
36. Murakami, Y., et al., Ornithine decarboxylase is degraded by the 26S
proteasome without ubiquitination. Nature, 1992. 360(6404): p. 597-9.
37. Hampton, R.Y., R.G. Gardner, and J. Rine, Role of 26S proteasome and
HRD genes in the degradation of 3-hydroxy-3-methylglutaryl-CoA
reductase, an integral endoplasmic reticulum membrane protein. Mol Biol
Cell, 1996. 7(12): p. 2029-44.
38. Frand, A.R., J.W. Cuozzo, and C.A. Kaiser, Pathways for protein
disulphide bond formation Trends in Cell Biology, 2000. 10(5): p. 203-210.
247
248
Chapter 6
Conclusions and Future Directions
249
1. Conclusions
The experiments discussed in the preceding chapters lay the foundation
for the study of TIA biosynthesis in C. roseus. Initial studies revealed the
substrate specificity of the gate-keeping enzyme strictosidine synthase.
Strictosidine synthase is capable of converting a range of tryptamine analogs to
the corresponding strictosidine analogs, the central intermediate to all TIA. This
conversion depends on the electronic and steric properties on the amine
substrate analogs. For example, the rate of catalysis by strictosidine synthase
decreases with electron withdrawing substitutions at all positions. Additionally,
STR converts the isosteric electron deficient benzofuran and benzothiophene
ethyl amines to the corresponding strictosidine analogs. STR does not accept
substrates with steric modifications at the 5- and 6-position of the indole ring.
Recently, the substrate specificity of strictosidine synthase from C. roseus and R.
serpentina has been mutated to accommodate tryptamines with steric
modifications at the 5-position [1, 2]. Strictosidine glucosidase (SGD) is highly
promiscuous for all strictosidine analogs generated and recent kinetic analysis of
conversion of strictosidine analogs by strictosidine glucosidase validates these
preliminary results [3]. The steps following strictosidine glucosidase remain
unknown on a genetic level for the biosynthesis of any TIA. Although enzyme
activities have been observed in C. roseus extracts capable of reducing the
strictosidine aglucone [4], to date these enzymes lack genetic characterization. T
Precursor directed biosynthesis (PDB) of TIA analogs by addition of
tryptamine analogs to the growth media of C. roseus hairy roots and seedlings
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generated alkaloid analogs representing the entire array of structures produced
by C. roseus in yields comparable to amounts produced from endogenous
precursors. PDB produced analogs of the corynanthe alkaloids ajmalicine,
serpentine, and isositsirikine; the strychnos alkaloid akuammicine; and the
aspidosperma alkaloids tabersonine and vindoline. Altering the concentration
and time of substrate analog addition modulated the production of the total
alkaloid analog and the amount of specific alkaloid analogs.
As expected, the profile of alkaloid analogs produced depends on the
tryptamine analog fed. Analysis of the profiles for a series of 4,5,6 and 7 -
position substitutions of tryptamine with fluoro, chloro, bromo, methyl and
methoxy allowed examination of the effect of electronic and steric perturbations
on these uncharacterized biosynthetic conversions. The analysis revealed that
electron withdrawing groups at the 4- and 5-position reduced the entry of these
compounds into the oxidative branch of the C. roseus biosynthetic pathway. The
cultures fed these precursors instead produced high yields of the isositsirikine,
which may be a precursor to the oxidative pathway. However, electron
withdrawing group substitution at the 6- and 7-position did not block the
production alkaloids on the oxidative branch of the biosynthetic pathway. Instead,
6- and 7-position substitutions resulted high yields of the akuammicine; a
deformylation product of pre-akuammicine, the initial product of the oxidative
pathway and intermediate to the aspidosperma and iboga alkaloids. In addition
to the compounds characterized in this initial analysis, many other alkaloid
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analogs were observed and varied depending on the substrate fed. The low
yields of these analogs prevented their characterization in this study.
The promiscuity of the biosynthetic pathway to accept substrate analogs
with various modifications led to the use of reactive tryptamine analogs to identify
previously uncharacterized biosynthetic enzymes. The method of activity based
protein profiling [5] was used to modify enzymes actively involved in TIA
biosynthesis. The bi-functional strictosidine analogs were generated by coupling
of 4-, 5-, 6-, and 7- azidotryptamine [6] and the pentyny ester analog of
secologanin [7, 8]. The 4-, 5-, 6-, or 7-azidostrictosidine pentynyl esters labeled
enzymes in a cell free extract of C. roseus. After bio-orthogonal modification with
biotin or rhodamine labels for detection, the labeled proteins were identified,
digested, and the resulting peptides were sequenced by mass spectrometry.
The sequenced peptides were used to search a database of C. roseus
expressed sequence tags (EST) to identify the genetic sequence encoding the
putative enzymes. The identified EST sequences had homology to known
enzymes with a variety of functions, including dehydrogenases, esterases,
enolases, aldolases, and peroxidases. Future studies to clone and functionally
analyze the proteins corresponding to the identified EST are underway.
In addition to photo-reactive substrate analogs, a commercially available
label transfer reagent (Pierce) was used to probe interactions between the crude
enzyme preparation and SGD. SGD purifies from C. roseus as a multi-enzyme
complex, however the specific binding partners are unknown. SGD was modified
with the biotin and triflurophenylazide label transfer reagent through disulfide
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bonds with surface exposed cysteines. When irradiated in the presence of the
"ajmalicine synthase" enzyme preparation, the label transfers to several proteins.
Interestingly the presence of both strictosidine and NADPH resulted in a
decrease in label transfer. The reason for the reduced labeling is unclear and
future experiments should aim to explore this observation. The label transfers
mainly to C. roseus proteins with homology to proteasome subunits, heat shock
proteins, and a protein disulfide isomerase. The label also transfers to proteins
with homology to dehydrogenases, esterases, enolases, aldolases, and
peroxidases.
2. Future Directions
2.1 Biological Activity of Alkaloid Analogs
PDB successfully produces biosynthetic analogs of serpentine,
akuammicine, isositsirikine, and vindoline. Future experiments should aim to test
if the new analogs have improved activity compared to the natural alkaloid.
Serpentine is a known topoisomerase II inhibitor [9]. Initial studies of
topoisomerase II inhibition a by the 10-fluoroserpentine analog revealed that it
has similar inhibitory activity to the natural serpentine (Figure 6.1). A
quantitative study of topoisomerase II inhibition should be explored with multiple
serpentine analogs. Other alkaloids produced by C. roseus show biological
activity. For example,akuammicine has known opioid activity [10, 11]. Ajmalicine
has biological activity as an adrenergic receptor antagonist and is used clinically
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Figure 6.1: Gel shift assay for the inhibition of topoisomerase II activity by
serpentine and 10-fluoroserpentine. Serpentine and 5-fluorosepentine (10, 50
and 100 gpM ) were assayed using a topoisomerase II inhibitions kit (TOPOgen)
using the standard protocol.
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4M serpentine 5
in rehabilitation following a stroke [12, 13]. Ajmalicine production was increased
with steric modification at all positions on the indole ring due to the prevention of
conversion to serpentine. Therefore, the production of sterically modified
ajmalicine analogs is attractive for the study of the effects of these substitutions
on the biological activity of ajmalicine. Isositsirikine analogs were also produced
in high yields in cultures treated with electron withdrawing substituents at the 4-
and 5- position and with the isosteric electron deficient benzofuran analog. The
biological activity of isositsirikine has not been previously examined and
represents a potentially knew natural product scaffold and its biological activity
should be explored.
2.2 Mechanism of Biosynthesis of Oxidized TIA
The profile analysis revealed that steps leading to the biosynthesis of pre-
akuammicine, akuammicine and tabersonine are dependent on substitutions
made to the tryptamine substrates. Analogs of geissoschizine with modification
to the indole ring (for instance 4-methyl, 4-chloro, 7-methyl, 7-chloro, and 7-
bromo) might examine the bio-mimetic formation of pre-akuammicine.
Comparison of the results of this chemical conversion to the results observed in
vivo would provide mechanistic insight into the formation of pre-akuammicine.
The in vivo results also suggest that isositsirikine may be the immediate
precursor to pre-akuammicine. Synthesis of labeled isositsirikine and feeding to
either cell culture or crude cell extracts should be attempted to examine its
potential intermediacy in this pathway branch.
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The oxidation of alkaloid intermediates to akuammicine and tabersonine
was decreased when electron withdrawing substitutions were placed at the 4-
and 5-position. This trend is not surprising, given that the mechanism to form the
pre-akuammicine intermediate invokes hydroxylation the indole-3-position in the
proposed electrophilic aromatic substitution reaction. However with electron
withdrawing substitutions at the 6- and 7-position, this trend is not observed.
Instead, these substrate analogs accumulated high amounts of oxidized products
derived from pre-akuammicine. The reason for this observation is not clear. It
would be interesting to compare the kinetics of oxidation at the indole-3-position
with 6- and 7-position substituted indoles to 4- and 5- substituted indoles using a
model substrate that is substituted at the indole-2 and 3-positions as is the
geissoschizine precursor. Exploration of the oxidative rearrangement of
substituted geissoschizine or isositsirikine analogs under the conditions used in
the bio-mimetic production of akuammicine [14, 15] would address this question.
Isositsirikine has been generated by sodium borohydride reduction of
strictosidine aglucone (cathenamine, or 4,21-dehydrogeissoschizine) under
acidic conditions [16] and geissoschizine has also previously been synthesized.
2.3 Identification of C. roseus Enzymes
Photo-affinity labeling of a crude enzyme preparation with NADPH
dependent "ajmalicine synthase" activity revealed potential enzymes, which could
be involved in the biosynthesis of TIA. Labeled proteins were subjected to mass
spectrometry based protein sequencing at the Danforth Proteomics Center. A
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large database of EST from C. roseus was used to identify genes corresponding
to the sequenced peptides. The genes corresponding to the matched EST
sequences should be cloned and expressed heterologously to determine the
activity of these enzymes toward the alkaloid intermediate substrates. An array of
substrates should be tested for conversion by these enzymes including the
strictosidine aglucone, geissoschizine, isositsirikine, and ajmalicine.
Other photo-labels or activity specific labels should be explored. Initial
attempts to synthesize aryl alkynes were successful. However, the resulting 5-
ethynyltryptamine was not converted to strictosidine via enzymatic or chemical
synthesis. Alternative approaches to the synthesis, including protection of the
ethynyl group prior to chemical synthesis of the strictosidine analog should be
explored.
Protein labeling with aryl-azides was limited to the soluble enzyme
preparation. However, many of the enzymes involved in the biosynthesis of TIA
may be insoluble or associated with the membrane fraction. Membrane proteins
are difficult to separate by 2-dimensional electrophoresis. Therefore, alternative
methods for the purification of labeled enzymes must be explored. One possible
way to identify any insoluble enzymes that bind to our strictosidine azide analogs
would be by affinity resin purification of the biotinylated enzymes. Initial attempts
to purify the labeled enzymes on a streptavidin resin did not show differences
compared to the control extracts, which were not biotinylated, indicating that high
levels of background binding to the streptavidin resin was taking place. One
possibility is that the biotin linker is not long enough to reach the streptavidin
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binding site. Testing alternative linker lengths may aide in the purification of these
labeled enzymes by this method.
The early observation that strictosidine-p-glucosidase purifies from C.
roseus as a multi-enzyme complex suggests that protein-protein interactions
between SGD and the cell free enzyme preparation may be observable. Photo-
reactive probes for protein-protein interactions are commercially available (Pierce
Biotechnology) and interactions between SGD and proteins in the cell free
extracts were observed. The probe identified proteasome subunits and heat
shock proteins as the majority of the interacting proteins. However, proteins with
potential biosynthetic activites, such as aldolases and dehydratases were also
identified. Interestingly, the interaction between these proteins and SGD
appeared to be blocked by the presence of both strictosidine and NADPH but not
either of these compounds alone. Potentially, the presence of the substrates
alters enzyme-complex and regulates the observed protein-protein interactions.
Analysis of changes in the labeled proteome under conditions in the presence or
absence of NADPH and strictosidine may provide insight into the purpose of the
multi-enzyme complex in the biosynthesis of TIA.
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Amine Substrate Analog Synthesis
Trytpamine analogs 5-fluorotryptamine lb, 6-fluorotryptamine Ic, 5-
chlorotryptamine le, 5-bromotryptamine 1g, 7-methyltryptamine in, 5-
methyltryptamine lo, 5-hydroxytryptamine 1q, Nl-methyltrytpamine I r, N-a-
methyltryptamine Is, , 5-methoxytryptamine 1v, 6-methoxytryptamine 1w, a-
methyltryptamine lx, ct,a,p,p-tetradeuterotryptamine ly, a,ca-
tetradeuterotryptarmine Iz, L-tryptophan 25, and tyramine 52 are commercially
available. Indole-3-methylamine and indole-3-propylamaine were synthesized by
Sarah O'Connor.
1. Tryptamine Analog Synthesis
1.1 Methods
1.1.1 Method A
Substituted indoles 58 were combined with 1-dimethylamine-2-
nitroethylene (0.9equ) and 1 ml of trifluoroacetic acid per equivalent of indole.
The reaction was stirred at room temperature for 30 minutes and then poured
over a solution of saturated sodium bicarbonate. The resulting solution was
extracted into ethyl acetate and the organic fractions were washed with brine and
dried over anhydrous sodium sulfate. The solvent was removed under vacuum
to yield a yellow/orange solid. The product was purified by silica gel
chromatography 20% acetone in hexanes to yield the indole-3-nitrostyrenes 59.
1.1.2 Method B
Substituted indoles 58 were dissolved in 3 mL of ether per mmol of
starting material and put on ice under nitrogen atmosphere. To this 2 equivalents
of oxalyl chloride was slowly added, and after complete addition the icebath was
removed. The reaction was stirred at room temperature for 30 minutes. The
solvent was evaporated under nitrogen and the product was then treated with 0.5
M ammonia in dioxane (10 equivalents). The reaction was stirred at room
temperature overnight. To this product was added sodium bicarbonate and the
dioxane was removed under vacuum. The solid was loaded onto a silica gel
column equilibrated in 3:1 hexanes: ethylacetate and run until the first spot is
eluted. Then the product is eluted with ethylacetate to yield the indole-
glyoxylamides 60.
1.1.3 Method C
Substituted indole-3-carbaldyhydes 61 and 1 equivalent of ammonium
acetate was stirred at reflux in 2.5 mL of MeNO 2 per equivalent of starting
material for 3 hours. The resulting indole-3-nitrostyrene 59 was dried under
vacuum and utilized without further purification.
1.1.4 Method D
Indole-3-nitroethylenes 59 and indole-3-glyoxylamides 60 were dissolved
in anhydrous dioxane and added to 10 equivalents of THF chilled on ice under
nitrogen. After addition the ice bath was removed and the solution was refluxed
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Figure A.I: Chemical synthesis of tryptamine analogs.
overnight. The reaction was returned to ice and quenched with 50% icewater
and dixoane. The aluminum precipitates were removed by filtration over celite.
The solvent was removed under vacuum. The resulting product was purified by
silica gel chromatography 95:5:1 dichloromethane : methanol: ammonium
hydroxide to elute the first spot followed by 90:10:1 to elute the tryptamine
product 1. The product was precipitated as a hydrochloride salt as previously
described.
1.1.5 Method E
This is an alternative reduction method used in the synthesis of
brominated tryptamines where treatment with LAH results in complete loss of
bromination. Boron trifluoride diethyletherate was added to an ice chilled solution
of sodium borohydride in 80 mL of anhydrous THF. The solution was then
allowed to equilibrate to room temperature for 15 minutes. The indole-2-
nitroethylene 59 is dissolved in anhydrous THF and added dropwise to the
stirring solution. The reaction is refluxed for 2 hours. The heat is then removed
and the reaction is stirred at room temperature overnight. The reaction is
quenched by addition of ice water and acidified with 1N HCI. The reaction is then
263
Method A
Method B
Method
Method F
il I
heated to 80-85 C for 2 hours. The reaction is then cooled and extracted with
3% HCI. The aqueous layer is collected and basified. The basic solution is
extracted with ether. The organic layers are collected, washed with brine and
dried over sodium sulfate. The solvent is removed under vacuum and the
tryptamine product 1 is purified by silica gel chromatography as described in
method E. The resulting product is precipitated as a hydrochloride salt as
previously described.
1.1.6 Method F
This general method was used for the synthesis of 7-position substituted
tryptamines. The synthesis is laborious and low yielding and is not suggested for
most 7-position tryptamine synthesis, with the exception of 7-nitrotryptamine
which would be reduced under the alternative synthetic procedures.
i) A solution of 3-carbethoxy-2-piperidone 62 (30 mmols) in KOH (60mL,
0.5 N) was incubated at 300C overnight to yield the free acid 63. The reaction
was neutralized with HCI (6 N, 3mL) at O0C. ii) A solution of NaNO 2 (2.2g, 32
mmol) in 2.7 M HCI (60mL) was added to the various ortho-substituted anilines
64 and was stirred for 15 minutes to yield a diazotized aniline 65. iii) The
neutralized piperidine 63 was slowly added to the diazotized aniline 65 at O0C.
Aqueous sodium acetate (13.5g in 25mL) was added and the reaction was stirred
for 5 hours at O0C. The yellow/orange precipitate formed was collected by
filtration and washed 3 times with 20 mL water and dried under vacuum overnight
to yield the Piperidine-2,3-dione 3-[(2-substitutedphenyl)hydrazone] 66. iv) The
product 66 was refluxed in 90% formic acid (25 mL) for 5 hours, cooled to room
temperature and the solvent was removed under vacuum. Ethyl acetate and
ammonium hydroxide were added to the solid and the solution was stirred until
the solid dissolved. The organic layer was collected, dried over sodium sulfate
and concentrated. The resulting solid was purified by flash chromatography (1:1
hexanes/ethyl acetate) to yield 67. v)The product 67 (6.2 mmol) was refluxed for
6 hours in ethanol (40 mL) and KOH (3.5 g) and then concentrated under
vacuum. The resulting solid was cooled to O0C and dissolved in water (30 mL).
Sulfuric acid (5 mL) was added dropwise, and the reaction was then brought to
reflux for 6 hours. The solution was cooled to room temperature and
dichloromethane (20 mL) was added. The solution was basified with sodium
hydroxide in water and the product was extracted with dichloromethane
(4x20mL). The organic layer was collected, dried over Na 2SO 4 and
concentrated. The product I was purified by preparative HPLC (10-60%
acetonitrile, C18).
1.2 Tryptamine analog characterization
1.2.1 4-fluorotryptamine
F
NH 2
la
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4-fluoroindole (0.49g, 3.6 mmols was synthesized by method B to yield 0.606
g (2.9 mmols, 94% yield) of 4-fluoroindole-3-nitroethylene. 4-fluoroindole-3-
nitroethylene was converted to 4-fluorotryptamine la (0.522g, 2.9 mmols) by
method D and precipitated to give the hydrochloride salt (0.321g, 52% yield). 1H
NMR (500 MHz, d4-methanol) 6 ppm 7.19 ( 1 H, s), 7.18 ( 1 H, s), 7.05 ( 1 H, dt, J
= 8.03, 7.99, 5.21 Hz), 6.70 ( 1 H, dd, J = 11.54, 7.79 Hz), 3.22 (4 H, td, J =
14.18, 6.86, 6.86 Hz). 13C NMR (500 MHz, d4-methanol) 8 ppm 140.719,
124.408, 122.598, 115.975, 108.317, 108.111, 104.120, 100.499, 41.155,
25.137.
1.2.2 4-chlorotryptamine
N INH2
H
4-chloroindole (0.8 ml, 6.64mmol), was converted by method B to yield 4-
chloroindole-3-nitroethylene (1.16g, 5.21 mmol, 82% yield). 4-chloroindole-3-
nitroethylene reduced by method D to yield 0.71g of 4-chlorotryptamine li (3.65
mmols, 70% yield). It was the precipitated as described to yield 0.68g of 4-
chlorotryptamine hydrochloride salt (2.9 mmol, 44% overall yield). 1H NMR (500
MHz, d4-methanol) 8 ppm 7.32 ( 1 H, dd, J = 7.98, 0.96 Hz), 7.24 ( 1 H, s), 7.05 (
1 H, t, J = 7.80, 7.80 Hz), 7.01 ( 1 H, dd, J = 7.59, 0.99 Hz), 3.29 ( 4 H, m). 13C
NMR (500 MHz, d4-methanol) 6 ppm 140.034, 126.586, 126.325, 124.824,
123.419, 120.903, 111.764, 110.542, 42.667, 25.737.
1.2.3 4-bromotryptamine
N NH2
N 1k
H
4-bromoindole ( 0.96 ml, 7.65 mmol) was converted by method B to yield 4-
bromoindole-3-nitroethylene (1.718g, 6.43 mmol, 88% yield). 1H NMR (500
MHz, d6-acetone) 6 ppm 9.31-9.13 (m, 1H), 8.42 (s, 1H), 7.90 (d, J = 13.40 Hz,
1H), 7.61 (dd, J = 8.15, 0.83 Hz, 1H), 7.44 (dd, J = 7.66, 0.84 Hz, 1H), 7.18 (t, J
=7.9, 1H). 13C NMR (500 MHz, d6-acetone) 6 ppm 134.597, 134.444, 131.839,
128.008, 126.435, 125.840, 114.873, 114.304, 109.944. 4-bromoinodle-3-
nitroethylene was converted by method E to yield 0.925g of 4-bromotryptamine
1k. The resulting product was then precipitated as described to yield 0.62g of
the hydrochloride salt (2.2mmols, 28% overall yield). 1H NMR (500 MHz, d4-
methanol) 6 ppm 7.38 ( 1 H, dd, J = 8.14, 0.82 Hz), 7.28( 1 H, s), 7.20 ( 1 H, dd,
J = 7.57, 0.82 Hz), 6.99 ( 1 H, t, J = 7.86, 7.86 Hz), 3.32 (4 H, m). 13C NMR
(500 MHz, d4-methanol) 6 ppm 139.841, 126.948, 124.413, 123.702, 114.210,
112.305, 111.047, 109.815, 42.731, 25.473.
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1.2.4 4-methyltryptamine
1.2.4.1 Method A and Method D
To an ice cold solution of 4-methylindole (1.835g, 13.9 mmol) was
converted by method A to yield 4-methylindole-3-glyoxylamide (2.0g, 9.89mmol,
71% yield). 1H NMR (300 MHz, d6-acetone) 6 ppm 8.83 (d, J = 3.39 Hz, 1H),
7.37 (dtd, J = 8.10, 1.17, 1.16, 0.56 Hz, 1H), 7.22-7.09 (m, 1H), 7.01 (tdd, J =
7.27, 1.72, 0.77, 0.77 Hz, 1H), 2.81 (s, 3H). 13C NMR (300 MHz, d6-acetone) 6
ppm 183.508, 168.003, 141.211, 139.447, 134.327, 126.947, 126.277, 125.622,
116.093, 111.642, 24.366. 4-methylindole-3-glyoxylamide was converted by
method D to yield 4- methyltryptamine Im (1.1791g, 69% yeild). The
hydrochloride salt was then precipitated to yield 4-methyltryptamine
hydrochloride (0.95g, 4.5 mmol, 39% overall yield). 1H NMR (500 MHz, d4-
methanol) 6 ppm 7.19 ( 1 H, d, J = 8.16 Hz), 7.12 ( 1 H, s), 6.97 ( 1 H, dd, J =
8.08, 7.19 Hz), 6.76 ( 1 H, d, J = 7.10 Hz), 3.25 ( 4 H, m), 2.68 ( 3 H, s). 13C
NMR (500 MHz, d4-methanol) 6 ppm 138.079, 129.954, 125.813, 123.699,
122.071, 120.989, 110.401, 109.862, 41.714, 25.647, 19.798.
1.2.4.2 Method C and Method D
4-methylindole-3-carbaldehyde (0.35 mmol) was converted by method C
to yield 4-methylindole-3-nitrostyrene . 1H NMR (500 MHz, d6-dimethylsulfoxide)
6 ppm 2.67 (3H, s), 6.96 (1H, d, J =7.2 Hz), 7.13 (1H, t, J= 7.2, 8.2 Hz) 7.35 (1H,
d, J= 8.2 Hz), 8.11 (1H, d, J= 12.7 Hz), 8.43 (1H, d, J= 2.8 Hz), 8.59 (1H, d, J =
13.2 Hz). 13C NMR (500 MHz, d6-dimethylsulfoxide) 6 19.6, 107.4, 110.0, 121.9,
122.6, 124.0, 129.0, 129.7, 130.7, 134.6, 136.2. ESI: m/z 203.0 [M+H] . 4-
methylindole-3-nitrostyrene ws (0.23 mmol) was converted to 4-methyltryptamine
Im by method D. 1H NMR (500 MHz, d4-methanol) 8 ppm 2.97 (2H, t, J=7.1),
3.09 (2H, t, J=7.1), 6.73 (1H, d, J=7.12 Hz), 6.96 (1H, t, J=8.2 Hz), 7.01 (1H, s),
7.16 (1H, d, J=8.3 Hz). ESI: m/z 175.1 [M+H]
1.2.5 4-methoxytryptamine
OMe
SNH 2
N lt
H
4-methoxyindole (0.9742g, 6.619mmols) is converted by method A to yield
4-methylindole-3-glyoxylamide (1.1 g, 4.81 mmol, 73% yield). Which is converted
by method D to yield 4-methyltryptamine hydrochloride It (0.45g, 1.99 mmol,
30% overall yield). 1H (500 MHz, d4-methanol) 6 ppm 7.03 ( 1 H, t, J = 7.88,
7.88 Hz), 7.02 ( 1 H, s), 6.97 ( 1 H, dd, J = 8.16, 0.73 Hz), 6.50 ( 1 H, d, J = 7.67
Hz),, 3.93 ( 3 H, s), 3.22 (4 H, td, J = 14.40, 8.07, 8.07 Hz). 13C NMR (500
MHz, d4-methanol) 6 ppm 139.487, 122.980, 122.716, 109.804, 105.389, 99.309,
54.800, 41.773, 25.689.
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1.2.6 7-fluorotryptamine
SiNH2
d
F H
1.2.6.1 Method A and method D
7-fluoroindole (1.039g, 7.6 mmols) was converted by method A to yield 7-
fluoroindole-3-glyoxylamide (0.5 g, 2.43 mmols). 7-fluoroindole-3-glyoxylamide
was converted by method D to yield 7-fluorotryptamine Id (0.328 g, 23% yield).
1H NMR (500 MHz, d4-methanol) 6 ppm 7.39 (d, J = 7.97 Hz, 1H), 7.25 (s, 1H),
7.00 (dt, J = 7.90, 7.88, 4.65 Hz, 1H), 6.86 (dd, J = 11.45, 7.76 Hz, 1H), 3.24 (t, J
= 7.48, 7.48 Hz, 2H), 3.13 (t, J = 7.38, 7.38 Hz, 2H). 13C NMR (500 MHz, d4-
methanol) 6 ppm 152.246, 150.313, 132.271, 132.225, 125.453, 120.413,
120.364, 115.071, 115.044, 111.431, 111.413, 107.414, 107.283, 41.192,
24.504.
1.2.6.2 Method B and Method D
7-fluoroindole (0.8146 g, 6.03 mmols was converted by method B to yield
7-fluoroindole-3-nitrostyrene (0.891g, 4.32mmols). 7-fluoroindole-3-nitrostyrene
(0.606 g 1/2.94 mmols) was converted by method D to yield 7-fluorotryptamine Id
(0.492g, 2.75 mmols, 63.6% yeild) and after precipitation 7-fluorotryptamine
hydrochloride 0.4913g, 2.28 mmols, 83%yeild, overall yield 38%). 1H NMR (500
MHz, d4-methanol) 6 ppm 7.39 (d, J = 7.97 Hz, 1H), 7.25 (s, 1H), 7.00 (dt, J =
7.90, 7.88, 4.65 Hz, 1H), 6.86 (dd, J = 11.45, 7.76 Hz, 1H), 3.24 (t, J = 7.48, 7.48
Hz, 2H), 3.13 (t, J = 7.38, 7.38 Hz, 2H). 13C NMR (500 MHz, d4-methanol) 5
ppm 152.246, 150.313, 132.271, 132.225, 125.453, 120.413, 120.364, 115.071,
115.044, 111.431, 111.413, 107.414, 107.283, 41.192, 24.504.
1.2.6.3 Method F
7-fluorotrypamine Id was synthesized by method F. A solution of NaNO 2(2.2 g) in 2.7 M HCI (60 ml) was added to the o-substituted aniline 64d (30
mmols) to yield 65d. Compound 65d was slowly reacted with 63 as described
above to yield the hydrazone 66d (70% overall yield). 1H NMR 6 2.03 (2H, m)
2.74 (2H, t, J=6.1 Hz ) 3.41 (2H, m) 6.85-6.78 (2H, m) 7.12-6.98 (2H, m) 7.59
(1H, m). 13C NMR 6 22.8, 31.3, 42.1, 113.9, 115.1, 115.3, 120.6, 124.8, 128.3,
164.4. ESI: m/z 222.3 [M+H]
Compound 67d was synthesized from compound 66d.. [M+H] 205.3. "H NMR
(CD 3CI-d 6-DMSO) 2.934 (2H, t, J =7.151 Hz), 3.54 (2H, m), 7.06 (2H, m), 7.41
(1H, dd), 7.71 (1H, s), 12.14 (1H, s). 7-fluorotryptamine 10 was synthesized from
67d to yield ld. 1H NMR (CD 30D) 6 3.11 (2H, t, J= 7.7 Hz), 3.23 (2H, t, J= 7.2
Hz), 6.83(1H, dd, J= 11.6 and 7.7 Hz), 7.00 (1H, m), 7.22 (1H,s), 7.38 (1H, d, J=
7.7 Hz). ESI: m/z 179.1 [M+H]
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1.2.7 7-bromotryptamine
KNH2
I
Br H
7-bromoindole was converted to 7-bromonitrosyrene by method B (0.9347
g, 4.76 mmols). 1H NMR (500 MHz, d6-acetone) 6 ppm 8.36 (d, J = 13.55 Hz,
1H), 8.23 (s, 1H), 8.00 (d, J = 8.00 Hz, 1H), 7.94 (d, J = 13.56 Hz, 1H), 7.51 (d, J
= 7.66 Hz, 1H), 7.23 (t, J = 7.85, 7.85 Hz, 1H). 13C NMR (500 MHz, d6-acetone)
6 ppm 137.017, 135.509, 135.332, 133.731, 127.290, 126.812, 123.900,
120.519, 110.398, 105.967.
Which was converted to 7-bromotryptamine 11 by method E yielding 0.1 lg (0.4
mmols, 8.5% yield) of the hydrochloride salt. 1H NMR (500 MHz, d4-methanol) 6
ppm 7.59 (dd, J = 7.93, 0.85 Hz, 1H), 7.31 (dd, J = 7.59, 0.74 Hz, 1H), 7.29 (s,
1H), 6.98 (t, J = 7.75, 7.75 Hz, 1H), 3.24 (t, J = 7.47, 7.47 Hz, 1H), 3.13 (t, J =
7.40, 7.40 Hz, 1H). 13C NMR (500 MHz, d4-methanol) 6 ppm 136.762, 129.826,
125.622, 125.593, 125.383, 121.362, 118.522, 111.793, 105.846, 41.180, 24.575
1.2.8 7-methoxytryptamine
NH2
/ lulu
OMeH
7-methoxyindole (1.208g, 8.2 mmols) was converted 7-methoxyindole-3-
glyoxylamide by method B. 1H NMR (500 MHz, d6-acetone) 6 8.48 (s, 1H), 8.11
(s, 1H), 7.71 (d, J = 8.01 Hz, 1H), 7.61 (s, 1H), 7.15 (t, J = 7.93, 7.93 Hz, 1H),
6.79 (d, J = 7.96 Hz, 1H), 3.86 (s, 1H). 13C NMR (500 MHz, d6-acetone) 6
183.754, 167.601, 147.439, 138.685, 128.461, 127.244, 125.150, 114.734,
113.546, 105.643, 56.487. 7-methoxyindole-3-glyoxylamide 1.05g of 7-
methoxytryptamine lu HCI by method D. 1H NMR (500 MHz, CD 3OD)5 7.17
(dd, J = 8.00, 0.70 Hz, 1H), 7.13 (s, 1H), 6.98 (t, J = 7.84, 7.84 Hz, 1H), 6.66 (d, J
= 7.67 Hz, 1H), 3.94 (s, 3H), 3.22 (t, J = 7.31, 7.31 Hz, 2H), 3.10 (t, J = 7.36, 7.36
Hz, 2H). 13C NMR (500 MHz, CD 30D) 6 148.071, 129.684, 128.613, 123.907,
120.758, 111.788, 110.718, 102.811, 55.778, 41.328, 24.717.
1.2.9 7-chlorotryptamine
NH2
-N/ j
Cl H
7-chlorotyrptamine lj was synthesized from 7-chloroindole (0.9946g, 6.56
mmols) by method A and Method D yeilding 0.66g (2.86 mmols, 44% yeild) of the
hydrochloride salt. 1H NMR (500 MHz, CD 30D) 7.54 (dd, J = 7.93, 0.85 Hz, 1H),
7.28 (s, 1H), 7.15 (dd, J = 7.57, 0.83 Hz, 1H), 7.03 (t, J = 7.76, 7.76 Hz, 1H), 3.24
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(t, J = 7.50, 7.50 Hz, 2H), 3.13 (t, J = 7.39, 7.39 Hz, 2H). 13C NMR (500 MHz,
CD 30D) 135.259, 130.091, 125.596, 122.248, 120.968, 118.022, 117.970,
111.692, 41.192, 24.522,
1.2.10 6-methyltryptamine
M NH2
Me N IpH
6-methylindole-3-carboxaldehyde (1.320g, 8.29 mmols) was converted by
Method C to yield 0.537 g (2.66 mmols) of 6-methylindole-3-nitrostyrene. 1H
NMR (300 MHz, d6-DMSO) 8.37 (d, J = 13.37 Hz, 1H), 8.17 (s, 1H), 7.97 (d, J =
13.37 Hz, 1H), 7.83 (d, J = 8.13 Hz, 1H), 7.30 (s, 1H), 7.06 (d, J = 8.12 Hz, 1H),
2.42 (s, 1H). 1H NMR (300 MHz, d6-DMSO) 138.123, 136.301, 134.873,
132.804, 130.739, 123.522, 122.298, 120.283, 112.565, 108.245, 21.170. 6-
methylindole-3-nitrostyrene (0.537g, 2.66 mmols) was converted to 6-
methyltryptamine Ip yielding 0.329 g (1.89 mmoles, 83.4% yeild, overall yield of
22.8%). The product was precipitated to yield 0.2714 g of 6-methyltryptamine
hydrochloride salt. 1H NMR (500 MHz, CD 30D) 7.45 (d, J = 8.10 Hz, 1H), 7.18
(s, 1H), 7.10 (s, 1H), 6.90 (dd, J = 8.08, 0.88 Hz, 1H), 3.22 (t, J = 7.40, 7.40 Hz,
2H), 3.10 (t, J = 7.36, 7.36 Hz, 2H), 2.42 (s, 3H). 13C NMR (500 MHz, CD 30D)
138.854, 132.508, 126.145, 123.681, 121.836, 118.654, 112.450, 110.114,
41.298, 24.659, 21.845.
1.2.11 6-Chlorotryptamine
C NH2
CIl N IfH
6-chlorotryptamine was synthesized from 6-chloroindole (0.9757g, 6.4
mmols) by method A and method D yeilding 0.84g (3.6mmols, 56% yeild) of the
hydrochloride salt. 1H NMR (500 MHz, CD 30D) 7.45 (d, J = 8.10 Hz, 1H), 7.18
(s, 1H), 7.10 (s, 1H), 6.90 (dd, J = 8.08, 0.88 Hz, 1H), 3.22 (t, J = 7.40, 7.40 Hz,
2H), 3.10 (t, J = 7.36, 7.36 Hz, 2H), 2.42 (s, 3H). 13C NMR (500 MHz, CD3OD)
138.854, 132.508, 126.145, 123.681, 121.836, 118.654, 112.450, 110.114,
41.298, 24.659, 21.845.
1.2.12 6-Bromotryptamine
r N H2
Br NH 2
H
6-bromoindole-3-nitroethylene was synthesized from 6-bromoindole-3-
carbaldehyde (1.1081g, 4.945 mmols) as described in method C yeilding 1.288g
(4.82 mmols, 97.5% yeild). 1H NMR (500 MHz, CD30D) 8.36 (d, J = 13.55 Hz,
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1H), 8.19 (s, 1H), 7.96 (d, J = 8.53 Hz, 1H), 7.92 (d, J = 13.52 Hz, 1H), 7.79 (dd,
J = 1.79, 0.50 Hz, 1H), 7.42 (dd, J = 8.52, 1.79 Hz, 1H). 13C NMR (500 MHz,
CD 30D) 136.789, 134.480, 134.050, 126.233, 123.338, 123.324, 117.796,
116.963. 6-bromoindole-3- nitroethylene was then reduced as described in
method D to yeild 0.31g (1.12 mmols, 23% overall yeild) 6-bromotryptamine
hydrochloride salt. 1H NMR (500 MHz, CD 30D) 7.54 (dd, J = 1.74, 0.52 Hz, 1H),
7.50 (dd, J = 8.45, 0.51 Hz, 1H), 7.21 (s, 1H), 7.16 (dd, J = 8.45, 1.74 Hz, 1H),
3.22 (t, J = 7.45, 7.45 Hz, 2H), 3.11 (t, J = 7.40, 7.40 Hz, 2H). 13C NMR (500
MHz, CD 30D) 139.152, 127.224, 125.335, 123.205, 120.493, 116.208, 115.436,
110.789, 41.193, 24.367.
2. Synthesis of Alternate Heterocycles
2.1 Benzofuran-3-ethanamine
~N
LAH
68 X =O 49 X =O
69 X =S 50 X =S
Figure A.2: Synthesis of benofuran-3-ethanamine and benzothiophene-3
-ethanamine.
Benzofuran-3-nitrile 68 was dissolved in ether and added carefully to 1M
LAH on in ice bath under nitrogen. The reaction was refluxed for 3 hours and
then cooled to room temperatureand quenched by addition of water. The reaction
was filtered over celite and the solvent was removed under vacuum to give
benzofuran-2-ethanamine 49 as an oil. The oil was then precipitated by
dissolving in ether and addition of 1 equivalent of ethanolic HCI. The precipitate
was collected, but was not pure. The mixture was further purified by C18 column
chromatography eluted with 7:3 H20:Methanol. 1H NMR (300 MHz, CD 30D) 6
3.11-3.05 (2H, m), 3.28-3.25 (2H, m), 7.38-7.24 (2H, m), 7.50 (1H, dd, J= 8.3 and
1.1 Hz), 7.67 ( 1H, dd, J= 8.3 and 1.1 Hz), 7.1 (1H, t, J= 1.1 Hz). ESI: m/z 162.1
[M+H]
2.2 Benzothiophene-3-ethanamine
Benzothiophene-3-ethanamine 50 was synthesized from benzothiophene-3-
nitrile as described for benzothiophene-3-nitrile 69 by Sarah O'Connor. 1H NMR
(CD 30D) 6 3.7-3.2 (4H, m), 7.48-7.36 (3H, m), 7.825 (1H, dd, J= 7.7 and 1.7 Hz)
7.901 (1H, dd, J= 6.6 and 1.1 Hz). ESI: m/z 178.1 [M+H]
2.3 Pyrrole-3-ethanamine
Pyrrole ethanamine was synthesized as previously described 3-acetyl-1-
(phenylsulphonyl)-pyrrole (2.08 mmol),68, was dissolved in ethanol (15 mL) and
NaBH 4 (5.96 mmol) was added and the reaction was and stirred for 3 hours. The
reaction was quenched with water (10 mL) and the product was extracted with 3
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x 20mL of methylene chloride. The organic layers were combined, washed with
brine, saturated bicarbonate, dried with Na2SO 4 and concentrated. The resulting
oil was dissolved in 1,4 dioxane (10 mL) and H3PO 4 (4.89 mmol) was added to
0 0
1. NaBH4 s4,Na4
2. H3PO4 Os4, NalO4 H
N N -- N
SO2Ph SO 2Ph SO 2Ph
70 71, 53% 72, 40%
NO2  NH2
MeNO 2  / \ LAH, THF
NH 3CH 3COO N NSO 2Ph H
73, 70% 51
Figure A.3: Synthesis of pyrrole-3-ethanamine.
the solution. The solution was refluxed for 12 hours, quenched with water and
the product was extracted with methylene chloride ( 2 x 10mL). The organic
fractions were combined, washed with saturated bicarbonate, dried over Na 2SO 4
and the solvent was removed under vacuum. The resulting brown oil 69 was
subjected to silica gel chromatography (1:1 hexanes: methylene chloride). (53%
yield). "H NMR (CDCI 3) 6 7.87 (2H, m), 7.47-7.6 (3H, m), 7.12 (2H, m), 6.54(2H,
m), 5.49 (1H, dd), 5.14 (1H, dd). 13C NMR (CDCl 3) 6 139.0, 134.1, 129.6, 128.4,
128.2, 127.0, 121.9, 118.7, 113.8, 111.2. ESI: m/z 234.3 [M+H]
Compound 69 (1.05 mmol) was placed in 1,4-dioxane and water (3:1, 6
mL) and stirred with Os04 (0.027 mmol) and NalO 4 (2.4 mmol) at room
temperature for 12 hours. The reaction was diluted with water (5 mL), extracted
three times with methylene chloride (3 x 10 mL) and concentrated. The resulting
oil was purified by silica gel (100% methylene chloride) to yield the aldehyde 70
in 40% yield. "H NMR (CDCI 3)5 9.80 (1H, s), 8.0-7.50 (6H, m), 7.20 (1H, m),
6.71 (1H, m). 13C NMR (CDCI 3)56 185.3, 137.9, 135.0, 129.9, 128.3, 127.3,
122.5, 111.1. ESI: m/z 236.4 [M+H] .
Aldehyde 70 (0.425 mmol) was dissolved in nitromethane (0.5 mL) containing 1
equivalent of ammonium acetate. The solution was refluxed for 3 hours, dried
under vacuum and the resulting solid was dissolved in ethyl acetate. After
washing with aqueous bicarbonate, the organic layer was dried with Na 2SO4 and
concentrated to yield a brown solid, 71 (70%yield). "H NMR (CDCI 3) 6 8.2x-7.0x
(9H, m), 6.46 (1H, s). 13C NMR (CDCI3) 6 138.0, 136.6, 134.9, 131.6, 129.9,
127.3, 125.2, 123.2, 120.2, 111.3.ESI: m/z [M+H]
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To a solution of 1.OM LAH in THF (2mL, 2mmol) cooled in an ice bath was
added a solution of 71 (0.32 mmol) in dry THF (10mL). The mixture was then
stirred at room temperature for 24 hours. The solution was filtered over celite
and the filtrate was dried over Na2SO 4. The solvent was removed under vacuum.
Pyrrole ethanamine (51) was purified by iatrobead chromatography eluting with
69:30:1 (Methylene Chloride: Methanol: Water). 1H NMR (CDCI 3) 6 3.00 (2H, t,
J= 7.2 Hz), 3.67 (2H, t, J=6.6 Hz), 6.70 (2H, m), 7.16 (1H, t, J= 8.3 Hz), 7.26 (1H,
d, J= 8.3 Hz). ESI: m/z 111.1 [M+H]+
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Appendix B
Table of HR-LCMS and Alkaloid Assignment
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The following section contains tabulate HR-LCMS data for the alkaloid analogs
detected in C. roseus hairy root extracts fed amine substrate analogs. The
substitution to the tryptamine ring is listed in row 1. Column 1 is the observed
retention time, column 2 is the molecular formula, column 3 is the experiemental
mass observed, column 3 is the mass calculated from the molecular formula,
column 4 is the part per million difference between the experimental mass and the
calculated mass, column 5 is the observed UV maxima, column 6 is the alkaloid
assignment, column 7 is the mean peak area and column 8 is the standard error
of the mean. The alkaloid assignment in column four correlates the analog of the
alkaloid in Figure B.1.
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Figure B.1: Alkaloids by structural assignment.
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Table B.1: 4-bromotryptamine
4BROMO
RT Formula Calc Exp ppm UV/ TIA Peak SE
mass mass VIS area
10.59 C21H20N203Br 427.0657 427.0668 2.6 5 0.6 0.2
11.14 C21H20N203Br 427.0657 427.0669 2.8 33 0.4 0.2
10.67 C21 H24N203Br 431.097 431.0984 3.2 4 2.3 1.8
8.67 C21H26N203Br 433.1127 433.1143 3.7 34 12.8 8.3
9.64 C21H26N203Br 433.1127 433.1145 4.2 34 3.0 1.5
9.63 C27H34N209Br 609.1448 609.1435 -2.1 3 1.2 0.5
4.49 C10H12N2Br 239.0184 239.0187 1.3 1 1245 371
Table B.2: 4-chlorotryptamine
4CHLORO
RT Formula Calc Exp ppm UVNIS TIA Peak SE
mass mass area
11.16 C20H22N202CI 357.137 357.1371 0.3 275 10 32 27
10.06 C21H20N203CI 383.1162 383.1154 -2.1 5 122 117
10.66 C21H20N203CI 383.1162 383.1173 2.9 33 34 30
10.11 C21 H24N203CI 387.1475 387.1471 -1 285 4 1256 1207
7.9 C21H26N203CI 389.1632 389.1628 -1 34 54 50
281,
8.08 C21H26N203CI 389.1632 389.1613 -4.9 225 34 921 812
8.31 C21H26N203CI 389.1632 389.1625 -1.8 34 126 120
8.87 C21H26N203CI 389.1632 389.1631 -0.3 34 542 497
281, 34
9.09 C21H26N203CI 389.1632 389.1613 -4.9 225 32 31
9.15 C27H34N209CI 565.1953 565.1945 -1.4 3 1153 783
3.94 C10H12N2CI 195.0682 195.0689 -3.6 1 1256 1207
10.57 C21H22N203CI 385.1319 385.1328 2.3 30 188 184
11.06 C21H22N203CI 385.1319 385.1322 0.8 30 29 28
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Table B.3: 4-fluorotryptmine
4FLUORO
RT Formula Calc Exp ppm UVNVIS TIA Peak SE
mass mass area
329, 288,
6.96 C20H22N202F 341.1665 341.1655 -2.9 236 10 534 290
8.47 C20H22N202F 341.1665 341.1659 -1.8 Other 110 70
8.08 C20H24N202F 341.1822 341.1826 1.2 Other 52 33
9.77 C20H24N202F 341.1822 341.1816 -1.7 Other 20 15
3.72 C21H24N202F 355.1822 355.1833 3.1 275, 240 Other 269 178
4.34 C21H24N202F 355.1822 355.182 -0.6 242 Other 269 180
220, 265,
6.4 C21H24N202F 355.1822 355.183 2.3 329 57 101 37
9.03 C21H24N202F 355.1822 355.1823 0.3 327, 289, 7 242 208
9.57 C21H26N202F 357.1978 357.1982 1.1 267 Other 28 23
8.65 C21 H20N203F 367.1458 367.1448 -2.7 248, 301 5 826 514
9.1 C21H20N203F 367.1458 367.1455 -0.8 249, 303 33 512 322
6.23 C21H22N203F 369.1614 369.1602 -3.3 249, 300 30 69 64
7.33 C21H22N203F 369.1614 369.1602 -3.3 30 31 21
330, 287, Loch-
7.37 C21H24N203F 371.1771 371.176 -3 222 7 312 262
8.46 C21H24N203F 371.1771 371.1772 0.3 4 377 247
6.41 C21H26N203F 373.1927 373.1913 -3.8 34 765 430
7.1 C21H26N203F 373.1927 373.1923 -1.1 34 34 17
7.34 C21H26N203F 373.1927 373.193 0.8 34 334 190
329, 286,
2.46 C21H24N204F 387.172 387.1701 -4.9 218 Hor-7 20 12
4.99 C21H24N204F 387.172 387.173 2.6 Other 18 16
7.63 C27H34N209F 549.2248 549.2235 -2.4 220 3 657 373
Table B.4: 4-methoxytryptamine
4Methoxy
RT Formula Calc Exp ppm UVNIS TIA Peak SE
mass mass area
9.49 C22H29N202 353.2229 353.222 -2.5 10 14 8
8.45 C22H27N204 383.1971 383.1986 3.9 4 144 55
6.3 C22H28N204 385.2127 385.2128 0.3 34 48 16
6.99 C22H28N204 385.2127 385.2144 4.4 34 11 3
7.19 C22H28N204 385.2127 385.214 3.4 34 51 13
7.63 C28H37N2010 561.2448 561.2473 4.5 3 40 18
2.65 C11H15N20 191.1184 191.1179 -2.6 1 537 185
292,
9.71 C22H27N203 367.2022 367.2037 4.1 245 Other 130 51
290,
9.17 C23H29N203 381.2178 381.2179 0.3 243 Other 91 32
296,
10.26 C22H29N202 369.2178 369.2195 4.6 256 Other 108 61
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Table B.5: 4-methyltryptamine
4METHYL
RT Formula Calc Exp ppm UVNIS TIA Peak SE
mass mass area
331, 295,
8.62 C21H25N202 337.1916 337.1925 2.7 238 10 1492 792
9.67 C21H25N202 337.1916 337.1913 -0.9 266, 227 Other 198 101
332, 294,
9.41 C21H27N202 339.2073 339.2064 -2.7 229 56 219 118
10.03 C21 H27N202 339.2073 339.2062 -3.2 Other 73 39
8.3 C22H27N202 351.2073 351.2057 -4.6 223 Other 164 43
9.21 C22H27N202 351.2073 351.2065 -2.3 328, 294 57 448 233
9.62 C22H27N202 351.2073 351.2086 3.7 Other 20 16
10.74 C22H27N202 351.2073 351.2062 -3.1 332, 296 7 93 51
9.87 C22H23N203 363.1709 363.1719 2.8 309 5 89 45
10.25 C22H23N203 363.1709 363.1706 -0.8 33 43 18
8.26 C22H25N203 365.1865 365.1862 -0.8 Other 21 11
10.05 C22H25N203 365.1865 365.1862 -0.8 Other 45 23
8.97 C22H27N203 367.2022 367.2021 -0.3 223, 275 4 983 532
6.81 C22H29N203 369.2178 369.2166 -3.3 281, 222 34 825 393
7.34 C22H29N203 369.2178 369.2167 -3 34 13 6
7.67 C22H29N203 369.2178 369.2166 -3.3 271, 219 34 374 197
8 C28H37N209 545.2499 545.2479 -3.7 3 14 12
Table B6: 5-bromostrictosidine
5-bromo
RT Formula Calc Exp ppm UV/ TIA Peak SE
mass mass VIS area
11.71 C20H22N202Br 401.0865 401.0883 4.5 1.4 0.6
12.07 C20H22N202Br 401.0865 401.0848 -4.2 0.9 0.2
12.43 C21H24N202Br 415.1021 415.1023 0.5 332, 7
302 3.1 0.3
13.26 C21H26N202Br 417.1178 417.1157 -5 dihydr
o -7 2.2 0.7
10.96 C21H20N203Br 427.0657 427.0675 4.2 5 16.0 4.7
11.44 C21H20N203Br 427.0657 427.0664 1.6 33 0.3 0.1
11.06 C21H24N203Br 431.097 431.0963 -1.6 4 41.9 7.2
9 C21H26N203Br 433.1127 433.1109 -4.2 34 112.
8 21.6
9.86 C27H34N209Br 609.1448 609.1434 -2.3 3 2.2 0.3
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Table B.7: 5-chlorostrictosidine
5-chloro
RT Formula Calc mass Exp mass ppm UV/I VIS TIA Peak SE
area
10.3 C20H22N202CI 357.137 357.1376 1.7 10 3.8 0.8
11.3 C20H22N202CI 357.137 357.1385 4.2 Other 5.7 1.3
11.8 C21H24N202CI 371.1526 371.1534 2.2 332, 303 7 27.3 4.7
Dihd
12.9 C21H26N202CI 373.1683 373.1688 1.3 258 -7 6.5 1.0
10.3 C21H20N203CI 383.1162 383.1147 -3.9 306, 234 5 48.6 9.6
10.8 C21H20N203CI 383.1162 383.117 2.1 33 6.0 0.7
10.4 C21H24N203CL 387.1475 387.1482 1.8 285 4 26.8 5.4
12.3 C22H28N202CI 387.1839 387.1848 2.3 4 2.6 0.4
8.31 C21 H26N203CI 389.1632 389.1616 -4.1 278, 227 34 48.2 8.5
9.17 C21H26N203CI 389.1632 389.1637 1.3 34 5.0 0.9
9.31 C27H34N209CI 565.1953 565.1927 -4.6 3 1.8 0.8
Table B.8: 5-fluorotryptamine
5-FLUORO
RT Formula Calc Exp ppm UVNIS TIA Peak SE
Mass mass area
7.65 C20H22N202F 341.1665 341.1665 0 285,221 10 21 9
8.1 C20H22N202F 341.1665 341.1679 4.1 280, 222 23 16
8.26 C20H22N202F 341.1665 341.1658 -2.1 276 61 14
8.59 C20H24N202F 343.1822 343.1831 2.6 56 13 3
9.49 C20H24N202F 343.1822 343.1837 4.4 4 1
213, 265,
4.54 C21H24N202F 355.1822 355.1809 -3.7 312 82 12
5.47 C21H24N202F 355.1822 355.1838 4.5 48 6
8.81 C21H24N202F 355.1822 355.1819 -0.8 14 5
9.71 C21H24N202F 355.1822 355.1818 -1.1 332, 298 7 106 33
341, 290, dihydro
5.89 C20H22N203F 357.1614 357.1608 -1.7 226 -7 67 15
8.97 C20H22N203F 357.1614 357.161 -1.1 221,265 23 12
11.04 C21H26N202F 357.1978 357.1971 -2 297 25 2
8.55 C21H20N203F 367.1458 367.1442 -4.4 305,248 5 514 132
8.96 C21H20N203F 367.1458 367.1447 -3 305,254 33 41 10
8.23 C21H24N203F 371.1771 371.1756 -4 280 4 156 51
8.6 C21H24N203F 371.1771 371.1775 1.1 Loch-7 34 9
5.96 C21H26N203F 373.1927 373.1914 -3.5 276 34 38 12
3.16 C21H24N204F 387.172 387.1721 0.3 330, 299 Hor-7 21 7
7.28 C27H34N209F 549.2248 549.2269 3.8 3 2 1
1 103 57
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Table B.9:5-methoxystrictosidine
5-methoxy
RT Formula Calc Exp ppm UVNIS TIA Peak SE
Mass mass area
9.69 C22H27N203 367.2022 367.2024 0.5 other 7.84 0.03
9.78 C22H29N203 369.2178 369.216 -4.9 other 79.05 4.76
9.91 C22H23N204 379.1658 379.1669 2.9 5 36.92 1.56
10.17 C22H23N204 379.1658 379.1648 -2.6 33 11.20 2.57
6.45 C22H27N204 383.1971 383.1956 -3.9 4 21.39 15.32
7.14 C22H27N204 383.1971 383.1954 -4.4 4 10.99 4.32
7.31 C22H27N204 383.1971 383.1958 -3.4 4 62.01 10.50
273,
4.67 C22H29N204 385.2127 385.2124 -0.8 220 34 73.73 33.31
Table B. 10: 5-methylstrictosidine
5-methyl
RT Formula Calc Exp ppm UVNIS TIA Peak SE
mass mass area
9.03 C21H25N202 337.1916 337.1903 -3.9 10 70 13
9.42 C21H25N202 337.1916 337.1904 -3.6 other 38 6
10.58 C21H25N202 337.1916 337.19 -4.7 other 24 5
8.87 C21H27N202 339.2073 339.2065 -2.4 other 16 6
9.83 C21H27N202 339.2073 339.2065 -2.4 56 12 3
10.44 C21H27N202 339.2073 339.2059 -4.1 other 21 5
10.14 C22H27N202 351.2073 351.2066 -2 9 14 5
328,
10.6 C22H27N202 351.2073 351.2064 -2.6 236 7 633 88
299,
11.99 C22H29N202 353.2229 353.224 3.1 250 Dihydro-7 416 53
309,
10.23 C22H23N203 363.1709 363.1693 -4.4 254 5 158 22
10.62 C22H23N203 363.1709 363.1698 -3 33 23 6
280,
9.47 C22H27N203 367.2022 367.2015 -1.9 224 4 638 121
274, 34
7.32 C22H29N203 369.2178 369.2164 -3.8 224 230 33
8.11 C22H29N203 369.2178 369.216 -4.9 34 51 12
8.48 C28H37N209 545.2499 545.2521 4 3 10 6
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Table B. 11 :6-bromostrictosidine
6-bromo
RT Formula Calc Exp ppm UV/I VIS TIA Peak SE
mass mass area
10.
10.0 C20H22N202Br 401.0865 401.0865 0 330, 275 Other 38.3 2
344. 78.
10.6 C20H22N202Br 401.0865 401.0851 -3.5 326, 303 10 2 6
11.7 C20H24N202Br 403.1021 403.1001 -5 325 56 14.9 3.5
12.0 C20H24N202Br 403.1021 403.1027 1.5 282, 227 Other 8.8 1.9
10.2 C21H24N202Br 415.1021 415.1028 1.7 323 57 53.2 7.5
11.8 C21H24N202Br 415.1021 415.101 -2.6 328, 298 Other 6.8 3.9
105. 33.
12.6 C21H24N202Br 415.1021 415.1013 -1.9 328 7 9 9
12.4 C21H26N202Br 417.1178 417.1185 1.7 Other 5.7 1.0
Dihydr
13.3 C21H26N202Br 417.1178 417.1161 -4.1 o -7 3.4 0.8
11.1 C21H20N203Br 427.0657 427.0654 -0.7 313, 248 5 66.7 1.6
11.4 C21H20N203Br 427.0657 427.0655 -0.5 316, 249 5 7.8 1.0
4 19.
11.1 C21H24N203Br 431.097 431.095 -4.6 285, 228 70.2 8
11.9 C21H24N203Br 431.097 431.0967 -0.7 4 11.1 1.6
8.8 C21H26N203Br 433.1127 433.1129 0.5 34 4.4 1.7
9.0 C21H26N203Br 433.1127 433.1137 2.3 34 4.8 0.9
9.6 C21H26N203Br 433.1127 433.1117 -2.3 34 7.9 2.7
9.8 C27H34N309Br 609.1448 609.1464 2.6 3 1.8 0.2
Table B.12: 6-chlorostrictosidine
RT Formula Calc Exp ppm UVNIS TIA Peak SE
mass mass area
9.44 C20H22N202CI 357.137 357.136 -2.8 268, 225 other 19.4 1.0
10.17 C20H22N202CI 357.137 357.1356 -3.9 316 10 91.4 6.2
11.19 C20H24N202CI 359.1526 359.1533 1.9 56 5.5 0.7
11.48 C20H24N202CI 359.1526 359.1527 0.3 other 2.9 0.2
9.63 C21H24N202CI 371.1526 371.1518 -2.2 328 57 26.5 3.0
11.25 C21H24N202CI 371.1526 371.1532 1.6 other 2.1 0.8
12.05 C21H24N202CI 371.1526 371.1536 2.7 7 8.7 2.3
13.04 C21H26N202CI 373.1683 373.1696 3.5 dihyd
ro-7 3.0 0.4
10.57 C21H20N203CI 383.1162 383.1159 -0.8 312, 247 5 48.7 2.7
10.87 C21H20N203CI 383.1162 383.1179 4.4 313, 245 5 13.9 2.8
11.17 C21H24N203CI 387.1475 387.1473 -0.5 4 7.6 1.0
8.39 C21H26N203CI 389.1632 389.1635 0.8 34 1.9 0.2
9.03 C21H26N203CI 389.1632 389.1646 3.6 34 1.5 0.4
9.47 C21H26N203CI 389.1632 389.1616 -4.1 34 1.7 0.1
9.3 C27H34N209CI 565.1953 565.1954 0.2 3 1.2 0.3
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Table B.13: 6-fluorotryptamine
6-fluoro
RT Formula Calc Exp ppm UVNIS TIA Peak SE
mass mass area
8.05 C20H23N202F 341.1665 341.1661 -1.2 324, 234 10 196.7 40.1
9.03 C20H24N202F 343.1822 343.1811 -3.2 326 56 2.9 0.7
9.48 C20H24N202F 343.1822 343.1807 -4.4 224, 281 Other 2.7 1.1
5.05 C21 H24N202F 355.1822 355.1805 -4.8 294, 245 Other 22.3 7.2
5.8 C21H24N202F 355.1822 355.1815 -2 292, 237 Other 11.4 4.3
7.56 C21H24N202F 355.1822 355.1806 -4.5 324 57 22.3 9.1
8.96 C21H24N202F 355.1822 355.1816 -1.7 9 1.2 0.7
9.83 C21H24N202F 355.1822 355.1817 -1.4 325, 231 7 85.3 43.0
Dihydro
9.2 C21H26N202F 357.1978 357.1994 4.5 -9 26.6 5.9
Dihydro
11.13 C21H26N202F 357.1978 357.1978 0 293, 249 -7 20.9 10.8
8.72 C21H20N203F 367.1458 367.1455 -0.8 307, 245 5 109.4 31.6
9.06 C21H20N203F 367.1458 367.1471 3.5 310, 213 5 21.1 7.1
8.36 C21H24N203F 371.1771 371.1768 -0.8 222 4 85.2 35.8
8.55 C21H24N203F 371.1771 371.176 -3 326 4 8.8 3.8
5.33 C21H26N203F 373.1927 373.1925 -0.5 Loch-7 28.1 18.7
7.33 C21H26N203F 373.1927 373.1929 0.5 34 17.8 5.7
3.34 C21H24B204F 387.172 387.1716 -1 324, 227 34 1.1 0.6
5.4 C21H24N204F 387.172 387.1708 -3.1 286, 216 Hor-7 1.0 0.6
7.36 C27H34N209F 549.2248 549.225 0.4 3 1.7 0.7
2.16 C10H12N2F 179.0985 179.0979 -3.4 1 43.8 10.1
Table B.14: 6-methoxystrictosidine
6-methoxy
RT Formula Calc mass Exp mass ppm UVNIS TIA Peak SE
area
8.13 C21H25N203 353.1865 353.1862 -0.8 326, 248 10 24.5 3.3
9.17 C21H25N203 353.1865 353.1872 2 other 9.9 1.5
9.45 C22H27N203 367.2022 367.2035 3.5 7 2.0 0.9
9.55 C22H23N204 379.1658 379.1649 -2.4 328, 249 5 48.5 2.8
10.8 C22H23N204 379.1658 379.1657 -0.3 328, 249 33 65.0 6.9
7.4 C22N27N204 383.1971 383.1954 -4.4 294, 222 4 23.8 0.9
7.53 C22N27N204 383.1971 383.1975 1 292, 224 4 163.
1 3.6
5.33 C22H29N204 385.2127 385.2139 3.1 224, 295 34 18.0 8.3
6.22 C22H29N204 385.2127 385.2146 4.9 226, 293 34 3.2 0.3
6.5 C28H37N201 561.2448 561.2453 0.9
0 3 9.8 0.6
7.74 C22H25N204 381.1814 381.1815 0.3 30 7.2 0.1
9.49 C22H25N204 381.1814 381.1807 -1.8 30 12.1 6.3
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RT Formula Calc Exp Ppm UVNIS Alkaloid Peak SE
mass mass area
9.25 C21H25N202 337.1916 337.1917 0.3 330,
299,
235 10 859 161
10.12 C21H27N202 339.2073 339.2063 -2.9 56 40 5
10.51 C21H27N202 339.2073 339.2069 -1.2 other 26 8
8.81 C21 H27N202 351.2073 351.2073 0 330,
299 57 130 26
10.77 C21 H27N202 351.2073 351.2057 -4.6 330,
299 7 421 123
10.31 C22H23N203 363.1709 363.1709 -0.8 5 126 23
10.62 C22H23N203 363.1709 363.1699 -2.8 33 28 4
9.38 C22H27N203 367.2022 367.201 -3.3 330,
298,
224 Loch-7 422 55
9.46 C22H27N203 367.2022 367.2029 1.9 223 4 473 103
7.33 C22H29N203 369.2178 369.2166 -3.3 34 30 10
8.03 C22H29N203 369.2178 369.2181 0.8 34 35 9
8.39 C28H37N209 545.2499 545.2513 2.6 3 139 123
able B.16: 7-bromotryptamine
7-bromo
RT Formula Calc Exp ppm UV/VIS TIA Peak SE
mass mass area
12.82 C20H22N202Br 401.0865 401.0864 -0.2 320 10 33.4 9.8
12.93 C20H24N202Br 403.1021 403.1006 -3.7 327 56 162.5 46.0
12.2 C21H24N202Br 415.1021 415.1025 1 324, 297,
234 57 186.2 70.5
10.42 C21H20N203Br 427.0657 427.0664 1.6 300, 255 5 2.0 0.9
11.33 C21H20N203Br 427.0657 427.0662 1.2 306, 253 5 0.5 0.3
10.63 C21H22N203Br 429.0814 429.0822 1.9 274 30 12.9 4.0
8.15 C21H26N203Br 433.1127 433.111 -3.9 34 2.0 0.6
8.29 C21H26N203Br 433.1127 433.1136 2.1 34 2.9 0.6
9.07 C21H26N203Br 433.1127 433.1122 -1.2 34 2.8 0.7
9.6 C27N34N309Br 609.1448 609.1469 3.4 3 1.7 0.9
4.47 C10H12N2Br 239.0184 239.0183 -0.4 1 309.3 51.8
283
Table B.15:6-methylstrictosidine
6-methyl
T
Table B.17: 7-chlorotryptamine
7-chloro
RT Formula Calc Exp ppm UVNIS TI Peak SE
mass mass A area
12.15 C20H22N203CI 357.137 357.1362 -2.2 235, 296,
324 10 813 70
12.39 C20H24N202CI 359.1526 359.1511 -4.2 222, 294,
322 56 1239 56
11.51 C21H24N202CI 371.1526 371.1516 -1 231,295, 13
324 57 1150 9
9.87 C21H20N203CI 383.1162 383.1144 -4.7 302, 250. 5 42 18
7.75 C21H22N203CI 385.1319 385.1302 -4.4 303, 252 30 128 17
10.45 C21H22N203CI 385.1319 385.1325 0.6 231, 275 30 310 81
10.18 C21H24N203CI 387.1475 387.1486 2.8 4 21 2
7.51 C21H26N203CI 389.1632 389.1615 -4.4 34 22 2
7.64 C21H26N203CI 389.1632 389.1618 -3.6 34 24 7
7.96 C21H26N203CI 389.1632 389.1628 -1 34 5 1
8.15 C21H26N203CI 389.1632 389.1635 0.8 34 7 4
8.44 C21H26N203CI 389.1632 389.1632 0 34 24 7
8.96 C27H34N209CI 565.1953 565.1959 1.1 3 5 4
3.85 C10H12N2CI 195.0689 195.0681 -4.1 1 292 75
Table B.18: 7-fluorotryptamine
7fluoro
RT Formula Calc mass Exp ppm UVNIS TIA Peak SE
mass area
326,
285,
8.94 C20H22N202F 341.1665 341.1663 -0.6 227 10 599.4 122
9.27 C20H24N202F 343.1822 343.1829 2 269, 222 other 20.8 6.8
9.56 C20H24N202F 343.1822 343.1822 0 323, 282 other 175.0 21.2
5.01 C21H24N202F 355.1822 355.1805 -4.8 236 56 383.6 37.2
5.96 C21H24N202F 355.1822 355.1813 -2.5 236 other 161.3 14.1
8.24 C21H24N202F 355.1822 355.181 -3.4 327, 280 other 252.2 19.8
10.3 C21H24N202F 355.1822 355.181 -3.4 325 57 136.2 39.0
8.75 C21H26N202F 357.1978 357.1961 -4.8 268 7 9.6 1.5
294,
249,
8.16 C21H20N203F 367.1458 367.1452 -1.6 218 5 378.2 24.3
9.34 C21H22N203F 369.1614 369.1608 -1.6 265, 222 30 149.7 11.6
8.22 C21H24N203F 371.1771 371.1768 -0.8 4 10.2 5.1
325,
285, loch-
9.48 C21H24N203F 371.1771 371.1766 -1.3 234 7 31.3 12.1
5.89 C21H26N203F 373.1927 373.1917 -2.7 34 9.1 0.2
7.3 C27H34N209F 549.2248 549.2203 -4.5 3 5.4 3.7
2.14 C10H12N2F 179.0985 179.0967 -1.8 1 284.9 187
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Table B.19: 7-methoxytryptamine
7-methoxy
RT Formula Calc Exp ppm UVNIS TIA Peak SE
mass mass area
8.48 C21H25N203 353.1865 353.1881 4.5 10 13 5
9.33 C22H23N204 367.1658 379.1677 5 5 20 10
9.78 C22H23N204 367.1658 379.1668 2.6 5 12 7
8.25 C22H27N204 383.1971 383.198 2.3 4 285 117
8.57 C22H27N204 383.1971 383.1984 3.4 4 42 22
6.12 C22H29N204 385.2127 385.213 0.8 34 48 17
6.21 C22H29N204 385.2127 385.2137 2.6 34 34 11
6.85 C22H29N204 385.2127 385.2143 4.2 34 5 2
7.07 C22H29N204 385.2127 385.2144 4.4 34 82 30
7.4 C28H37N2010 561.2448 561.2452 0.7 3 180 44
2.27 C11H15N20 191.1184 191.1182 -1 1 582 133
Table B.20: 7-methyltryptamine
7-methyl
RT Formula Calc Exp ppm UV/VIS TIA Peak SE
mass mass area
10.52 C21H25N202 337.1916 337.1912 -1.2 329, 293 10 2003 761
10.94 C21 H27N202 339.2073 339.207 -0.9 329, 290 56 682 304
10 C22H27N202 351.2073 351.2072 -0.3 330, 291,
225 57 633 146
10.48 C20H23N203 363.1709 373.1694 -4.1 7 0 0
9.7 C22H25N203 365.1865 365.1852 -3.3 272, 223 5 27 11
9.7 C22H27N203 367.2022 367.2025 0.8 272, 223 30 562 280
7.35 C22H29N203 369.2178 369.2176 -0.5 268, 218 4 284 167
8.18 C22H29N203 369.2178 369.2169 -2.4 55 54 8
4.54 C22H27N204 383.1971 383.1956 -3.9 34 19 8
8.38 C28H37N209 545.2499 545.2482 -3.1 3 14 13
289 C11H15N2 175.1235 175.1227 -4.6 1 499 287
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Table B.21: benzofuran-3-ethanamine
benzofuran
RT Formula Calc Exp ppm UV/VIS TIA Peak SE
mass mass area
8.61 C20H22NO3 324.16 324.1596 -1.2 10 13 7
8.28 C21H20NO4 350.1392 350.1387 -1.4 5 106 49
5.4 C21H26NO4 356.1862 356.1862 0 34 624 255
7.03 C27H34NO10 532.2183 532.2185 0.4 3 11 6
2.54 C1OH12NO 162.0919 162.0915 -2.5 1 316 37
" LI. I 1 'h.Ia[ I - L I=J , 1__ie .LL: LaDele trypamine ly
RT
7.1 327.1758 10
327.1758 other
7.62 327.1758 other
7.85 329.1916 other
8.33 329.1916 56
3.77 341.1916 other
4.55 341.1916 other
6.55 341.1916 other
7.03 341.1916 other
7.88 341.1916 9
8.5 341.1916 7
4.93 343.1709 other
8.11 343.2073 Dihydro-9
8.02 351.1552+ 350.1552 5
8.39 350.1552+351.1552 5
5.46 355.1709 30
6.06 355.1709 30
6.25 355.1709 30
9.42 355.1709 30
4.64 357.1865 other
7.06 357.1865 LOCH-7
7.28 357.1865 4
9.66 357.1865 other
4.62 359.2022 34
5.01 359.2022 34
5.21 359.2022 6
5.24 359.2022 34
6.02 359.2022 34
6.23 359.2022 34
2.38 373.1814 HOR-7
6.52 535.2343 3
1.48 165.1079 1
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Appendix C
Characterization of Alkaloid Analogs
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1. 9-fluoroserpentine 5a
2. 10-fluoroserpentine 5b
3. 11-fluoroserpentine 5c
4. 1-oxo-serpentine 5.49
5. 12-bromoserpentine 51
6. 12-methylserpentine 5n
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11. 12-methylsitsirikine 34n
12.11-fluoroakuammicine 10c
13.12-methylakuammicine 10n
14.12-methyl-1 9,20-dihydroakuammicine 55n
15.12-bromo-19,20-dihydroakuammicine 551
16.11 -fluoro-1 9,20-dihydroakuammicine 55c
17. N-methyl-1 2-methylakuammicine 56n
18.14-fluorotabersonine 7a
19. 16-fluorovindolidine 48c
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1. 9-Fluoroserpentine 5a.
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Figure C.1: Proton NMR of 9-fluoroserpentine 5a.
1H NMR (600 MHz, CD3CN) 6 8.33 (d, J = 6.5, 1H, H-6), 8.11 (d, J = 8.2, 1H, H-
5), 7.71 (d, J= 6.8, 1H, H-11), 7.69 (d, J = 1.5, 1H, H-17), 7.58 (d, J = 7.4, 1H, H-
12), 7.10 (t, J= 8.5, 1H, H-11), 4.77 (dd, J = 13.7, 4.2, 1H, H-21B), 4.73 (dd, J =
6.6, 4.1, 1H, H-19), 4.68 (dd, J = 18.7, 5.4, 1H, H-14A), 4.50 (t, J = 13.0, 1H, H-
21A), 3.78 (s, 3H, H-23), 3.18 - 3.10 (m, 1H, H-14B), 3.01 - 2.92 (m, 1H, H-15),
2.66 - 2.58 (m, 1 H, H-20), 1.29 (d, J = 6.7, 3H, H-23).
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Figure C.2: 9-Fluoroserpentine COSY.
Table C.1: 9-Fluoroserpentine
291
9-fluoroserpentine
I NMR summar.
CARBON 1H COSY
2
3
5 7.71 6
6 8.33 5
7
8
9
10 11
11 7.1 10, 12
12
13
14 4.68 15, 14B
3.18 15
15 3 14B, 14A
16
17 7.66
18 1.29 19
19 4.73 18
20 2.66 21A
21 4.5 20, 21B
4.77 21A
22
23 3.78
2. 10-Fluoroserpentine 5b NMR.
6 5
F10. 9- Q \ ^. 21
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Figure C.3: 10-Fluoroserpentine proton NMR.
1H NMR (600 MHz, CD 30D) 6 8.52 (d, J = 6.6, 1H, H-6), 8.35 (d, J = 6.6, 1H, H-
6), 8.12 (dd, J = 8.5, 2.5, 1H), 7.78 (dd, J = 9.1, 4.1, 1H), 7.73 (d, J = 1.5, 1H, h-
17), 7.61 (td, J = 9.1, 2.5, 1H), 4.77 (dd, J = 6.7, 4.1, 1H, H-21B), 4.73 (dd, J =
18.5, 5.2, 1 H, H-19), 4.65 (t, J = 13.0, 1 H, H-14A), 3.82 (s, 3H, H-23), 3.24 - 3.19
(m, 1H, H-14B), 3.13 - 3.06 (m, 1H, H-15), 2.72 (tt, J = 12.2, 4.1, 1H, H-20), 1.35
(d, J = 6.7, 3H, H-18).
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3. 11-Fluoroserpentine 5c NMR
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Figure C.4: 11-Fluoroserpentine proton NMR.
I I I
3.0 2.0
1H NMR (600 MHz, CD 3CN) 6 8.36 (d, J = 5.4, 1H, H-6), 8.34 (d, J= 6.0, 1H, H-
12 ), 8.14 (d, J = 6.6, 1H, H-5), 7.66 (d, J = 1.6, 1H H-17), 7.57 (dd, J = 9.6, 2.2,
1H, H-10), 7.24 (td, J = 9.4, 2.3, 1H, H-9), 4.75 (dd, J = 13.5, 4.2, 1H, H-21b),
4.72 (dd, J = 6.7, 4.0, 1H, H-19), 4.62 (dd, J = 18.8, 5.4, 1H, H-14a), 4.48 (t, J =
13.0, 1H, H-21a), 3.77 (s, 3H, H-23), 3.20 - 3.12 (m, 1H, H-14b), 3.01 - 2.93 (m,
1H, H-15), 2.62 (tt, J = 12.5, 4.2, 1H, H-20), 1.33- 1.22 (m, 3H, H-18).
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Figure C.5: 11-Fluoroserpentine COSY
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Figure C.6: 11-Fluoroserpentine HSQC
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Figure C.7: 11-Fluoroserpentine HMBC
Table C.2: 11-Fluoroserpentine summary.
11-fluoroserpentine 5c
CARBON 1H 13C HMBC COSY
2 136.8 12,14A
3 141.5 5,21B,14A/B
5 8.14 134.5 12, 21B 6
6 8.36 116.8 5 9,5
7 132.1 5
8 118.1 9
9 7.24 118.1 10, 6 6, 10
10 7.57 100.6 9
11
12 8.34 116.76
13 146.3 12
14 4.62 32.39 14B, 15
3.2 32.55 15, 21A
15 3 25.7 17, 21A/B, 14A/B 20, 14B/A
16 107.3 17, 14B, 15
17 7.66 155.8 10, 17, 19
18 1.33 29.78 19
19 4.72 72.5 15, 18 18
20 2.62 37.8 15, 21A/B, 14A 15, 21A/B
21 4.48 57.5 5 20, 14B, 21B
4.75 57.44 21A, 20
22 167.12 6, 10, 17, 18
23 3.77 50.3 14B, 15
4. 1-Oxo-serpentine 5.49
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Figure C.8: 1-Oxo-serpentine proton NMR.
1H NMR (600 MHz, CD 30D) 6 8.71 - 8.66 (m, 1H), 8.63 - 8.58 (m, 1H), 8.46 -
8.41 (m, 1 H), 8.03 - 7.94 (m, 2H), 7.79 - 7.74 (m, 1 H), 7.74 - 7.68 (m, 1 H), 4.87
- 4.82 (m, 1H), 4.79 (dd, J = 6.7, 4.0, 1H), 4.66 (q, J = 12.9, 1H), 3.74 - 3.63 (m,
3H), 3.12 - 3.04 (m, 1H), 2.80 - 2.71 (m, 3H), 1.42 - 1.35 (m, 4H).
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5. 12-Bromoserpentine 51 NMR
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Figure C.10: 12-Bromoserpentine proton NMR
1H NMR (600 MHz, CD 3CN) 6 8.45 (d, J = 6.4, 1 H, H-6), 8.39 (d, J = 7.4, 1 H, H-
11), 8.25 (d, J = 6.7, 1 H, H-5), 8.03 (dd, J = 7.7, 0.9, 1 H, H-9), 7.72 (d, J = 1.5,
1H, H-17), 7.44 (t, J= 7.8, 1H, H-10), 4.82 (dd, J= 13.2, 4.2, 1H, H-21B), 4.74
(ddd, J = 24.3, 13.0, 4.9, 2H, H-19 and H-14A), 4.56 (t, J = 12.7, 1H, H-21A),
3.82 (s, 3H, H-23), 3.30 (d, J = 5.1, 1 H, H-14B), 3.04 (d, J = 4.2, 1 H, H-15), 2.81
(t, J = 6.0, 1H, H-20), 1.35 - 1.30 (m, 3H, H-18).
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Table C.3: 12-Bromoserpentine summary.
12-BROMOSERPENTINE
CARBON 1H COSY
2
3
5 8.25 6
6 8.45 5
7
8
9 8.03 10
10 7.44 11,9
11 8.39 10
12
13
15,
14 4.74 14B
3.3 14A
15 3.04 14A
16
17
18 1.35 19
19 4.74 18
20 2.81 21A
21 B,
21 4.56 20
4.82 21A
22
23 3.82
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6. 12-Methylserpentine 5n NMR
6 5
9 21
10 N+1 23 / 4
11 / 2 14
mcn 01 00 k4%% N
V-qN fnm Mr11- '.
cdrK r< r r4*i< v:I I-) e o
c 1- 'i- m 0
Cj " T-- CDj~
N0, C N 0 0 N O N . ",
C-;-dd0 0
S i I I ' I ' I ' I ' I r
Figur
8 7 6 5 4 3
f (ppm)
e C.12: 12-Methylserpentine proton NMR
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'H NMR (600 MHz, CD 30D) 6 8.49 (d, J = 6.6, 1H), 8.34 (d, J = 6.6, 1H), 8.20 (d,
J = 8.1, 1H), 7.73 (s, 1H), 7.59 (d, J = 7.0, 1 H), 7.41 - 7.35 (m, 1H), 3.83 (s, 5H),
3.79 (d, J = 13.5, 3H), 3.10 (dd, J = 13.2, 5.1, 2H), 2.70 (s, 2H), 1.35 (d, J= 6.7,
3H).
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Figure C.13: 9-Fluoroajmalicine proton NMR.
'H NMR (600 MHz, CD 3CN) 6 7.54 (d, J = 1.8, 1H), 7.20 (d, J = 8.2, 1H), 7.10 (q,
J = 7.0, 1 H), 6.75 (dd, J = 11.1, 7.9, 1H), 4.50 (dd, J = 6.5, 4.2, 1H, H-3), 4.09 -
3.96 (m, 1H, H-), 3.71 (s, 1H), 3.70 (s, 3H, h-23), 3.48 (dd, J = 11.1, 5.1, 1H),
3.45 - 3.38 (m, OH), 2.34 - 2.27 (m, 6H), 1.43 - 1.37 (m, 1H), 1.18 (d, J = 6.6,
3H), 0.88 (t, J = 6.9, 2H).
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Figure C.14: 9-Fluoroajmalicine COSY
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Figure C.15: 9-Fluoroajamlicine HMBC.
9 8 7 6
-0
-20
-40
-60
-80
100
120
140
160
180
200
8.0 6.0 4.0 2.0
f2 (ppm)
Figure C.16: 9-Fluoroajmalicine HSQC.
. 13.
Table C.4: 9-Fluoroajmalicine COSY peaks.
fl f2
(ppm) (ppm)
1 7.76 7.16
2 7.09 6.74
3 4.91 4.56
4 4.8 4.53
5 4.73 1.29
6 4.64 3.17
7 4.58 3.08
8 4.5 1.17
9 4.13 1.45
10 4.11 3.29
11 3.99 1.34
12 3.97 3.71
13 3.95 1.4
14 3.76 3.11
15 3.69 3.43
16 3.61 3.12
17 1.57 1.28
18 1.29 0.88
Table C.5: 9-Fluoroajmalicine HSQC peaks table.
fl f2
(ppm) (ppm)
1 171.84 1.97
2 171.65 1.99
3 166.64 3.73
4 104.61 7.23
5 103.11 2.22
6 78.05 7.79
7 72.17 1.2
8 72.17 1.2
9 40.13 2.53
10 38.85 1.2
11 38.61 1.21
12 31.86 0.9
13 29.29 1.29
14 29.16 1.44
15 21.73 0.9
16 14.03 1.3
17 13.38 1.09
308
8. 10-Fluoroajmalicine 4b NMR
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Figure C.17: 10-Fluoroajmalicine proton NMR
'H NMR (600 MHz, CD3CN) 6 9.62 - 9.54 (m, 1H), 7.54 (d, J = 1.5, 1 H), 7.35
(dd, J = 8.9, 4.5, 1H), 7.18 (dd, J = 9.7, 2.2, 1H), 6.95 (td, J = 9.3, 2.3, 1H), 4.49
(dd, J = 6.4, 3.8, 1 H), 3.70 (s, 1 H), 3.70 (s, 3H), 3.59 - 3.51 (m, 1 H), 3.27 (s, 2H),
2.69 - 2.58 (m, 1 H), 2.55 - 2.46 (m, 1 H), 2.32 - 1.78 (m, 51 H), 1.65 - 1.57 (m,
1H), 1.17 (d, J = 6.6, 4H), 0.93 - 0.82 (m, 1 H).
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Figure C.19: 10-Fluoroajmalicine HSQC
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Figure C.20: 10-Fluoroajmalicine HMBC
Table C.6: 10-Fluoroajmalicine peak table.
COSY HSQC HMBC
fl f2 fl f2 fl f2
(ppm) (ppm) (ppm) (ppm) (ppm) (ppm)
1 7.42 6.93 1 155.38 7.52 1 167.92 7.53
2 7.21 6.93 2 120.6 5.31 2 167.78 3.68
3 5.69 5.36 3 114.94 6.82 3 159.69 7.35
4 5.68 2.61 4 113.48 7.34 4 157.99 7.18
5 5 1.97 5 111.35 6.95 5 155.65 7.38
6 4.92 2.98 6 104.28 7.18 6 155.53 4.49
7 4.91 2.83 7 99.94 4.54 7 155.51 7.68
8 4.57 2.94 8 97.83 5.29 8 149.01 1.3
9 4.51 1.16 9 77.61 3.23 9 145.36 1.61
10 3.8 3.11 10 74.26 3.94 10 140.28 1.42
11 3.59 3.21 11 73.55 4.49 11 134.35 6.93
12 3.57 3.26 12 72.87 3.5 12 134.3 7.17
13 3.53 1.59 14 62.67 3.72 13 127.61 7.35
14 3.4 2.15 15 62.61 3.56 14 107.11 7.53
15 3.3 2.2 16 61.76 3.65 15 104.89 6.92
16 3.17 2.92 17 57.72 3.77 16 103.6 7.32
17 2.88 2.62 18 55.65 3.49 17 73.54 1.17
18 2.69 1.58 19 51.69 3.69 18 73.48 7.53
19 2.68 1.94 20 50.08 3.27 19 50.03 3.38
20 1.32 0.88 21 30.01 1.26
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9. 9-Fluoroisositsirikine 34a NMR
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Figure C.21: 9-Fluoroisositsirikine proton NMR
'H NMR (600 MHz, CD30D) 5 7.20 (d, J = 8.2, 1H), 7.13 (td, J = 8.0, 5.1, 1H),
6.76 (dd, J = 10.7, 7.8, 1H), 6.04 (q, J = 7.1, 1 H), 4.02 (d, J = 12.9, 1H), 3.85 (d,
J = 13.3, 1H), 3.78 (s, 4H), 3.69 (qd, J= 12.7, 7.2, 2H), 3.64 - 3.51 (m, 2H), 2.62
(dt, J = 15.1, 5.4, 1H), 2.45 (dt, J = 11.1, 5.8, 1 H), 2.41 - 2.34 (m, 1H), 1.84 (d, J
= 6.9, 4H).
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Figure C.22: 9-Fluoroisositsirikine COSY
0* 20
-40
S-60
-80
-100
• 120
-140
-160
* 1180
I -200
I ' I ' I ' I ' I I ' I ' I '
8 7 6 5 4 3 2 1
f2 (ppm)
Figure C.23: 9-Fluoroisositsirikine HSQC
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Figure C.24: 9-Fluoroisositsirikine HMBC
Table C.7: 9-Fluoroisositsirikine peak table
COSY HSQC HMBC
fl f2 fl f2 fl f2
(ppm) (ppm) (ppm) (ppm) (ppm) (ppm)
1 7.02 6.65 1 122.9 7.17 1 173.47 3.74
2 5.93 1.74 2 107.71 7.26 2 130.5 1.73
3 4.83 2.31 3 104.41 6.84 3 127.86 1.73
4 4.82 2.5 4 77.83 7.62 4 104.44 7.25
5 3.91 3.72 5 60.97 3.44 5 77.95 7.79
6 3.9 1.72 6 51.35 3.75 6 77.92 7.43
7 3.38 2.23 7 26.7 1.29 7 29.13 1.29
8 3.34 2.26
9 3.32 2.33
10 2.5 2.3
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10. 1-Oxo-isositsirikine 34.49 NMR
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Figure C.25: 1-Oxo-isositsirikine proton NMR
'H NMR (600 MHz, CD 3CN) 6 7.64 (d, J = 7.7, 1H), 7.55 (d, J = 8.1, 1H), 7.41 (t,
J = 8.2, 1H), 7.37 (t, J = 7.0, 1H), 5.90 (q, J = 7.1, 1H), 4.10 -4.04 (m, OH), 4.01
(dd, J = 11.4, 6.5, OH), 3.88 - 3.82 (m, OH), 3.74 (s, 3H), 3.65 - 3.58 (m, OH),
3.49 - 3.43 (m, OH), 3.13 - 3.06 (m, OH), 3.04 - 2.98 (m, OH), 2.77 (dd, J = 4.9,
4.4, OH), 2.33 (t, J = 7.5, 1 H), 1.74 (dd, J = 6.9, 1.5, 3H).
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Figure C.27: 1-Oxo-isositsirikine HSQC
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Figure C.28: 1-Oxo-isositsirikine HMBC
Table C.8: 1-Oxo-isositsirikine peak tables.
COSY HSQC HMBC
fl f2 fl f2 fl f2
(ppm) (ppm) (ppm) (ppm) (pm) (ppm)
1 7.64 7.35 1 124.98 7.41 1 173.46 3.74
2 7.58 7.39 2 123.41 7.37 2 128.51 1.74
3 5.9 1.72 3 119.72 7.64 3 77.96 7.79
4 3.85 1.73 4 111.44 7.55 4 77.9 7.43
5 3.84 3.64 5 78.05 7.62 5 29.16 1.29
3.59 3.1 61.18 3.35
7 3.47 3.34 7 61.12 3.46
8 3.38 2.37 8 51.36 3.74
9 3.35 2.07 9 48.83 3.3
10 3.15 2.99 10 28.98 1.3
2.7 2.38
12 2.31 1.58
13 1.6  1.31
14 1.31 0.91
11. 12-Methylsitsirikine 55n NMR
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Figure C.29: 12-Methylsitsirikine proton NMR
'H NMR (600 MHz, CD3CN) 6 7.62 (s, 1H),
2H), 5.75 - 5.63 (m, 1H), 5.48 (s, OH), 5.39
J= 11.1, OH), 3.64 (s, 2H), 3.53 (d, J= 5.1,
2.8, 1 H), 2.53 (d, J = 12.0, 3H).
7.32 (d, J = 7.2, 1H), 7.08 - 6.91 (m,
- 5.23 (m, 1H), 3.95 (s, 1H), 3.82 (d,
OH), 3.31 (s, 2H), 2.93 (td, J = 6.6,
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Figure C.30: 12-Methylstisirikine COSY
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Figure C.31: 12-Methylsitsirikine HSQC
Table C.9: 12-Methylsitsirikine peak table
COSY HSQC
fl f2 fl f2
(ppm) (ppm) (ppm) (ppm)
1 8.38 8.19 1 122.42 6.97
2 8.2 7.39 2 122.27 7.01
3 7.58 7.16 3 119.74 6.98
4 7.32 7 4 119.69 7.03
5 5.82 5.36 5 118.85 5.28
6 5.7 1.69 6 115.54 7.3
7 5.67 5.3 7 115.51 7.34
8 4.65 4.5 8 60.3 3.69
9 4.28 3.54 9 50.69 3.62
10 4.14 1.34 10 50.66 3.65
11 3.99 3.23
12 3.97 3.72
13 3.95 2.95
14 3.72 2.91
15 3.69 3.4
16 3.69 3.47
17 2.56 1.47
18 2.3 1.58
19 1.61 1.29
20 1.31 0.92
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12. 1 1-Fluoroakuammicine 10c NMR
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Figure C.32: 11-Fluoroakuammicine proton NMR
'H NMR (600 MHz, CD3CN) 6 9.05 (s, 1H), 7.50 (dd, J = 8.3, 5.2, 1H), 6.76 (dd, J
= 9.6, 2.3, 1H), 6.70 - 6.62 (m, 1H), 5.69 (q, J = 7.9, 1H, H-19), 4.68 (s, 1H, H3),
4.23 (d, J = 16.2, 1H, H-12a), 4.05 (s, 1H, H-15a), 3.86 (td, J = 13.5, 6.4, 1H),
3.80 (s, 3H, H-23), 3.51 (d, J= 15.0, 1H, H-6a), 3.39 (dd, J= 12.3, 7.4, 1H, H-
21b), 2.62 (td, J = 13.6, 6.9, 1H, H-5b), 2.30 (t, J= 7.5, 1H, H-6b), 1.63 (d, J=
7.0, 3H, H-18), 1.45 (d, J= 12.5, 1H, H-14R).
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Figure C.34: 11 -Fluoroakuammicine HSQC
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Figure C.35: 11-Fluoroakuammicine HMBC
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Table C.10: 11-Fluoroakuammicine peak tables.
COSY HSQC HMBC
Proton 1H (ppm) COSY Proton 1H (ppm) 13C Carbon # 1H HMBC
3 4.68 15A/ 14RS 3 4.68 62 3 4.68 62
5a 3.5 5a 3.5 55 5 3.5 55
5b 2.62 6A 5b 2.62 2.62
6A 3.85 5B, 21B 6A 3.85 54 6 3.85 54
6B 3.39 6A 6B 3.39 54 3.39
9 7.5 10 9 7.5 123 7 133
10 6.7 9 10 6.7 108 8 165
12 6.76 12 6.76 99 9 7.5 123
14r 1.45 14S, 15A,3 14r 1.45 10 6.7 108
14s 2.51 14R, 15A, 3 14s 2.51 11
15 4.05 18 14R, 14s, 3 15 4.05 12 6.76 99
18 1.63 15A, 19, 21A 18 1.63 13
19 5.69 18, 15A 19 5.69 129 14 1.45
21a 4.23 19, 18, 5A, 21B 21a 4.23 55 2.51
21b 3.52 21A 21b 3.52 55 15 4.05
23 3.8 23 3.8 52 16
18 1.63
19 5.69 129
20 132
21 4.23 55
3.52 55
22 168
23 3.8 52
13. 12-Methylakuammicine 10n NMR
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Figure C.36: 12-Methylakuammicine proton NMR
'H NMR (600 MHz, CD 3CN) 6 8.74 (s, 1H, NH), 7.37 (d, J = 7.2, 1H, H9), 7.07 (d,
J = 7.9, 1H, H12), 6.91 (t, J = 7.9, 1H, H10), 5.70 (q, J = 8.3, 1H, H19), 4.69 (s,
1H, H3), 4.24 (d, J = 15.4, 1H, H14S), 4.05 (s, 1H, H15a), 3.80 (s, 4H, H23), 3.52
(d, J = 14.7, 1H, H5a), 3.36 (d, J = 53.0, 1H, H21b), 2.65 (td, J= 13.9, 7.5, OH,
H5a), 2.27 (s, 3H, Ar-CH3), 1.65 (d, J = 6.4, 3H, H18), 1.45 (d, J = 14.1, 1H,
H14R).
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Figure C.37: 12-Methylakuammicine COSY
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Figure C.38: 12-Methylakuammicine HSQC
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Figure C.39: 12-Methylakuammicine HMBC
Table C.11: 12-Methylakuammicine NMR summary table.
# 1H split COSY HSQC HMBC
3 4.69 s 15, 14R, 14S 62.5
5 3.52 d 55.04
6
7
8 143.05
9 7.37 d 10 120.1
10 6.91 t 9, 11 122.9
11 7.07 d 9 131.2
12 135.02
13 143.05
14 1.45 d 30.67
2.51
15 4.05 s 14R, 14S, 18
16
17
18 1.65 d
19 5.7 q 129.5
20 133.1
21 4.24 d 18, 5 55.06
3.36 d 14S 54.61
22 168.21
23 3.8 s 52.2
14. 12-methyl-19,20-dihydroakuammicine 56n NMR
CO 2Me23
I'' , 1
6-66&
co C o
wooo
C CO')
(yi c i
rl: o')
I ii
'oiM co - r-
eki- 6 6
(0 O(V
6
fl
5 4 3 2 1 0
(ppm)
Figure C.40: 12-Methyl-19,20-dihydroakuammicine proton NMR
'H NMR (600 MHz, CD 3CN) 6 8.58 (s, 1H), 7.59 (s, 1H), 7.21 (d, J = 7.5, 1 H),
7.03 (d, J = 7.6, 1H), 6.88 (dd, J = 15.9, 8.4, 1 H), 4.56 (s, 1H), 3.80 (s, 1H), 3.75
(s, 2H), 3.62 - 3.47 (m, 2H), 3.18 (d, J = 10.2, 2H), 3.03 - 2.94 (m, 1H), 2.91 (s,
OH), 2.87 - 2.78 (m, 1H), 2.50 (s, 1H), 0.87 (dd, J = 12.1, 7.2, 2H), 0.69 (t, J=
7.4, 2H).
338
am O ) 0x (0o
U, 0 ( 00 00 00
,cR8- r-cic cd e6
4-00
300
200
100
0
-100
.J L _L.I~I I ... I1 Y L WI~
I " I " I "
aPr.... **P
U Ii
.2.
U
10 9 8 7 6 5
f2 (ppm)
Figure C.41: 12-Methyl-1 9,20-dihydroakuammicine COSY
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Figure C.42: 12-Methyl-19,20-dihydroakuammicine HSQC
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Figure C.43: 12-Methyl-19,20-dihydroakuammicine HMBC
Table C.12: 12-Methvl-19.20-dihvdroakuammicine peak table
2.05
15 3.6 2.06
16 3.59 3.22
17 3.59 2.87
18 3.53 3.02
19 3.52 1.97
20 3.26 3.1
21 3.22 2.85
22 3.2 1.96
23 3.19 2.05
24 3.02 2.07
25 3.01 1.95
26 2.88 2.07
27 2.69 2.1
28 2.56 1.48
29 2.17 0.88
30 1.29 0.91
31 0.89 0.72
14 120.17 6.9
15 120.03 2.28
16 120.03 2.27
17 120 6.91
18 118.2 7.05
19 78.12 7.79
20 77.81 7.43
21 40.13 2.53
22 38.79 0.72
23 38.7 0.7
24 38.64 0.71
25 30.66 1.33
26 29.27 1.45
27 22.39 0.7
28 22.24 0.72
29 22.15 0.73
30 15.26 2.38
31 15.22 2.17
32 10.08 0.61
33 10 0.82
34 9.69 0.61
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COSY HSQC HMBC
fl f2 fl f2 fl f2
(ppm) (ppm) (ppm) (ppm) (ppm)L (ppm)
1 7.39 6.92 1 129.62 7.06 1 167.55 3.78
2 7.23 6.89 2 121.58 6.91 2 166.9 3.82
3 7.11 2.28 3 118.71 7.39 3 142.32 7.06
4 7.07 6.89 4 117.55 7.24 4 142.2 2.28
5 5.71 1.66 5 78.09 7.62 5 142.14 7.24
6 4.7 1.47 6 69.5 3.63 6 141.98 7.07
7 4.59 3.2 7 69.45 3.63 7 138.99 1.45
8 4.59 2.17 8 64.09 4.59 8 133.53 6.91
9 4.27 3.53 9 51.64 3.61 9 133.48 6.9
10 4.27 1.67 10 51.52 3.22 10 133.09 2.07
11 4.07 2.55 11 50.91 3.75 11 129.84 2.28
12 3.91 2.64 12 50.85 3.78 12 129.75 7.24
13 3.9 3.44 13 50.85 3.82 13 129.69 2.28
15. 12-Bromo-19,20-dihydroakuammicine 561 NMR
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Figure C.44: 12-Bromo-19,20-dihydroakuammicine 561 proton NMR
1H NMR (600 MHz, CD3CN) 6 12.08 (s, 1H), 8.75 (s, 1H), 7.37 (d, J = 8.2, 2H),
6.89 (t, J = 7.8, 1 H), 4.56 (s, 1 H), 3.76 (s, 3H), 3.62 - 3.45 (m, 2H), 3.20 (dd, J =
11.1, 6.7, 2H), 2.97 (dq, J = 18.3, 5.9, 1H), 2.88 (ddd, J = 14.4, 11.8, 7.7, 1H),
2.14 - 2.07 (m, 2H), 2.04 - 1.98 (m, 1 H), 0.95 - 0.81 (m, 2H), 0.70 (t, J = 7.4,
3H).
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Figure C.45: 12-Bromo-19,20-dihydroakuammicine 561 COSY
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Figure C.46: 12-Bromo-19,20-dihydroakuammicine 561 HSQC
50
100 .
150
I ' I ' I ' I ' I ' I ' I I I
9 8 7 6 5 4 3 2 1
f2 (ppm)
Figure C.47: 12-Bromo-19,20-dihydroakuammicine 561 HMBC
Table C.13: 12-Bromo-1 9,20-dihydroakuammicine peak table
COSY HSQC HMBC
fl f2 fl f2 fl f2
(ppm) (ppm) (ppm) (ppm) (ppm ppm)
1 7.4 6.9 1 132.31 7.36 1 168.83 3.76
2 4.63 2.16 2 132.26 7.41 2 143.58 7.36
3 4.59 3.2 3 124.51 6.88 3 136.53 6.87
4 4.25 3.49 4 124.46 6.93 4 136.3 2.11
5 3.62 3.21 5 123.42 6.88 5 132.16 7.37
6 3.59 2.09 6 121.1 7.35 6 120.77 7.36
7 3.55 1.88 7 121.04 7.4 7 104.45 7.36
8 3.54 2.94 8 120 7.4 8 104.39 6.88
9 3.24 2.87 9 119.99 7.35 9 65.61 0.87
10 3.2 1.97 10 65.44 4.55 10 65.5 3.19
11 3.01 2.01 11 52.97 3.56 11 54.17 7.36
12 2.54 1.48 12 52.91 3.2 12 54.08 3.21
13 2.19 0.85 13 52.6 3.75 13 40.02 0.68
14 0.89 0.69 14 52.58 3.71 14 39.82 0.86
51.85 3.56 30.11 0.84
16 51.82 3.2 16 23.55 0.69
17 51.48 3.75 17 11.46 0.59
18 45.95 3.49 18 11.41 0.78
19 45.94 2.95 19 11.35 0.88
41.37 2.85
21 41.24 2.09
22 39.76 2.16
23 30.42 3.18
24 30.37 3.18
25 29.29 3.19
26 26.42 1.91
347
16. 11-Fluoro-19,20-dihydroakuammicine 56c NMR
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Figure C.48: 11-Fluoro-19,20-dihydroakuammicine 56c proton NMR
'H NMR (600 MHz, CD 30D) 6 7.37 (dd, J = 8.2, 5.2, 1H), 6.78 (dd, J = 9.5, 2.3,
1H), 6.68 - 6.57 (m, 1H), 4.61 (s, 1H), 3.84 - 3.77 (m, 4H), 3.71 - 3.60 (m, 2H),
3.60 - 3.46 (m, 3H), 2.98 (ddd, J = 19.9, 9.5, 5.2, 1H), 2.15 - 2.05 (m, 3H), 2.03
- 1.95 (m, 2H), 1.18 (t, J = 7.0, 1H), 0.92 (ddd, J = 20.7, 14.3, 7.1, 5H), 0.77 (t, J
= 7.4, 3H).
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17. N-methyl-1 2-methylakuammicine 57n NMR
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Figure C.49: N-methyl-12-methylakuammicine 57n proton NMR
1H NMR (600 MHz, CD 3CN) 6 8.74 (s, 1H), 7.37 (d,
1H), 6.91 (t, J = 7.2, 1H), 5.71 (s, OH), 4.69 (s, 1H),
(s, 1H), 3.80 (s, 4H), 3.53 (s, 1H), 3.36 (d, J = 47.6,
(m, 3H), 1.45 (d, J = 13.9, 1H).
J = 6.2, 1H), 7.07 (d, J = 7.4,
4.24 (d, J = 14.0, OH), 4.05
1H), 2.27 (s, 3H), 1.71 - 1.62
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Figure C.50: N-methyl-12-methylakuammicine COSY
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Figure C.51: N-methyl-1 2-methylakuammicine HSQC
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Figure C.52: N-methyl-12-methylakuammicine HMBC
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Table C.14: N-methyl-12-methylakuammicine peak tables.
COSY HSQC HMBC
fl f2 fi f2 fi f2
(ppm) (ppm) (ppm) (ppm) (ppm) (ppm)
1 7.29 6.95 1 131.61 7.1 1 168.24 3.79
2 7.1 6.92 2 129.82 5.76 2 143.39 2.27
3 5.76 1.73 3 122.82 6.93 3 131.66 2.27
4 4.49 1.18 4 119.37 7.29 4 130.69 1.72
5 4.38 1.56 5 74.11 4.38 5 130.38 1.73
6 4.38 2.49 6 66.44 3.88 6 121.35 2.26
7 4.11 1.52 7 66.39 4 7 121.15 2.27
8 4.11 1.74 8 65.38 3.74 8 74.02 3.28
9 4.1 2.44 9 52.36 3.79 9 65.82 3.28
4.02 1.72 52.33 3.28
11 3.89 1.73 11 51.32 3.27
12 3.75 2.83 12 50.34 3.29
13 3.74 2.12 13 30.46 1.23
2.86 2.11
15 2.44 1.56
16 2.3 1.56
17 1.55 1.28
Table C.15: N-methyl-12-methylakuammicine summary.
# 1H split HSQC HMBC
3 4.69 s
5 3.53 d
6 2.26
7 121.35
8 143.05
9 7.37 d 119.37
10 6.91 t 122.82
11 7.07 d 131.61
12 135.02
13 143.05
14 1.45 d 30.46
15 4.05 s
16
17
18 1.71 d
19 5.71 q 129.82
20 130.69
21 4.24 d 74.11
3.36 d 52.33
22 168.24
23 3.8 s 52.36
N-ME 74.02
18. 14-Fluorotabersonine 7a NMR
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Figure C.53: 14-Fluorotabersonine 7a proton NMR
1H NMR (600 MHz, CD 3CN) 6 7.12 (dt, J = 15.6, 7.7, 1H), 6.89 (dd, J = 16.8, 7.4,
1H), 6.75 (dd, J = 13.2, 7.8, 1H), 5.86- 5.76 (m, OH), 5.48 (s, 1H), 4.19-4.01
(m, 1H), 4.03 - 3.95 (m, 1H), 3.79 (s, 2H), 0.91 (t, J = 7.0, 3H).
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19. 16-Fluorovindolidine 48c NMR
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Figure C.54: 16-Fluorovindolidine proton NMR
'H NMR (600 MHz, CD 3CN) 6 7.59 (s, OH), 7.25 (dd, J= 5.6, 8.3, 1H), 6.56 (td, J
= 2.3, 9.4, 1H), 6.41 (dd, J = 2.2, 10.4, 1H), 5.88 (ddd, J = 1.7, 5.2, 6.3, 1 H), 5.45
(s, OH), 5.35 (d, J = 10.6, 1 H), 5.31 (s, 1H), 5.07 (s, OH), 3.93 - 3.84 (m, OH),
3.78 (d, J = 2.5, 5H), 3.27 (s, 1 H), 2.64 (s, 3H), 2.58 - 2.48 (m, 1 H), 2.00 (s, 3H),
1.96 (s, 5H), 1.67 (dd, J= 7.7, 14.6, 1H), 1.42 (s, OH), 1.28 (d, J = 25.0, 2H), 1.11
(dd, J = 7.3, 14.1, 1H), 0.43 (t, J = 7.4, 3H).
356
ISE
aI
v -Z j4
o
0
9 G
SI
S 6
• - II
oo 9~1
U.,r
*i
9 8 7 6 5 4
f2 (pprTl)
Figure C.55: 16-Fluorovindolidine COSY
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Figure C.56: 16-Fluorovindolidine HSQC
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Figure C.57: 16-Fluorovindolidine HMBC
-42
-40
-80
100
120
EO_
o_
r
140
160
180
2)00
220I
Table C.16: 16-Fluorovindolidine peak table.
COSY HSQC HMBC
fl f2 fl f2 fl f2
(ppm) (ppm) (ppm) (ppm) (ppm) (ppm)
1 9 3.35 1 131.69 5.36 1 172.58 3.77
2 7.28 6.58 2 125.08 7.25 2 172.5 3.77
3 6.64 6.4 3 122.91 5.88 3 171.45 5.3
4 5.91 3.88 4 109.72 0.39 4 171.43 1.99
5 5.91 5.35 5 107.28 1.17 5 171.39 2
6 4.95 4.77 6 107.28 6.57 6 165.13 7.23
7 4.49 4.28 7 98.57 6.41 7 155.31 7.22
8 4.13 3.01 8 81.28 3.78 8 155.3 2.63
9 3.92 3.48 9 81.21 5.68 9 149.01 1.29
10 3.85 2.51 10 75.38 5.31 10 141.59 1.39
11 3.84 3.25 11 72.17 5.07 11 131.77 1.1
12 3.68 1.79 12 69.59 3.36 12 81.29 2.63
13 3.28 2.53 13 53.68 3.78 13 80.13 3.78
14 1.71 1.1 14 50.21 3.26 14 75.36 3.78
15 1.69 0.43 15 38.65 2.63 15 69.57 3.78
1.31 0.88 67.61 2.2
17 52.53 3.78
18 44.83 15.28
17 1.12 0.42
Appendix D
Western Blots and Tabulated Peptide Sequences
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1. Gel Images
i
Figure D.1: Western blot of 5-azidostrictosidine pentynyl ester labeled proteins
detected with biotin
Figure D.2: Western blot of 4-azidostrictosidine pentynyl ester labeled proteins
detected with biotin
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SFigure D.3: Western blot of 6-azidostrictosidine pentynyl ester labeled proteins
detected with biotin
Figure D.4: Western blot of 7-azidostrictosidine pentynyl ester labeled proteins
detected with biotin
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Figure D.5: Control SDS-PAGE of "ajmalicine synthase" extract stained with
SyproRuby from which the proteins were picked for sequencing
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Figure D.6: SDS-PAGE of 6-azidostrictosidine pentynyl ester labeled proteins
detected with rhodamine.
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Figure D.7: Western blot of SGS-S-S-X labeled proteins.
Figure D.8: Control SDS-PAGE of "ajmalicine synthase" extract stained with
SyproRuby from which the proteins were pick for sequencing.
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Table D.1: Peptides identified by Azidostrictosidine labeling and biotin detection. Peptides from gel in DI-D4.
accession # MW probability % of total Predicted function species Peptide sequence
(Da) spectra
1 gij116659973 44 99.80% 0.83% cysteine poteinase Platycodon AVANQWSVAIEGSSR
grandiflorus DFQHYDSGI FTGK
2 gil164555967 49 100.00% 0.40% unnamed protein Vitis vinifera ESLLEALTEHVK
gill 64556593 product TVPS IVVYVTVPN K
gil 64556639 TVPSIWYVTVPNKEAGK
gi 164560747 VPGVESVYEWK
gil 64560777
gil164561000
3 gil116655181 47 99.30% 0.20% Malate Eucalyptus DDLFNINAGIVK
dehydrogenase, gunnii SEVAGYMGEDQLGQALE-
mitochondrial GSDVVIIPAGVPR
3 giJ164552087 52 99.80% 0.20% heat shock protein 90 Nicotiana ADLVNNLGTIAR
gi 1 64555856 tabacum ITLFLK
5 gi1116656081 50 100.00% 0.34% malate Zea mays EFAPSIPAK
dehydrogenase5 MELVDAAFPLLK
VLVTGAAGQIGYALVPM IAR
6 gi1164559297 78 99.50% 0.20% cytosolic ascorbate Nicotiana ALLSDPAFRPLVEK
gil 64559645 peroxidase tabacum EGLLQLPSDK
gi1164560995
6 gi1164558535 73 100.00% 0.41% unnamed protein Vitis vinifera AVEKEFEMALQDR
gil 64559097 product EFEMALQDR
FDHIDLVEK
YATPILLSAEVR
accession # MW probability % of Predicted species Peptide sequence
(Da) total function
spectra
7a gil116655042 54 99.80% 0.21% fructose- Solanum GILAADESTGTIGK
gil164552554 bisphosphate tuberosum LASINVENVESNRR
gi1164558997 aldolase
gi 1164559800
7a gil116655181 47 100.00% 0.62% Malate Eucalyptus DDLFNINAGIVK
dehydrogenase, gunnii KVAVLGAAGGIGQPLALLMK
mitochondrial SEVAGYMGEDQLGQALEGSD-
VVIIPAGVPR
VAVLGAAGGIGQPLALLMKLNPLVSR
7a gi1164552628 62 99.80% 0.21% malate Nicotiana KMDSTAEELSEEK
gi1164553503 dehydrogenase tabacum LNVPVSEVK
gi1164554791 MDSTAEELSEEK
TSAGEKPVR
7a gi1116656081 50 100.00% 1.04% malate Zea mays ALGQISER
dehydrogenase5 EFAPSIPAK
MELVDAAFPLLK
VLVTGAAGQIGYALVPM IAR
VLVVANPANTNALILK
7a gil 116656009 46 99.50% 0.21% cytosolic malate Arabidopsis ALGQISER
dehydrogenase thaliana EFAPSIPAK
LNVPVSEVK
TSAGEKPVR
7a gi1171846058 53 99.80% 0.21% malate Glycine max ANLPDEDIK
dehydrogenase NGVEEVLGLGPLSDFEQ-
QGLEALKPELK
7b gi164556296 57 100.00% 0.38% fructose-1,6- Lycopersicon AQAAFLTR
gil 64557328 bisphosphate esculentum TMPAAVPAVVFLSGGQS-
aldolase EEEATVNLNAMNK
VAPEVIAEYTVR
accession # MW probability % of Predicted function species Peptide sequence
(Da) total
spectra
7b gi1116655042 65 100.00% 0.57% fructose- Solanum GILAADESTGTIGK
gi1164552554 bisphosphate tuberosum IGPNEPSQLAINENANGLAR
gil 64558997 aldolase-like protein LASINVENVESNR
gil 64559800 LASINVENVESNRR
TADGKPFVDVMK
7b gi1116655181 47 100.00% 0.76% Malate Eucalyptus DDLFNINAGIVK
dehydrogenase gunnii KVAVLGAAGGIGQPLALLMK
SEVAGYMGEDQLGQALEGSD-
WI IPAGVPR
VAVLGAAGGIGQPLALLMK
7b gi1116656081 50 100.00% 0.57% malate Zea mays EFAPSIPAK
dehydrogenase5 MELVDAAFPLLK
VLWANPANTNALI LK
8a gi1116660124 49 99.30% 0.22% putative elongation Solanum MLVIGSEAPFK
factor 1-gamma-like tuberosum VGGFLQR
8a gi1164552997 48 100.00% 0.44% heat shock protein Nicotiana EQVFSTYSDNQPGVLI-
gill 64553238 70-3 tabacum QVYEGER
gi1164556092 FELSGIPPAPR
ITITNDK
NALENYAYNMR
8a gi1164558535 73 99.80% 0.22% unnamed protein Vitis vinifera EFEMALQDR
gi 1 64559097 product YATPILLSAEVR
8a gi1164559209 62 99.20% 0.22% Proteasome subunit Petunia x SPSPLLLPAR
gil 64559782 beta type-1 hybrida SVMASSGFQADVR
8c gi1116656661 50 100.00% 0.47% Triosephosphate Spinacia GGAFTGEISVEQLK
gill64558819 isomerase, oleracea LESDVDVVVAPPFVYIEQVK
chloroplastic LVSDLNSAK
WVILGHSER
accession # MW probability % of Predicted function species Peptide sequence
(Da) total
spectra
8c gi1164559297 78 100.00% 0.57% cytosolic ascorbate Nicotiana ALLSDPAFRPLVEK
gi1164559645 peroxidase tabacum EGLLQLPSDK
gil 164560995 QMGLTDQDIVALSGGHTLGR
SYPTVSEEYQK
TGGPFGTMR
YAADEDAFFADYAVAHLK
8c gi1164552997 48 99.90% 0.28% heat shock protein 70-3 Nicotiana ITITNDK
gill64553238 tabacum NALENYAYNMR
gi1164556092
8c gil116654411 51 100.00% 0.38% unnamed protein Vitis vinifera FVVVVDDSK
product LGELLASGK
LTNIVGVPTSK
TFEQANSLN I PLATLDTH PR
9 gi1164556296 57 99.80% 0.31% fructose-1,6- Lycopersicon AQAAFLTR
gi1164557328 bisphosphate aldolase esculentum VAPEVIAEYTVR
9 gill 16655042 54 100.00% 0.21% fructose-bisphosphate Solanum GILAADESTGTIGK
gi1164552554 aldolase tuberosum LASINVENVESNRR
gil 64558997
gil164559800
9 gi1116655181 47 100.00% 0.31% Malate dehydrogenase, Eucalyptus DDLFNINAGIVK
mitochondrial gunnii KVAVLGAAGG IGQPLALLMK
VAVLGAAGG IGQPLALLMK
9 gil164560435 78 99.70% 0.21% hypothetical protein Vitis vinifera EILPSGAVDQSTR
EQLLSFLK
9 gil116656081 50 100.00% 0.42% malate Zea mays EFAPSIPAK
dehydrogenase5 MELVDAAFPLLK
VLVTGAAGQIGYALVPM IAR
VLVVANPANTNALILK
accession # MW probability % of total Predicted function species Peptide sequence
(Da) spectra
10 gill 116657768 49 99.40% 0.20% hypothetical protein Vitis vinifera FVEFLAR
NPPIEEVIQSGWPR
10 gi1164560015 73 99.10% 0.20% unknown Populus ITVITQGADPVVVAEDGK
trichocarpa LFPVIPLPK
11 gill 116657768 49 99.80% 0.19% hypothetical protein Vitis vinifera FVEFLAR
NPPIEEVIQSGVVPR
11 gi1164560015 73 100.00% 0.39% unknown Populus ITVITQGADPVVVAEDGK
trichocarpa LFPVIPLPK
RITVITQGADPVVVAEDGK
VLPYVDYLFGNETEAR
11 gi1116656091 50 99.70% 0.19% enolase-like Solanum EGLELLK
gi1164559965 tuberosum LAMQEFMILPVGASSFK
13 gi1164556296 49 99.50% 0.22% fructose-1,6- Lycopersicon AQAAFLTR
gill 164557328 bisphosphate esculentum VAPEVIAEYTVR
aldolase
13 gij116655042 50 100.00% 0.65% fructose- Solanum GILAADESTGTIGK
gi1164552554 bisphosphate tuberosum GQYADELIANATYIGTPGK
gi1164558997 aldolase-like protein IGPNEPSQLAINENANGLAR
gi1164559800 LASINVENVESNR
LASINVENVESNRR
13 gi1116655181 47 100.00% 0.44% Malate Eucalyptus DDLFNINAGIVK
dehydrogenase, gunnii KVAVLGAAGGIGQPLALLMK
mitochondrial VAVLGAAGGIGQPLALLMK
13 gi1116656081 50 100.00% 0.98% malate Zea mays ALGQISER
dehydrogenase5 EFAPSIPAK
MELVDAAFPLLK
VLVTGAAGQIGYALVPM IAR
VLWANPANTNALILK
accession # MW probability % of Predicted function
(Da) spectra
14 gi1164551925 55 100.00% 2.12% triose phosphate
isomerase cytosolic
isoform-like
14 gi1164552639 48 99.80% 0.30% triose phosphate
isomerase cytosolic
isoform
gi1164558209 99.70% 0.24% enoyl ACP reductase Olea
europaea
Peptide sequence
ELAAKPDVDGFLVGGASLKPEFIDII
ESGSTMAWAAQTK
LI LGETN EFVGDKVAYALSQGLK
NWIAYEPVWAIGTGK
RLILGETNEFVGDK
VATPDQAQEVHFELR
VAYALSQGLK
DWEVVVSPPFVFLPLVK
ESGSTMAWAAQTK
IVSTLNSAEIPSK
LILGETNEFVGDKVAYALSQGLK
NWIAYEPVWAIGTGK
RLILGETNEFVGDK
VAYALSQGLK
IIPGYGGGMSSAK
VNTISAGPLR
20 gi1116659973 44 99.80% 0.30% cysteine proteinase Platycodon AVANQWSVAIEGSSR
grandiflorus DFQHYDSGIFTGK
20 gi1116654236 46 99.80% 0.20% cytochrome c oxidase Arabidopsis LETAPADFR
gij 1 64559643 subunit, putative thaliana SPSLVEDYLLK
21 gi116659973 44 99.80% 0.28% cysteine proteinase Platycodon AVANQWSVAIEGSSR
grandiflorus DFQHYDSGIFTGK
22 gi1164557328 49 99.50% 0.22% fructose- Solanum AQAAFLTR
bisphosphate tuberosum VAPEVIAEYTVR
aldolase-like protein
22 gil116655042 54 100.00% 0.65% fructose- Solanum GILAADESTGTIGK
gi1164552554 bisphosphate tuberosum GQYADELIANATYIGTPGK
gi1164558997 aldolase-like protein IGPNEPSQLAINENANGLAR
gil 64559800 LASINVENVESNR
LASINVENVESNRR
accession # MW probability % of Predicted function species Peptide sequence
(Da) spectra
22 gi1116655181 47 100.00% 0.44% Malate Eucalyptus DDLFNINAGIVK
dehydrogenase, gunnli KVAVLGAAGGIGQPLALLMK
mitochondrial VAVLGAAGGIGQPLALLMK
22 gi1116656081 50 100.00% 0.98% malate Zea mays ALGQISER
dehydrogenase5 EFAPSIPAK
MELVDAAFPLLK
VLVTGAAGQIGYALVPM IAR
VLWANPANTNALILK
24 gi1116659589 40 100.00% 0.78% glutathione S- Catharanthus AINQYIVQAYGDK
transferase roseus FDPAASK
LGEILDVYEAR
VHGSVLSPAVLR
25 gi1164558490 79 100.00% 1.08% unnamed protein Vitis vinifera AVSLAIAR
gil 64561006 product EGMTQDEAEKLWK
proteasome LLSYNNK
subunit SGSAADSQIVSDYVR
NTN-hydrolase TSTGMYVANR
superfamily TVTINSEGVTR
VAANLVR
YFLHQHTIQLGQPATVK
26 gi1116655042 54 99.80% 0.21% fructose- Solanum EAGVLPGIK
gi1164552554 bisphosphate tuberosum IGPNEPSQLAINENANGLAR
gi1164558997 aldolase
gi1164559800
26 gi1164559209 62 100.00% 1.34% Proteasome Petunia x DAVTPLSEAEAIDLVK
gi1164559782 subunit beta type- hybrida LEIVILNANGIR
1 MSTGYNILTR
SPSPLLLPAR
SVMASSGFQADVR
VGYSSQGSGSTLIMPFLDNQLK
accession # MW probability % of Predicted function species Peptide sequence
(Da) spectra
27 gi1164559297 78 99.90% 0.35% cytosolic ascorbate Nicotiana ALLSDPAFRPLVEK
gil 64559645 peroxidase tabacum EGLLQLPSDK
gi 1 64560995 YAADEDAFFADYAVAHLK
27 gi1164558191 71 100.00% 0.94% Proteasome Glycine EGWLAVEK
gi1164558212 subunit alpha type- max GVNTFSPEGR
5 ITSPLLEPSSVEK
LFQVEYAIEAIK
LGSTAIGLK
TKEGWLAVEK
VTPNNVDIAK
28 gi1164557328 49 99.70% 0.23% fructose- Solanum AQAAFLTR
bisphosphate tuberosum VAPEVIAEYTVR
aldolase
28 gi1116655042 54 100.00% 0.45% fructose- Solanum GILAADESTGTIGK
gill64552554 bisphosphate tuberosum IGPNEPSQLAINENANGLAR
gil 64558997 aldolase LASINVENVESNRR
28 gil116655181 47 99.80% 0.23% Malate Eucalyptus DDLFNINAGIVK
dehydrogenase gunnii KVAVLGAAGGIGQPLALLMK
28 gil116656081 50 100.00% 0.79% malate Zea mays ALGQISER
dehydrogenase5 EFAPSIPAK
MELVDAAFPLLK
VLVTGAAGQIGYALVPM IAR
VLWANPANTNALILK
31 gill116655832, 47 99.70% 0.35% T-cytoplasm male Zea mays FADLVEK
gi 1 64556709 sterility factor 2 TFPTLDPR
31 gil116658794 49 100.00% 0.23% aldehyde [Nicotiana EEIFGPVQSILK
dehydrogenase tabacum] FGLAAGVFTQNIDTANTLMR
31 gi1116653702 48 100.00% 0.35% S-adenosyl-L- C.roseus AEFGPSQPFK
homocysteine LVGVSEETTTGVKR
hydrolase
accession # MW Probab- % of Predicted function species Peptide sequence
(Da) ility spectra
33 gi1164559297 77 100.00% 0.90% cytosolic Nicotiana tabacum AEQAHGANNGIDIAIR
gill64559645 ascorbate ALLSDPAFRPLVEK
gill64560995 peroxidase EGLLQLPSDK
QMGLTDQDIVALSGGHTLGR
YAADEDAFFADYAVAHLK
34 gi1116657437 42 99.20% 0.21% cysteine protease Nicotiana tabacum YAVGLVRPVSIAFEVVSGFR
YNGGLDTEEAYPYMAK
34 gi1164559297 78 100.00% 0.42% cytosolic Nicotiana tabacum ALLSDPAFRPLVEK
gil 64559645 ascorbate EGLLQLPSDK
gil 64560995 peroxidase QMGLTDQDIVALSGGHTLGR
YAADEDAFFADYAVAH LK
34 gi1164551985 50 100.00% 0.95% Stromal 70 kDa Pisum sativum DAISGGSTQAIK
heat shock-related DAMAALNQEVMK
protein, EFGDKVPAGVK
KQDITITGASTLPGDEVER
LGELKDAISGGSTQAIK
NQADSIVYQTEK
QDITITGASTLPGDEVER
35 gil 116660546 45 100.00% 0.46% protein S C. roseus FTAVNLAASGINEK
ISLAVFLNAIMPDTK
NRPSYVLEEYTAK
VILVGHSGGGMTAAVGMEK
35 gi1164559659 76 100.00% 0.28% cyclase family Arabidopsis EIILVEGLK
protein thaliana LLGAEGSPIR
VLNGPALLIDVPR
35 gi1116660683 40 100.00% 0.74% protein S Catharanthus FTEEGFGSVPR
gill64559132 alpha/beta roseus ILVRPGSLFIEDLLK
gill64561505 hydrolase TIPPEFQR
VYVIAAEDK
accession # MW probability % Predicted species Peptide sequence
(Da) spectra function
36 gil164557328 49 100.00% 0.50% fructose- Solanum ALNDHHVLLEGTLLKPNMVTPGSDSP
bisphosphat tuberosum AQAAFLTR
e aldolase- TMPAAVPAVVFLSGGQSEEEATVNLN
like protein VAPEVIAEYTVR
36 gi1116655042 66 100.00% 0.70% fructose- Solanum GILAADESTGTIGK
gill64552554 bisphosphat tuberosum GQYADELIANATYIGTPGK
gi1164558997 e aldolase- IGPNEPSQLAINENANGLAR
gi1164559800 like protein LASINVENVESNRR
VDKGTVELPGTNGETTTQ-
GLDGLAQR
36 gil116655181 47 100.00% 1.01% Malate Eucalyptus DDLFNINAGIVK
dehydrogen gunnii KVAVLGAAGGIGQPLALLMK
ase, SEVAGYMGEDQLGQALEGS-
mitochondri DWVVIIPAGVPR
al VAVLGAAGGIGQPLALLMKLNPLVSR
36 gi1164560435 78 100.00% 0.50% hypothetical Vitis vinifera EILPSGAVDQSTR
protein EQLLSFLK
VGSEPGFLER
VLGLPYK
36 gil171846058 53 100.00% 0.70% malate Glycine max ANLPDEDIK
dehydrogen GIQFANK
ase NGVEEVLGLGPLSDFEQQGLEALKPE
TQDGGTEWVVEAK
39 gi1116654684 45 99.60% 0.31% ascorbate Vigna EDIKELLR
peroxidase unguiculata FEVELK
39 gill 16654270 51 100.00% 0.31% unnamed Vitis vinifera EGALAEENMR
protein GGGQVIPTAR
product VIYASQITAKPR
39 gi1171846034 61 99.70% 0.20% carboxylest Actinidia AIGVSIEYR
erase eriantha LYLAGDSPGANIVHNTLIR
accession # MW probability % of total Predicted function species Peptide sequence
(Da) spectra
39 gi1164557739 38 99.00% 0.20% unnamed protein Vitisvinifera DPDGYLFELIQR
GGSSVIAFVK
40 gil164558209 59 100.00% 0.38% enoyl ACP reductase Olea IIPGYGGGMSSAK
europaea VLAFEAGR
VNTISAGPLR
40 gi1171846034 61 99.80% 0.38% CXE Actinidia AIGVSIEYR
carboxylesterase eriantha LYLAGDSPGANIVHNTLIR
dehydratase
48 gi1116660124 49 99.80% 0.22% putative elongation Solanum EVDINDEAQKER
factor 1-gamma-like tuberosum VGGFLQR
48 gi1164556092 74 100.00% 0.43% heat shock protein Nicotiana EQVFSTYSDNQPGVLIQVYE
70-3 tabacum GER
FELSGIPPAPR
ITITNDKGR
NTTIPTKK
Table D.2: Peptides identified by Azidostrictosidine labeling and rhodamine detection. Peptides from Figure D.6
S ot 2
Accession # MW (Da) Protein % of Similar protein species Peptide sequence
identification total
probability spectra
1 gi1116656081 50,770.60 100.00% 0.83% malate Zea mays EFAPSIPAK
dehydrogenase5 MELVDAAFPLLK
VLVTGAAGQIGYALVPMIAR
VLWANPANTNALILK
2 gi1116655042 50,722.40 100.00% 0.83% fructose- Solanum EAGVLPGIKVDK
gil 164552554 bisphosphate tuberosum GQYADELIANATYIGTPGK
gil 64558997 aldolase-like IGPNEPSQLAINENANGLAR
gil 64559800 protein LASINVENVESNR
LASINVENVESNRR
TADGKPFVDVMK
VDKGTVELPGTNGETTT-
QGLDGLAQR
3 gi1116655181 47,547.30 100.00% 0.63% Malate Eucalyptus DDLFNINAGIVK
dehydrogenase, gunnii KVAVLGAAGGIGQPLALLMK
mitochondrial VAVLGAAGGIGQPLALLMK
4 gi1171846058 53,276.30 99.80% 0.31% malate Glycine max ANLPDEDIKALTK
dehydrogenase TQDGGTEVVEAK
5 gi1164560435 78,110.00 99.90% 0.21% hypothetical Vitis vinifera LIFANALYYK
protein VGSEPGFLER
6 gi1164552628 62,690.90 99.70% 0.31% malate Nicotiana LNVPVSEVK
gill64553503 dehydrogenase tabacum MDSTAEELSEEK
gi1164554791
7 gi1164556296 57,297.30 100.00% 0.42% fructose-1,6- Lycopersicon AQAAFLTR
bisphosphate esculentum TWAGKEENVQK
aldolase VAPEVIAEYTVR
YAGGAAGGAAAESLHVK
S ot I
Accession # MW (Da) Protein % of Similar protein species Peptide sequence
identification total
probability spectra
1 gi1116657936 48,416.40 99.40% 0.21% unknown Populus ILLLLVSSYR
gi1 16661519 trichocarpa SLEEDVAHHTTGDYRK
gi1164552889
gi1164555189
gi1164558706
gil164561040
2 gi1116656081 50,770.60 100.00% 1.03% malate Zea mays ALGQISER
dehydrogenase5 EFAPSIPAK
MELVDAAFPLLK
NVI IWGNHSSTQYPDVN-
HATVK
VLVTGAAGQIGYALVPMIAR
VLVVANPANTNALILK
3 giJ116655042 54,405.10 99.90% 0.31% fructose- Solanum GILAADESTGTIGK
gi1164552554 bisphosphate tuberosum LASINVENVESNRR
gi11645589971 aldolase-like
gi 1 64559800 protein
4 giJ116655181 47,547.30 99.90% 0.41% Malate Eucalyptus KVAVLGAAGGIGQPLALLMK
dehydrogenase gunnii VAVLGAAGGIGQPLALLMK
5 gi1171846058 53,276.30 100.00% 0.41% malate Glycine max ANLPDEDIK
dehydrogenase ANLPDEDIKALTK
TQDGGTEVVEAK
6 gi1164552628 62,690.90 100.00% 0.83% malate Nicotiana KMDSTAEELSEEK
gil 164553503 dehydrogenase tabacum LNVPVSEVK
gil 64554791 MDSTAEELSEEK
NVI IWGNHSSTQYPDVNHATVK
7 gi1164556296 57,297.30 100.00% 0.31% fructose-1,6- Lycopersicon AQAAFLTR
bisphosphate esculentum VAPEVIAEYTVR
aldolase YAGGAAGGAAAESLHVK
8 gi1164558620 72,317.10 99.60% 0.21% glyceraldehyde 3- Nicotiana IGINGFGR
phosphate langsdorffii TLLFGEKPVK
dehydrogenase
S ot 3
Accession # MW Protein % of Similar protein species Peptide sequence
(Da) identification total
probability spectra
1 gill64558059 47,088 100.00% 0.31% Enolase 1 Hevea AGWGVMASHR
brasiliensis IEEELGAEAVYAGASFR
YNQLLR
2 gi1116656800 34,209 100.00% 0.51% Enolase Solanum EGLELLK
lycopersicum KYGQDATNVGDEGGFAPNIQENK
MGVEVYHHLK
WIGMDVAASEFYADKR
YDLNFK
YDLNFKEEK
YGQDATNVGDEGGFAPNIQE-
NKEGLELLK
4 gill 116658794 49,049 99.00% 0.20% aldehyde Nicotiana EEIFGPVQSILK
dehydrogenase tabacum YKDLDEVIR
(NAD+)
5 giJ164559965 65,974 100.00% 1.83% enolase-like Solanum AAVPSGASTGIYEALELR
tuberosum AGAAVLNIPLYK
AVNNVNSI IAPALIGK
EGLELLK
KYGQDATNVGDEGGFAPN IQENK
LAMQEFMILPVGASSFK
LVLPVPAFNVINGGSHAGNK
MGVEVYHHLK
YGQDATNVGDEGGFAPNIQENKE-
GLELLK
Spot 4
Accession # MW Protein % of Similar protein species Peptide sequence
(Da) identification total
probability spectra
1 gill116654894 36 99.80% 0.30% Enolase Ricinus AGWGVMASHR
communis ISGDQLKDLYK
VNQIGSVTESIEAVR
2 gi1164556709 40 100.00% 0.30% mitochondrial Sorghum bicolor AFDEGPWPR
aldehyde FADLVEK
dehydrogenase TFPTLDPR
3 gi1164553669 68 100.00% 0.30% hypothetical Oryza sativa IGGASEAEVGEK
gil 64556407 protein IGVQI IQNALK
OsJ 030550 LPTANFDQK
4 gi1164558059 47 99.80% 0.20% Enolase 1 Hevea AGWGVMASHR
brasiliensis YNQLLR
5 gi1116656800 34 99.00% 0.30% Enolase Solanum MGVEVYHHLK
lycopersicum WIGMDVAASEFYADKR
YDLNFK
6 gi1116658794 49 100.00% 0.40% aldehyde Nicotiana AWTPLKNPAWL
dehydrogenase tabacum EEIFGPVQSILK
(NAD+) FGLAAGVFTQNIDTANTLMR
YKDLDEVIR
7 gi1164559965 65 100.00% 0.89% enolase-like Solanum AAVPSGASTGIYEALELR
tuberosum AGAAVLNIPLYK
AVNNVNSI IAPALIGK
DGGSDYLGK
LAMQEFMILPVGASSFK
LVLPVPAFNVINGGSHAGNK
MGVEVYHHLK
Spot 5
Accession # MW (Da) Protein % of Similar protein species Peptide sequence
identification total
probability spectra
1 gil116654900 39,314.20 99.80% 0.20% Glutamine Vigna TLPGPVSDPSK
gi1116660947 synthetase aconitifolia WNYDGSSTGQAPGE
nodule isozyme
2 gi1116653947 38,905.80 99.80% 0.30% Sinapyl Alcohol Populus AYGWAAR
gi1116657264 Dehydrogenase tremuloides DSSGILSPFNFSR
gi 116658169 Complexed YPLVPGFETVGVASEVGSK
gi 116658395 With Nadp+
gill 16659294
3 gi1164560037 59,915.80 100.00% 0.60% alcohol NADP+ Solanum KDEAVNFLGADGFLVSSD-
gi1164560193 oxidoreductase tuberosum AEQMK
gi 164560952 RTVASSIGGSTK
TVASSIGGSTK
VTVISTSPSK
VTVISTSPSKK
4 giJ116657561 49,113.00 99.80% 0.60% Sinapyl Alcohol Populus AYGWAAR
Dehydrogenase tremuloides DTSGILSPFK
Complexed MTAAYGSVDR
With Nadp+
5 gi1164558700 56,335.30 100.00% 0.70% alcohol Dimocarpus DYDKPVQEVIAEMTGGGVDR
dehydrogenase longan FITHEVTFSEINK
I IGVDLNPAR
INPLAPLDK
SDLPSVVEK
THPMNFLNER
YMTGELELEK
6 gij164559965 65,974.80 99.80% 0.20% enolase-like Solanum EGLELLK
Stuberosum LVLPVPAFNVINGGSHAGNK
Sp ot 6
Accession # MW Protein % of Similar protein species Peptide sequence
(Da) identification total
probability spectra
1 gill 116656008 49 100.00% 0.36% phosphoserine Vitis AQILYDTIDASNGFFR
aminotransferase vinifera FGVIYAGAQK
YTNIPAFDSLEQSPDAK
2 gi 116655573 46 100.00% 0.36% elongation factor- Nicotian GFVASNSKDDPAK
gi 116656968 1 alpha a IGGIGTVPVGR
gi1164553198 tabacum LPLQDVYK
gi1164560392
3 gil 16656081 50 99.80% 0.24% malate Zea MELVDAAFPLLK
dehydrogenase5 mays VLVTGAAGQIGYALVPMIAR
4 gi1116659546 41 99.80% 0.24% Sinapyl Alcohol Populus NEWGISTYPLVPGHEIVGEVTEVGG
gill16659611 Dehydrogenase tremuloi K
gil 116659800 Complexed With des TYGLAAHDSSGVLSPFK
gill 16660274 Nadp+
gi1116660428
gi1116661416
gi1164556967
5 gill 16655146 49 99.50% 0.24% hypothetical Cucumis DFEQIAEFLHR
gill 116655200 protein melo GLVEKDFEQIAEFLHR
gi1164561584 serine hydroxyl-
gil171846178 methyltransferase
gi1171846224
6 gi1116659056 39 99.70% 0.24% 10- Cathara SPEVEHPVK
gil 116659208 hydroxygeraniol nthus YPIVPGHEIVGIVTEVGSK
oxidoreductase roseus
7 gi1116655042 50 100.00% 0.47% fructose- Solanu GILAADESTGTIGK
gi1164552554 bisphosphate m GQYADELIANATYIGTPGK
gi1164558997 aldolase-like tuberosu IGPNEPSQLAINENANGLAR
gi 1 64559800 protein m LASINVENVESNRR
8 gi1164557798 34 99.80% 0.24% unnamed protein Vitis ASIYNAMPLAGVEK
gi1164558401 product vinifera SLMNVPFTLAK
phosphoserine
aminotransferase
9 gi116655181 47 99.80% 0.24% Malate Eucalypt DDLFNINAGIVK
dehydrogenase, us VAVLGAAGGIGQPLALLMK
mitochondrial gunnii
10 gij164559241 80 100.00% 1.19% aspartyl protease Populus FVQPIYIAMR
tremula FVQPIYIAMRDEFR
GSSSVPIASGQQVLNVGNYVI R
LANDVIPK
LGPVGQPR
VPIAPELLAFDPNTGAGTVVDSGTVI
TR
VRVPIAPELLAFDPNTGAGTWDSG
TVITR
11 gi1116659735 48 100.00% 0.47% 10- Camptot FVLDVAK
gil 16660097 hydroxygeraniol heca HAl IPLLGLLK
oxidoreductase acumina LVLLGAPPEPLDLHSAPLLMGR
ta VTVISTSEGKK
12 gill 116659568 45 99.80% 0.24% 10- Cathara IIAGSAIGGLK
hydroxygeraniol nthus LILVGAPEKPLELPSFPLIAGR
oxidoreductase roseus
13 gi1 16659641 47 99.80% 0.24% Glutamate Actinidia DDGTLASFVGFR
dehydrogenase 1 chinensi SLLIPFR
s
14 gi1164556296 57 99.80% 0.24% fructose-1,6- Lycoper VAPEVIAEYTVR
bisphosphate sicon YAGGAAGGAAAESLHVK
aldolase esculent
um
15 gi164559931 65 100.00% 0.36% Aspartate Daucus GLDFEGLLEDLSAAPSR
aminotransferase carota VFTLAGLTVK
I VKEYLPIVGLADFNK
Spot 7
Accession # MW (Da) Protein % of Similar species Peptide sequence
identification total protein
probability spectra
1 gi1164554344 57,527.40 99.80% 0.21% unknown Populus AVDNSGTVIGIK
gi1164555291 proteasome trichocarpa VFQIEYAAK
gil 64555599 alpha
subunit 1
2 gi1116660683 48,029.60 100.00% 1.36% protein S Catharanthu FTEEGFGSVPR
gill1164559132 s roseus ILVRPGSLFIEDLLK
gill64561505 TIPPEFQR
VYVIAAEDK
VYVIAAEDKTIPPEFQR
WMIENNPVK
3 gi1116653688 46,456.20 99.80% 0.21% ascorbate Spinacia ALLSDPAFRPLVEK
gill116660224 peroxidase oleracea EGLLQLPSDK
gi1164559297
gi1164559645
gi1164560995
4 gi1116660546 45,542.60 100.00% 1.68% protein S Catharanthu FTAVNLAASGINEK
s roseus HFVTVHGVGHGAWVYYK
ISLAVFLNAIMPDTK
NRPSYVLEEYTAK
SSIDYAAPLLEVLDSVPENEK
VILVGHSGGGMTAAVGMEK
VILVGHSGGGMTAAVGMEKFPN
K
5 gi1164559241 80,057.60 99.90% 0.21% aspartyl Populus VPIAPELLAFDPNTGAG-
protease tremula TVVDSGTVITR
VRVPIAPELLAFDPNTG-
AGTWDSGTVITR
6 gi1164559659 76,212.00 100.00% 0.42% cyclase Arabidopsis EIILVEGLK
family thaliana FTSETPVGIPEGVGQYLK
protein LLFSMK
VLNGPALLIDVPR
Spot 8
Accession # MW (Da) Protein % of Similar protein organism Peptide sequence
identification total
probability spectra
1 gi1116655541 50,372.30 99.80% 0.21% S-adenosyl-L- Catharanthus LVGVSEETTTGVK
homocysteine roseus VAWAGYGDVGK
hydrolase
2 gi1116661598 44,132.40 100.00% 0.31% Citrate Daucus HLPDDPLFQLVSK
synthase, carota LYEVVPPVLTELGK
mitochondrial YYTVLFGVSR
3 gi1164559965 65,974.80 100.00% 0.92% enolase-like Solanum AAVPSGASTGIYEALELR
tuberosum AGAAVLNIPLYK
AVNNVNSI IAPALIGK-
EGLELLK
LAMQEFM ILPVGASSFK
LVLPVPAFNVINGGSHAG-
NK
YGQDATNVGDEGGFAPNI
-QENK
Table D.3: Peptides identified by SGD-ss-x label
accession numbers Predicted function Sequence Peptide sequence
Coverage
1 gill 116653644 Protein disulfide 48% K.VLPFIR.S
isomerase R.SEPIPEVNNEPVK.V
K.VVVTNSLEDMVFK.S
K.SNVAPDQIEQWLK.D
K.EDQVPLIIIQNTVGTK.Y
1 gi1116654520 Chaperone 60 alpha- 50% R.FVVKAAAK.E
subunit R.TALQAGIDK.L
K.EIAFDQQSR.T
K.LADAVGLTLGPR.G
R.NVVLDEFGTPK.V
K.TVQGLVDELEK.K
-.PAVQDCPSGWY.-
K.LGLLSVTSGANPVSVK.K
R.AIELPDAMENAGAALI R.E
1 gi1164554471 Putative rubisco subunit 11% -.SMAFLLVP.-
binding protein K.VGAATEAELEDR.K
K.ELSETDSVYDSEK.L
1 gill 16656558 Protein disulfide 28 R.LAPEYER.A
isomerase K.IQGFPTIK.I
R.DADGIVAYLK.-
R.AASVLSSH DPPI ILAK.I
1 gi1164553669 Chaperone CPN-60-1 8 K.IGGASEAEVGEK.K
K.IGVQIIQNALK.M
K.IGGASEAEVGEKK.D
1 gi1116659652 23 K.SVAAGMNAMDLR.R
R.ALMLQGVEELAEAVK.V
accession Predicted function Sequence Peptide sequence
numbers Coverage
2 gi1164560015 Adenosine kinase 31% R.CLCAQR.R
isoform 2s K.LFPVIPLPK.E
K.LFPVIPLPK.E
K.ISEWPLAQGK.Q
R.AGCYAANIVIQR.S
R.SLVANLSAANCYK.S
K.YNVEYIAGGATQNSIR.I
R.ITVITQGADPVVVAEDGK.V
K.VLPYVDYLFGNETEAR.T
R.NLSNLLLNTQLQTTRFS.-
2 gill 16658350 Protein disulfide 15 -.IQGFPTIK.I
isomerase R.QVGPASVEIK.-
3 gi1116655090 70kDa Heat shock 15 R.LLPMTK.V
cognate protein R.VEIIANDQGNR.T
4 gi1116659973 Cysteine proteinase 31 R.YNSSGGPR.G
R.QNEAALQK.A
R.DFQHYDSGIFTGK.C
K.AVANQVVSVAIEGSSR.D
R.NVPQAVGLCGIAVEPSYPIK.N
4 gi1116659957 Adenosine kinase 11 K.LNNAILAEDK.H
K.HLPMYEEMASK.Y
K.NAPMTVSMSIIMK.M
K.MNQSQLVLAVSVCSGEK.G
5 gi1164560015 Adenosine kinase 14 K.LFPVIPLPK.E
isoform 2S K.NAPMTVSMSIIMK.M
R. ITVITQGADPVVVAEDGK.V
K.VLPYVDYLFGNETEAR.T
5 gi1116659973 Cysteine proteinase 31 YNSSGGPR
QNEAALQK
QPLHFSYIDHM
DFQHYDSGIFTGK
AVANQWSVAIEGSSR
NVPQAVGLCGIAVEPSYPIK
LYCNSTKAYSLWHIPLH PYVAVLSPA
5 gi1171845668 CXE 12 RASQQSS
carboxylesterase GIHSKNQRP
DVPISSQVSAR
R.KIPNSLIWSWIS.-
R.LYLAGDSPGANIVHNTLIR.A
5 gill 16661854 Annexin 23 R.GTEEGALTR.V
R.AEVDMQIIK.E
R.YSGDEVNMTLAK.S)
K.ESITMMTNSQGF.-
6 gi1116659973 Cysteine proteinase 26 R.DFQHYDSGIFTGK.C
R.DFQHYDSGIFTGK.C
K.AVANQWSVAIEGSSR.D
R.NVPQAVGLCGIAVEPSYPIK.N
6 gill 16660224 Ascorbate 6 K.EGLLQLPSDK.A
peroxidase -.PYQGLQPVCXY.-
7 gi 1116659973 Cysteine proteinase 8 -.QVPPNSK.I
K.MQRLSQSMVMK.M
K.AVANQVVSVAIEGSSR.D
7 gi1164558212 Proteasome
subunit alpha
7 gi116653688 Ascorbate
peroxidase
7 gij164558191 Proteasome
subunit alpha
K.EGVVLAVEK.R
R.GVNTFSPEGR.L
K.VTPNNVDIAK.V
R.ITSPLLEPSSVEK.I
K.VSPTYHLYTPSEV.-
K.GLDMDSSSPSPNRR.A
K.MPSLLIML.-
K.EGLLQLPSDK.A
-.LCCSSFEAF.-
-.NSKMFLASAMR.K
K.ALLSDPAFRPLVEK.Y
K.HPSNGHNPWWHRED.-
K.LGSTAIGLK.T
K.EGVVLAVEK.R
R.GVNTFSPEGR.L
K.VTPNNVDIAK.V
K.TKEGWLAVEK.R
R.ITSPLLEPSSVEK.I
R.LFQVEYAIEAIK.L
K.RITSPLLEPSSVEK.I
K.AIGSGSEGADSSLQEQYNK.D
-.STHCTANMFINLHNFLHTAGFQK.G
7 gi1164552002 Proteasome 24 K.VTPNNVDIAK.V
subunit alpha K.VSPTYHLYTPSEVEAVITR.L
7 gi1164551985 Chaperone HSP 70 26 K.DAISGGSTQAIK.D
K.DAMAALNQEVMK.L
K.NQADSIVYQTEK.Q
K.KQDITITGASTLPGDEVER.M
7 gi0164555856 Heat shock protein 90 14 K.ITLFLK.E
-.PLTLSVLTGR.H
K.ADLVNNLGTIAR.S
R.ELISNSSDALDK.I
K.KDLFVAVESVDDK.T
7 gil164558191 20S proteasome 19 K.LGSTAIGLK.T
K.EGWLAVEK.R
R.GVNTFSPEGR.L
K.VTPNNVDIAK.V
R.RGVQMVSWR.D
R.ITSPLLEPSSVEK.I
R.LFQVEYAIEAIK.L
K.RITSPLLEPSSVEK.I
7 gi 1116653862 HSP 70 22 R.QSSGLMAIN.-
K.VEDAIDEAIK.W
K.KVEDAIDEAIK.W
K.VEDAIDEAIKWVDG-
NQLAEADEFEDK.M
7 gi1116659341 Unknown protein product K.LIPYGNAK.I
R.DFIPFVCK.A
R.KPVDECYNSGLGK.K
K.IFDNGLIDIINLK.L
7 gill 16653688 Ascorbate peroxidase R.ALSEGSCR.R
K.EGLLQLPSDK.A
K.ALLSDPAFRPLVEK.Y
K.HPSNGHNPWWHRED.-
7 gill 116654411 Putative ribose-5-phosphate -.YTSPNRPR.H
isomerase K. FVVVVDDSK.L
K.LTNIVGVPTSK.R
R.IDLAIDGADEVDPNLDLVKGR.G
8 No protein Hit
9 gi1116657467 Putative glycine rich RNA R.GFGFVTFGDEK.S
gil116655161 binding protein K.DAIEGMNGQTLDGR.N
gill16657597 -.CYNGFCRCGVQMLR.R
K.SMKDAIEGMNGQTLDGR.N
9 gil 16656687 Elongation factor- K.LLEEAVR.K
gil 64556462 K. LVPVGYG IK. K
gi1164556636 K.DRDHHHR.H
gill 164560922 -.MYSEQGSTVR.C
gi1 64560935
10 gi1151301856 putative translationally K.VVDIVDTFR.L
controlled tumor protein -.NIIQSNKAQK.T
R.LQEQPAFDKK.Q
R.GETNCLERSESR.Y
K. DLQFFVGESMTDDSALVFAYYK. E
11 gil164561721 Unnamed protein prduct- K.INIGVR.N
p23 co chaperone -.IGINGWTK.M
R.NIFCVLEK.D
K.VFLTVMLPDAK.N
K.LNLHDAVNVEESK.I
K.FGDMGMGGMGMGGMDMAAWVM.-
11 gill64560511 Unnamed protein product - R.LSGTGSEGATIR.V
phosphoglucomutase
11 giJ164553376 O-acetylserine -.KNSVKPI.-
gill 64559283 K.QIKQTGNNK.N
K.VVDIVDTFR.L
13 gi1164557328 Fructose-bisphosphate 23 R.VLAACYK.A
aldolase-like K.VAPEVIAEYTVR.A
K.ALNDHHVLLEGTLLKP-
NMVTPGSDSPK.V
13 gi1164558997 23 R.VLAACYK.A
gig164559800 K.EAGVLPGIK.V
K.IGPNEPSQLAINENANGLAR.Y
K.GTVELPGTNGETTTQGLDGLAQR.C
K.VDKGTVELPGTNGETTTQGL-
DGLAQR.C
13 gi116653218 Dienelactone hydrolase 18 K.ISQFDNGYK.A
gil 164556936 R.GDTTFDAYVVGK. D
gi1164557377
gi1164558223
gil164559204
gi8164559658
gi1164561815
14 gil164561954 Triosphosphate isomerase 38 -.PVPIAQTGS.-
K.VAYALSQGLK.V
K.CNGTIDEVKK.I
K.IVSTLNSAEIPSK.D
K.VIACVGETLEQR.E
R.ESGSTMAWAAQTK.A
R.LILGETNEFVGDK.V
K.KIVSTLNSAEIPSK.D
R.RLILGETNEFVGDK.V
14 gi1164551925 Triosphosphate isomerase 34 K.VAYALSQGLK.V
R.IIYGGSVNGGNCK.E
K.VIACVGETLEQR.E
R.ESGSTMAWAAQTK.A
R.LILGETNEFVGDK.V
K.VATPDQAQEVHFELR.K
14 gill164558403 Xylucanendotransgluconase R.IVFSVDGTPIR.E
K.VVILTFFTLMCSAKER.V
15 gi1116656081 Malate dehydrogenase 5 53 R.ALGQISER.L
K.EFAPSIPAK.N
K.MELVDAAFPLLK.G
K.SQASALEQYAAPNCK.V
K.VLVVANPANTNALILK.E
R.VLVTGAAGQIGYALVPMIAR.G
R.GVMLGADQPVILHMLDIPPAAE-
ALNGVK.M
15 gi1116656009 Malate dehydrogenase R.ALGQISER.L
K.EFAPSIPAK.N
R.THLSIHPWRPK.C
R.KLSSALSAASAACDHIR.D
-.DPSEYTPMETQVPSGVPRTQSR.
15 gi1164552628 Malate dehydrogenasee 12 K.MDSTAEELSEEK.A
gi 164553503 R.KLSSALSAASAACDHIR.D
gill64554057
gi1164554791
15 gi1164557328 Unknown 9 K.AQAAFLTR.C
K.VAPEVIAEYTVR.A
R.HEAPMNHLSLPSMRMPMA
15 gi1116656081 Malate dehydrogenase 5 46 K.NVSIYK.S
K.NVTCLTR.L
R.ALGQISER.L
K.MELVDAAFPLLK.G
K.VLWVVANPANTNALILK.E
R.VLVTGAAGQIGYALVPM IAR.G
K.GWATTDVAEACAGVN IAVMV-
GGFPR.K
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